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ABSTRACT 
 
Background: Inflammation plays a pivotal role in pancreatic cancer etiology and 
can be modulated by diet. We aimed to examine the association between inflammatory 
potential of diet, assessed with the Dietary Inflammatory Index (DIITM), and pancreatic 
cancer risk in two prospective cohorts, the Prostate, Lung, Colorectal and Ovarian 
(PLCO) Cancer Screening Trial and the National Institutes of Health American 
Association of Retired Persons (NIH-AARP) Diet and Health Study. We explored effect 
modification by important inflammation-related lifestyle factors, and investigated 
whether type-2 diabetes mediated the association in a pooled analysis of both studies. 
Methods: A total of 101,449 and 533,286 participants aged between 50 to 78 years at 
baseline were included in the analytical cohort of PLCO and NIH-AARP, respectively. 
Energy-adjusted DII (E-DII) scores were computed based on food and supplement intake. 
Multivariable-adjusted Cox proportional hazards models were used to estimate hazard 
ratios (HRs) and 95% confidence intervals (CIs) for pancreatic cancer by E-DII quintiles 
with participants in the lowest E-DII quintile (most anti-inflammatory scores) as the 
referent. We estimated natural direct effect, natural indirect effect, and marginal total 
effect of both categorical and continuous E-DII scores on pancreatic cancer with type-2 
diabetes as a mediator using causal mediation approach. Results: A total of 328 and 
3,338 pancreatic cancer cases were identified in the PLCO and NIH-AARP, respectively. 
There was no significant association between dietary inflammatory potential and 
pancreatic cancer risk in either the PLCO or NIH-AARP. However, time significantly 
vi 
modified the association in PLCO (P-interaction=0.02). An inverse association in the first 
four years of follow up was observed (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15), 
while there was a positive trend among those with ≥4 years of follow-up (HRQ5vsQ1 
=1.36; 95% CI=0.85-2.17; P-trend=0.03). Type-2 diabetes significantly mediated the E-
DII and pancreatic cancer association (P<0.05). Conclusion: Findings from these two 
large prospective cohorts did not support the association between inflammatory potential 
of diet and pancreatic cancer risk. Reverse causality owing to undetected disease may 
account for the inverse association observed in the first four years of follow-up in the 
PLCO. Type-2 diabetes explained an underlying mechanism through dietary 
inflammatory potential to pancreatic cancer development.  
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CHAPTER 1 
 
INTRODUCTION 
1.1 Statement of the problem  
Pancreatic cancer is the fourth leading cause of cancer mortality in the United 
States among both men and women and has the highest case-fatality rate among major 
cancers with 7% 5-year survival rate for all stages combined.1,2 Most pancreatic cancer 
(95%) are cancers of the exocrine pancreas, which produces enzymes to digest food. 
Neuroendocrine tumors (5%) are much rarer, and have a younger median age at diagnosis 
and better prognosis than exocrine pancreatic cancer.1 Because there is so far no reliable 
screening method for early detection, pancreatic cancer is often diagnosed at an advanced 
stage when survival statistics are even worse (2% 5-year survival for patients diagnosed 
at distant stage).1 Thus, identifying modifiable risk factors for pancreatic cancer is an 
important strategy for reducing the burden of this disease.3 The main risk factors include 
age, cigarette smoking, diabetes, family history, obesity, and chronic pancreatitis, though 
taken together these risk factors do not explain all of the risk for this malignancy.4 There 
is biologic evidence showing chronic inflammation is related to pancreatic cancer 
development, and substantial amount of studies support that some dietary factors could 
increase cancer incidence or mortality risk through modulating inflammation.5 Thus, 
understanding the effect of dietary inflammatory potential on pancreatic cancer 
development may help guide dietary intervention strategies and clinical guidelines for 
preventing this cancer.   
2 
Many dietary factors, such as saturated fat and fruits and vegetables, have been 
shown to affect inflammation through pro-inflammatory or anti-inflammatory 
mechanisms. A Western style diet characterized by greater intake of pro-inflammatory 
foods which are high in sugar, refined grains, red and processed meats, and fried foods 
can increase pro-inflammatory biomarkers such as C-reactive protein (CRP), interleukin-
6 (IL-6) and tumor necrosis factor alpha (TNF-α).6 In contrast, the Mediterranean diet, 
high in whole-grains, fruit, green vegetables, and fish, and low in red meat and butter, 
with moderate alcohol and olive oil intake, has been associated with reduced chronic 
inflammation.7-9 However, most often nutrients or dietary components have been studied 
separately for their potential association with pancreatic cancer and inconsistent results 
have been found.10-12 A dietary pattern approach, which takes into account the complex 
interactions among dietary components, has advantages over individual foods or nutrients 
when being studied for associations with disease risk.13 Given the fact that no nutrient is 
consumed alone but in conjunction with other nutrients or non-nutrient components of 
food, several dietary patterns or indices such as the Healthy Eating Index (HEI)14 have 
been studied in relation to PanC.15-21 However, these dietary indices are limited by the 
relatively small numbers of dietary components and lack of focus on specific biologic 
pathways for explaining their mechanism. Until the dietary inflammatory index (DII™) 
was developed based on extensive review of research articles published through 2010 on 
the effect of dietary parameters on six well established inflammatory markers (IL-1β, IL-
4, IL-6, IL-10, TNF- α and CRP),22 none of these a priori indices had focused on 
inflammation as a main mechanism explaining diet’s effects on disease. The DII 
calculated with dietary data from different dietary assessment tools has been construct-
3 
validated where higher DII scores (representing more pro-inflammatory diets) were found 
to be positively associated with higher inflammatory biomarker levels.23-30 Higher DII 
scores also have been associated with increased risk of different types of cancer in 
multiple studies.31-33,34-37   
Given the role of inflammation in pancreatic carcinogenesis, a dietary index with 
inflammation as the underlying biological mechanism and which assesses the 
inflammatory potential of the entire diet, has advantages for its potential association with 
pancreatic cancer compared to other dietary patterns focused solely on a specific food 
item or more general dietary guidelines. Among the literature, only two case-control 
studies have examined the association between the DII and pancreatic cancer. One study 
conducted in Italy between 1991 and 2008 with 326 incident cases and 652 controls 
reported a positive association between the DII and pancreatic cancer.38 Another case-
control study with 817 cases and 1,756 controls in the US by Antwi et al. reported a 2.54-
fold excess odds of pancreatic cancer among subjects in the highest quintile of DII 
compared to those in the first quintile (odds ratio (OR)Q5vsQ1=2.54, 95% confidence 
interval (CI)=1.87-3.46, P-trend<0.0001).39 Given the possibility of selection bias and 
inextricable recall bias of diet measurement in case-control studies, a prospective cohort 
study design may be a more appropriate study design compared to case-control design on 
this research topic.  
Although two case-control studies found a significant positive association 
between dietary inflammatory potential and pancreatic cancer, little is known about the 
mechanism underlying the pathway from dietary inflammatory potential to pancreatic 
cancer development. Type-2 diabetes has been shown to have a positive relationship with 
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pancreatic cancer.  Recent data from pooled analyses reported concordant findings, 
showing that diabetics had 40% to 90% increased pancreatic risk compared to non-
diabetics.40,41 Given the strong positive association between type-2 diabetes and 
pancreatic cancer and the inflammatory nature of diabetes,42 type-2 diabetes may play a 
role as a mediator linking the dietary inflammatory potential to pancreatic cancer 
development.  
1.2 Purpose and objectives  
We used data from two large, nationally representative, prospective cohort studies 
[i.e. the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the 
National Institutes of Health American Association of Retired Persons (NIH-AARP) Diet 
and Health Study] with rich dietary and other comprehensive covariate information to 
examine the inflammatory potential of diet and pancreatic cancer association in a 
prospective manner. We also investigated effect modification by inflammation-related 
lifestyle factors including body mass index (BMI), cigarette smoking, alcohol drinking, 
diabetes history, and non-steroidal anti-inflammatory drug (NSAIDs) use. As it is unclear 
whether diets with high inflammatory potential increase the risk of pancreatic cancer 
through occurrence of type-2 diabetes mellitus, we also conducted a causal mediation 
analysis with combined PLCO and NIH-AARP data to examine whether incident type-2 
diabetes was playing a role as a mediator in the causal pathway between dietary 
inflammatory potential and pancreatic cancer and if so, what was the mediation 
proportion of diabetes. Our three specific aims were as follows:  
Aim 1: Examine the association between inflammatory potential of diet and 
pancreatic cancer in the PLCO and examine effect modification by sex and BMI. 
5 
PLCO is a randomized controlled trial with the aim to assess if cancer screening tests can 
reduce cancer mortality.43 Briefly, a total of 154,897 eligible participants (76,682 men 
and 78,215 women), aged 55–74 years, were enrolled into the trial from 1993 to 2001 
from ten centers across the US and randomized based on sex and age group into either a 
control arm (77,453 participants) where usual care was received, or an intervention arm 
(77,444 participants) where screening exams for prostate, lung, colorectal or ovarian 
cancers were received.44 In general, a majority of recruited participants were non-
Hispanic white, married or living as married, had higher education level than some 
college, were overweight at baseline, and above 85% of female participants were 
postmenopausal.45 We calculated the energy-adjusted DII (E-DII) score for each subject 
using dietary data from the Diet History Questionnaire (DHQ) and calculated BMI at 
baseline to examine its effect modification on the E-DII and pancreatic cancer 
relationship. We hypothesized that higher E-DII scores were associated with higher risk 
of developing pancreatic cancer and that associations were stronger among males and 
overweight or obese subjects.  
Aim 2:  Examine the association between inflammatory potential of diet and 
pancreatic cancer in the NIH-AARP and examine effect modification by sex and 
inflammation-related lifestyle factors including BMI, cigarette smoking, alcohol 
drinking, diabetes history, and NSAIDs use. The NIH-AARP Diet and Health Study 
was initiated to examine a number of important diet and cancer hypotheses. The initial 
study population of this cohort was 567,169 eligible study participants (340,148 men and 
227,021 women) after excluding respondents whose responses on the questionnaire were 
not reliable. Participants were 50 to 71 years old with mean age of 62 years at baseline 
6 
and lived in one of six states (California, Florida, Pennsylvania, New Jersey, North 
Carolina, or Louisiana) or two metropolitan areas (Atlanta, Georgia or Detroit, 
Michigan).46 Participants are predominantly white and have higher education level than 
the general US population. The percentage of current smokers in the NIH-AARP are 
lower than national estimates.47,48 We hypothesized that a pro-inflammatory diet (i.e., 
higher E-DII score) was associated with increased risk of pancreatic cancer.  As more 
pancreatic cancer cases were available in the NIH-AARP dataset than the PLCO, we a 
priori proposed to examine more effect modifiers in these analyses than in Aim 1, 
including sex, BMI, cigarette smoking, alcohol drinking, diabetes history, and NSAIDs 
use. We hypothesized that males, overweight or obese individuals, individuals with 
previous smoking history, high level of alcohol drinking, those who had presence of 
diabetes history, or less frequent NSAIDs use would have an enhanced effect of E-DII on 
pancreatic cancer risk compared to their counterparts.  
Aim 3:  Investigate causal mediation by type-2 diabetes in the association 
between inflammatory potential of diet and pancreatic cancer in PLCO and NIH-
AARP pooled analysis. We first conducted a causal mediation analysis to investigate the 
causal mediated effect of type-2 diabetes on the pathway from E-DII to pancreatic cancer 
risk in PLCO and NIH-AARP studies separately. Given that PLCO and NIH-AARP 
studies had very similar food frequency questionnaire (FFQ) and other covariate 
information as well as study population demographics, and for the purpose of increasing 
pancreatic cancer cases and incident type-2 diabetes cases, we combined primary data 
from these two cohorts into a single dataset after demonstrating that there was no 
significant heterogeneity between two studies. We hypothesized that incident type-2 
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diabetes played a role as a mediator in the DII and pancreatic cancer association in both 
cohorts and the pooled analyses.  
1.3 Significance and relevance of the dissertation research  
1.3.1 Public health and clinical impact 
Pancreatic cancer is a highly malignant cancer with low survival chance and no reliable 
screening method. Findings from this dissertation had both clinical and public health 
significance. Quantifying the effect of inflammatory potential of diet on pancreatic cancer 
risk and the interactive effects of important inflammation-related lifestyle factors is 
crucial, not only for healthy people who may reduce their chance of developing 
pancreatic cancer through modulating dietary inflammation, but also important for those 
who are already at risk of this malignancy such as obese or diabetic individuals.  By 
elucidating the role that type-2 diabetes may play in the pathway of DII and pancreatic 
cancer, we may better understand the mechanism through which dietary inflammatory 
potential could lead to development of pancreatic cancer. Findings of mediation analyses 
also may provide clinical evidence and guidance to identify possible intermediate 
biomarkers to screen high risk population of developing pancreatic cancer, especially for 
those who consume more pro-inflammatory diets. In addition, it could help with the 
design and guidance of an effective dietary intervention to reduce risk of pancreatic 
cancer through intervening on type-2 diabetes.  
1.3.2 Scientific relevance or significance 
This dissertation work was significant in the following aspects: (1) Use of data 
from two large, well-characterized prospective cohorts minimized the recall and selection 
bias that may exist in a typical case-control study. Aims 1 and 2 were the first two studies 
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to investigate the inflammatory potential of diet and pancreatic cancer association in a 
prospective manner with adequate number of  pancreatic cancer cases and with 
comprehensive dietary factors and covariates assessed before pancreatic cancer onset; (2) 
the joint effect of E-DII and other common inflammation-related lifestyle factors on 
pancreatic risk was examined in a prospective study for the first time, and (3) this was the 
first mediation analysis with the method of pooling studies to examine the mediated 
effect of type-2 diabetes on the pathway from DII to a cancer endpoint.   
1.4 Dissertation outline  
  Chapter 1 provides a brief overview of the problem of interest with an 
introduction to the relationships between diet/dietary patterns and inflammation, and 
between inflammation and pancreatic cancer. We also present the tentative scope of the 
dissertation: three aims with respective hypothesis. Chapter 1 concludes with the clinical 
and public health relevance of the dissertation as well as scientific significance. Chapter 2 
provides a detailed overview of the previous literature with aspects related to the 
dissertation work including the biological mechanisms of chronic inflammation and 
pancreatic cancer; biological and epidemiological perspectives of the association between 
dietary factors and inflammation; an overview of dietary patterns research and 
introduction to a few a priori dietary patterns; and current evidence of risk factors for 
pancreatic cancer as well as summary of study results related to diet and pancreatic 
cancer risk in the PLCO and NIH-AARP. Chapter 3 provides a description of the 
methods used for each aim which includes study population description, variable 
information, and statistical analysis methods. Chapters 4 to 6 include detailed 
manuscripts for each aim. Chapter 7 is the synthesis and discussion for my overall 
9 
dissertation.
 10 
 
CHAPTER 2 
2 2 
BACKGROUND 
2.1 Relationship between chronic inflammation and pancreatic cancer   
2.1.1  Biological mechanism for chronic inflammation and cancer  
Inflammation, a crucial function of the innate immune system, protects against 
pathogens and initiates specific immunity.49 Acute inflammation is a rapid and self-
limiting process during which chemical mediators are induced in a tightly regulated 
sequence, and immune cells move in and out of the affected area, destroying infectious 
agents, repairing damaged tissue, and initiating a specific and long-term response to the 
pathogen.49 Acute inflammation is not regarded as a risk factor for the development of 
neoplasia, although many of the same molecular mediators are generated in both acute 
and chronic inflammation.50 Frequent acute inflammation results in unresolved wound 
healing with consequent chronic inflammation. Chronic inflammation could be caused by 
a variety of factors, including bacterial, viral, and parasitic infections, chemical irritants, 
and non-digestible particles. Chronic exposure to inflammatory mediators including 
metabolites of arachidonic acid, cytokines, chemokines, and free radicals leads to 
increased cell proliferation, mutagenesis, oncogene activation, and angiogenesis. The 
ultimate result is the proliferation of cells that have lost normal growth control.50 Several 
lines of evidence, including general or cell-specific gene inactivation and population-
based studies, support the view that inflammation plays an important role in cancer 
causation which include the following: (1) many cancers arise at sites of chronic 
 11 
 
inflammation, and chronic inflammation increases cancer risk, (2) immune cells with the 
function to mediate chronic inflammation are found in cancers and they promote growth 
of tumor, (3) cancers could produce chemical mediators that regulate inflammation, (4) 
development of experimental cancers are inhibited after deletion or inhibition of 
inflammatory mediators, (5)  genetic variation of inflammatory genes can alter 
susceptibility to and severity of cancer, and (6) the long term use of NSAIDs reduces the 
risk of some cancers.49  The types of chronic inflammation that lead to cancer are varied. 
In some cases, the inflammation initiation factors are known which may include chronic 
bacterial and parasitic infections, chemical irritants, and non-digestible particles. In 
animal cancer models, these cells and mediators of chronic inflammation act as tumor 
promoters for malignant progression of  Barrett’s esophagus and esophageal cancer,51 
inflammatory bowel disease,52 gastric cancer,53 liver cancer54 and colon cancer.55 In other 
cases, the underlying cause of the chronic inflammation is complex due to the diversity of 
inflammatory reactions that is dictated by the primary stimulus as well as by exogenous 
and endogenous modifying signals.49 At one end of the spectrum, type 1 inflammation, 
characterized by granuloma formation, is elicited by intracellular pathogens. At the other 
extreme, inflammatory reactions to parasites are characterized by eosinophil and mast 
cell infiltration and by extensive tissue remodeling (type 2 inflammation).49  
More recently, the role of inflammation in cancer development was highlighted 
by Brucher and Jamall who proposed a new paradigm for the epistemology of the origin 
of cancer.56 They stated that less than 10% of all cancers are hereditary. According to 
their view, the origin of cancer follows a sequence of events beginning with (1) a 
pathogenic stimulus which can be biologic or non-biologic (including diet), (2) followed 
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by chronic inflammation from which fibrosis develops, with associated changes in the 
cellular microenvironment if the inflammation does not resolve, (3) a pre-cancerous niche 
then develops which triggers a chronic stress escape strategy that transforms a normal 
cell to a cancer cell if the chronic stress does not resolve.56 Based on this hypothesis, we 
have a better chance to reduce cancer burden in the nation should we intervene to reduce 
chronic inflammation which may be triggered by potentially modifiable risk factors such 
as diet. 
2.1.2  Relationship between chronic inflammation and pancreatic cancer 
development  
Inflammation has been identified as a significant factor in the development of 
solid tumor malignancies including pancreatic cancer. Both hereditary and sporadic 
forms of chronic pancreatitis are associated with an increased risk of developing 
pancreatic cancer.57 The combined increase in genomic damage and cellular proliferation, 
both of which are involved with inflammation, transform normal pancreatic cells to a 
malignancy. Cytokines, reactive oxygen species, and mediators of the inflammatory 
pathway (e.g., nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2)) have been 
shown to increase cell cycling, cause loss of tumor suppressor function, and stimulate 
oncogene expression, all of which may lead to pancreatic malignancy.57 Like other tumor 
types, pancreatic cancer has been shown to overexpress COX-2, a modulatory molecule 
in inflammation and carcinogenesis which has been implicated in the positive regulation 
of growth and tumorigenesis.58 Systemic low-grade chronic inflammation in addition to 
local inflammation in the pancreas is involved in the pathogenesis of pancreatic 
cancer.57,59,60 Using laser-capture microdissection (LCM), gene array, and 
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immunohistochemistry, some researchers found the potential inflammatory components 
in epithelial and stromal cells that may contribute to both chronic pancreatitis and 
pancreatic cancer, illustrated as follows: (1) increased expression of IL-8, an activator of 
the inflammatory factor NF-κB, (2) decreased expression of IκB (an inhibitor of NF-κB) 
in chronic pancreatitis ductal cells compared with normal ducts, (3) increased expression 
of tumor related genes including S100A4, cyclin E1, and epidermal growth factor (EGF) 
receptor, and (4) expression of matrix metalloproteinase 2, a pro-invasive factor for 
tumor cells.61  
Epidemiology studies have reported associations between certain chronic 
inflammatory biomarkers and pancreatic cancer risk with inconsistent results. Several 
hospital-based case–control studies showed that CRP levels, an acute phase protein 
produced in the liver which is part of the systemic inflammatory response to the tumor, 
were significantly higher in pancreatic cancer cases compared with controls.62-64 In 
addition, serum levels of IL-6 and TNF-α have been repeatedly reported in several case-
control studies to be significantly higher among pancreatic cancer patients than healthy 
controls. 62-66 One study also found significantly higher levels of IL-8 and macrophage 
inflammatory protein-3α in sera of pancreatic adenocarcinoma patients compared to 
healthy controls.67 However, two nested case-control and two prospective cohort studies 
reported no association or weak inverse associations between pre-diagnostic CRP and 
pancreatic cancer,68-71 while three studies have reported positive point estimates.69-71 Only 
one study examined pre-diagnostic IL-6 and TNF-α receptor levels in relation to 
pancreatic risk, and neither biomarker was reported to be significantly associated with 
pancreatic cancer.69 The inconsistent results across studies may be due to differences in 
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study designs, populations, different confounding factors, or statistical power.   
Other evidence that supports a relationship between inflammation and pancreatic 
cancer is demonstrated by NSAID’s effect to reduce its risk. One meta-analysis involving 
7,252 pancreatic cancer cases and more than 120,0000 healthy control subjects showed 
that high-dose aspirin intake was marginally associated with decreased risk for pancreatic 
cancer in the overall analysis (OR=0.88, 95% CI=0.76-1.01) and stratified analysis for 
Americans showed a similar result (OR=0.82, 95% CI=0.65-1.02).72 
2.2 Relationship between diet and chronic inflammation  
2.2.1 Biological mechanisms linking diet and chronic inflammation  
Dietary factors have consistently been shown to affect inflammation, through both 
pro-inflammatory and anti-inflammatory mechanisms. Dietary components that are 
beneficial against carcinogens seem to have multiple mechanisms of action and many 
share a common mechanism of reducing inflammation, often via the NF-κB pathway.73 
NF-κB is a transcription factor that activates expression of multiple genes related to 
inflammation and is also upregulated in response to oxidative stress.74 Another well-
accepted mechanism for a protective effect of diet against inflammation is that healthy 
diets can reduce obesity and insulin resistance75 which are factors likely to initiate 
inflammation,76,77 and decrease oxidative damage78 and change gene expression.79  Many 
dietary components in mammals including folate, vitamin B6, vitamin B12, betaine, 
methionine and choline can induce changes in deoxyribonucleic acid (DNA) methylation. 
79 A lot of dietary factors including fruits and vegetables,80,81 isoflavones (such as 
genistein and diadzein),82,83 flavonols (such as kaempferol and quercetin),84 stilbenes,85 
curcumin,86 isothiocyanates,87 and omega-3 fatty acids88  have been shown to have anti-
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cancer ability though decreasing pro-inflammatory cytokines, suppressing the activity of 
NF-κB, or promoting antioxidant defense.   
2.2.2 Relationship between individual dietary factors and chronic inflammation  
Several studies have investigated the association between an individual dietary 
factor and inflammatory biomarkers. Factors that were reported to be associated with 
lower inflammation levels included fruits and vegetables,89-91 omega-3 polyunsaturated 
fatty acids (PUFAs),92-94 fiber,95,96 whole grains,97-99  moderate alcohol intake,100,101 
vitamin E,102,103 vitamin C,102,104 β-carotene,102,105,106 anthocyanin and flavonols.107  On 
the contrary, some dietary factors were observed to be related to higher inflammation 
levels which included saturated fat,108,109 high daily intake of carbohydrate from honey, 
sucrose, or high-fructose corn syrup,110 high dietary glycemic index (GI) and/or glycemic 
load (GL),111-113 animal protein and meat protein, as well as total protein intake within an 
energy-restricted diet.114   
2.2.3 Relationship between dietary patterns and chronic inflammation  
2.2.3.1 An overview of dietary pattern research and different types of dietary 
patterns 
The traditional nutritional epidemiological studies usually focused on the relation 
between specific nutrients, food items, or food groups and disease, but people consume a 
wide variety of food items, not isolated nutrients or foods. Additionally, impacted by 
different living environmental conditions, religions, personal preferences, food 
availability, economical statuses and many other cultural factors, people may have 
culture-specific dietary patterns. Dietary pattern research thus provides a more 
comprehensive scope to examine diet-disease associations than an individual food or 
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nutrient approach. The dietary pattern approach has several advantages over the 
traditional individual food/nutrient approach which have been discussed as follows:115-120 
(1) biologically, nutrients may interact with each other via impacting bioavailability and 
absorption; single nutrient-based research does not consider the complex interactions 
among nutrients; (2) increased consumption of one food item may be always associated 
with reduced consumption of other food items since the total energy intake is considered 
to be stable; (3) many nutrients, especially macronutrients such as fat, and total energy 
are highly correlated and studying their separate effects  may produce a collinearity issue 
in the statistical model; (4) the effect of a single nutrient may be too small to be detected 
but the cumulative effects of multiple nutrients in a dietary pattern may be sufficiently 
large to be identified; (5) analysis of individual nutrients may be confounded by dietary 
patterns; and (6) analysis of a large number of individual nutrients or food groups may 
produce significant associations simply by chance.  
      There are basically two broad categories of dietary pattern approach: the a priori 
dietary pattern which is also known as index-based or score-based dietary pattern, and the 
a posteriori dietary pattern which is also known as a data-driven approach. Both index-
based and data-driven dietary patterns take into account the whole diet instead of a single 
nutrient, thus overcoming most limitations of single nutrient research, and results are 
more meaningful and interpretable. There are both strengths and limitations of each 
approach. The index-based approach is analytically simple to compute, and easily 
reproducible and can be comparable across different studies because it provides a 
standardized assessment of a set of recommendations which allows researchers to define 
criteria exactly the same way.13 However, scores that dichotomize components (met or 
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not met) do not consider the full range of amount of foods consumed. Those that include 
a range of points for each component do consider variability in intake of foods but not 
amounts at the extremes. The scoring algorithm of the index is based on the underlying 
dietary guidelines, which are generally not targeted at certain type of disease. Subjectivity 
may be introduced during index construction in terms of the selection of foods for 
inclusion, number of foods or nutrients being selected, scoring algorithm, and 
interpretation of the result. Also, the equally weighted diet components implies that each 
component is equally related to health, which may not be the case.115 
      The data-driven methods can be broadly grouped into two categories: data-driven, 
outcome independent and data-driven, outcome dependent.13 Factor analysis and cluster 
analysis are two data-driven, outcome independent methods to identify dietary patterns, 
because both are derived from analysis of dietary data (factor analysis examines 
correlations between food group variables and finds linear combinations of those 
variables that explain overall variance in the data so it is a continuous variable; and 
cluster analysis identifies clusters of individuals with similar dietary patterns according to 
food groups defined by investigator so it is a categorical variable) and both are derived 
independent of their potential relationship to a health outcome. Therefore, the resulting 
factors or clusters may be significantly associated with a health outcome, but the 
interpretation does not mean that this factor or cluster necessarily represents the dietary 
pattern most associated with disease. Another limitation of factor analysis is subjectivity 
introduced at multiple levels including food groups determination, the number of factors, 
names of the factors (often called patterns), and treatment of input items (e.g., whether to 
use grams, servings, percent energy or standardized intake). Unless methods of collecting 
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the data are comparable and food group construction is standardized, results are not 
comparable across studies.13 In addition, factors are not mutually exclusive and therefore 
do not represent the entire eating pattern for a group of individuals. Another challenge 
both factor and cluster analysis face is that the population under study can dramatically 
affect results because patterns are derived based on data variability under the study 
population. It is almost unlikely that the exact same pattern could be identified by using 
another population, therefore generalizability of the results and reproducibility is 
necessarily limited.13 Reduced rank regression (RRR) and classification and regression 
tree analysis (CART) are two data-driven, outcome dependent methods. RRR is typically 
used to identify combinations of food that explain the most variation in a set of 
intermediate health biomarkers and in subsequent confirmatory analysis it links the 
pattern to the outcome of interest. CART is an emerging method and it makes 
determinations in stepwise fashion, first determining which dietary component explains 
the most variation in the health outcome and then determining which component explains 
the next most variation based on value for the initial component, until the last component 
is reached. Results from RRR and CART are reproducible across studies to the extent 
that study population exhibit the same relationship between diet and health outcome.13 
Regarding the relationship of dietary patterns and inflammation, the Western-type 
diet, which is typically defined as high in refined grains, red and processed meat, high-fat 
dairy, sweets and desserts, fries and soft drinks has been associated with higher levels of 
CRP and IL-6.6,121-124 In a cross-sectional study with 486 healthy Iranian women, higher 
Western pattern score was associated with elevated CRP (beta=0.08, P<0.001), serum 
amyloid A (SAA) (beta =0.11, P<0.05), and IL-6 (P<0.001).124 In contrast, the 
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Mediterranean diet, which is high in whole-grains, fruit and green vegetables, fish, low in 
red meat and butter, with moderate alcohol and olive oil intake, has been associated with 
lower levels of inflammatory biomarkers, such as CRP,125-127  IL-6,128, IL-8,127 and IL-
10.129  
As my dissertation focuses on an a priori dietary pattern as exposure, I mainly 
describe in the following sub-sections a few selected well-established a priori dietary 
patterns including introduction of each dietary pattern’s scoring algorithm and its 
association with inflammatory biomarkers and some disease outcomes.  
2.2.3.2 Healthy Eating Index 
The HEI was developed by the US Department of Agriculture (USDA) to 
measure concordance with the Dietary Guidelines for Americans (DGA) and the Food 
Guide Pyramid.130 The overall structure of HEI included 10 components: five food 
groups (grains, vegetables, fruits, milk and meat), four nutrients (percent energy from 
total fat, percent energy from saturated fat, cholesterol intake, sodium intake), and the 
number of different kinds of foods in person’s diet over a 3-day period.131 Recipe 
ingredients of mixed food item were allocated to appropriate food groups. The exact 
score assigned to a person in every component of HEI was determined by the number of 
servings the individual consumed per day for a given energy intake. For example, the 
recommended dietary allowance (RDA) for total energy for a 40-year-old woman is 
2,200 kcal and the USDA food guide pyramid indicated that four servings of vegetables 
per day are recommended at this energy level. Thus, a woman of 40-year-old should have 
at least four servings of vegetables per day to obtain the maximum score of 10 in this 
category.131 Each of the 10 components has a score ranging from 0 to 10, so the total 
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index score is 100. If an individual consumed the recommended number of servings for 
each food component or met the recommended guidance for nutrient intake, then this 
individual would receive a score of 10 for this component. A score of 0 was assigned to 
people who had no serving within a food group or below the criteria for minimum score 
of 0 for nutrients intake. Between 0 and 10, the score of each component was calculated 
proportionately.131 
Some studies have investigated the association of the HEI score and inflammation 
with the main findings showing that the HEI score was not associated with systemic 
inflammation biomarkers such as CRP,7,132,133 SAA133 and IL-6.7,132,133 Only one cross-
sectional study using data from the Third National Health and Nutrition Examination 
Survey (NHANES III) showed that higher HEI score predicted lower CRP level among 
8719 disease-free adults (P-trend=0.04).134 HEI only weakly predicted major chronic 
disease risk in men but not in women and it generally did not predict cancer risk in men 
or women.135,136 The HEI’s low predictive ability for chronic inflammation and chronic 
disease outcomes could be improved had it distinguished between unsaturated and 
saturated fats, the form of carbohydrates, or protein sources.137 These limitations were 
addressed by the development of an alternate HEI (AHEI) with the goal to capture 
specific dietary pattern and eating behavior consistently associated with lower chronic 
disease risk in clinical and epidemiological investigations. AHEI has 9 components, and 
compared to the original HEI, the AHEI removed potato and potato products from the 
vegetable component; whereas HEI considered all types of meat, AHEI gave more credit 
for consuming white over red meat (included a component: white to red meat ratio). 
AHEI also included a separate component for beneficial non-meat protein sources which 
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were nuts and soy products and gave credit for higher cereal fiber intake in the grain 
category. The ratio of polyunsaturated to saturated fat was included in AHEI to capture 
beneficial effects of unsaturated oils which was not considered in HEI; moderate alcohol 
consumption and a long-term multivitamin use were also added into the AHEI. Except 
for the multivitamin use (contributing either 7.5 points for regular use >5 years and 2.5 
points for all others), the other 8 components of AHEI were assigned a score from 0 to 
10. All individual component scores were summed for a total AHEI score ranging from 
2.5 (worst) to 87.5 (best).135,137 A study comparing the disease predictive ability of the 
HEI and AHEI using same study population and during same follow up periods found 
that the AHEI was nearly twice as predictive of overall chronic disease risk as was the 
HEI and most of additional reduction of risk resulted from reduction in cardiovascular 
disease (CVD) risk.138  However, AHEI was more predictive of CVD risk than cancer 
risk, perhaps because CVD outcome is more homogeneous than is cancer outcome.138  
The association between AHEI and plasma concentrations of inflammation biomarkers 
was assessed in two studies with main findings showing higher AHEI scores were 
associated with lower inflammatory biomarker levels such as IL-6 and TNF-α.7, 139 
       Since DGA are issued every 5 years by the USDA and U.S. Department of Health 
and Human Services, the HEI-200514 and HEI-2010140 reflected the dietary 
recommendations from 2005 edition of the Dietary Guidelines and the 2010 edition, 
respectively. The HEI-2010 keeps several features of the 2005 version: (1) it has 12 
components, many unchanged, including 9 adequacy (adequacy items are those higher 
intake indicate higher score) and 3 moderation components (those reverse scored food 
items); (2) it uses an energy density approach to set standards, e.g., nutrients are adjusted 
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for total energy as a percent of calories; and (3) the standards for the maximum scores are 
the least-restrictive (easiest to achieve) recommendations among those that vary by 
energy level, sex, and/or age. Changes to the HEI-2010 include: (1) Greens and Beans 
replaces Dark Green and Orange Vegetables and Legumes because Greens and Beans are 
considered as the subgroups for which intakes are furthest from recommended levels; (2) 
Seafood and Plant Proteins has been added to capture specific choices from the protein 
group; (3) Fatty Acids, a ratio of poly- and mono-unsaturated to saturated fatty acids, 
replaces Oils and Saturated Fat to acknowledge the recommended beneficial effect of 
replacing saturated fat with mono-and polyunsaturated fatty acids; and (4) a moderation 
component, Refined Grains, replaces the adequacy component, Total Grains, to reflect 
the recommendation of restricting the over-consumption of refined grains.140 The HEI-
2010 allows for flexibility in food choices and lack of any one commodity does not 
prevent from having a perfect HEI-2010 score. In contrast to the adequacy components of 
the HEI-2010 where assigning the minimum score of zero was determined by no intake, 
the 85th percentile of the 2001–2002 population distribution of 1-day intakes is used for 
the minimum score of zero for those moderate components because these components are 
reverse-scored and there is no clear scientific evidence to specify how high of an intake 
deserves a score of zero.140 Although the suitability of the HEI-2010 for ethnic and 
cultural groups has not yet been determined, the index would be expected to be useful for 
assessing the diets for subpopulations for which the DGA are appropriate.  
HEI-2005 was found to have an inverse association with CRP.141,142 The higher 
HEI-2005 score was found to be related to lower risk of colorectal cancer,143 reduced 
symptoms of depression,144 lower risk of cardiovascular risk factors,145 reduced risk of 
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overall chronic diseases,146 and lower risk of stroke.147 HEI-2010 was also found to be 
related to lower risks of all-disease mortality, cardiovascular disease mortality, and 
cancer mortality in the low-income Southeast US population.148 Among specific cancer 
types, an inverse association was found for HEI-2010 with risk of melanoma,149 lung 
cancer,150 and colorectal cancer.151  
2.2.3.3 Dietary Approaches to Stop Hypertension (DASH)  
The DASH-style diet was initially developed in the middle 1990s to lower blood 
pressure and prevent hypertension in the US. It is a healthy dietary pattern that contains 8 
components: fruits, vegetables, whole grains, low-fat dairy products, legumes and nuts, 
sodium, red and processed meat, and sugar-sweetened beverages.152 There are several 
versions of DASH scoring algorithms: one version assigns scores from 1 to 5 to each 
quintile of component intake (higher quintile of recommended food items intake receive 
higher point while higher quintile of undesired food items intake was assigned lower 
score)153 with total score ranging from 8 to 40; a second version has minimum and 
maximum component scores between 0 and 10 with total score from 0 to 80;154 while a 
third version has 11 components with scores from  0 to 1 assigned to each component 
thus making total DASH score from 0 to 11.155 A recent meta-analysis of twenty-two 
randomized clinical trials that investigated the effect of DASH diet intervention on CVD 
risk factors reported that compared to control, DASH diet significantly decreased systolic 
blood pressure (BP), diastolic BP, the concentrations of total cholesterol and low-density 
lipoprotein.156 Importantly, the beneficial effects of the DASH diet are not limited to BP 
and CVD risk factors, some studies have reported significant improvements in weight 
loss,157 insulin sensitivity,158,159 inflammation,160,161 and oxidative stress.159 The DASH 
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diet has been shown to be associated with reduced risk of several inflammation-related 
chronic diseases such as type-2 diabetes,154,162,163, colorectal cancer,164 all cancer 
mortality,165 heart disease and stroke,153,166 and all-cause mortality.165 In a NIH-AARP 
study followed from 1995 to 2006, Miller et al. compared four DASH indices defined by 
Dixon (7 food groups, saturated fat, and alcohol), Mellen (9 nutrients), Fung (7 food 
groups and sodium), and Günther (8 food groups) with regard to their associations with 
colorectal cancer risk.167 They concluded that higher scores of all four indices were 
consistently associated with reduced risk of colorectal cancer in men and higher scores on 
three of the indices (except the Dixon defined index) were associated with reduced risk 
among women.167  
2.2.3.4 Mediterranean Diet Score (MDS) 
 The Mediterranean diet score (MDS) was originally developed by Trichopoulou 
et al.168 to measure the degree of adherence to the traditional Mediterranean diet. It 
includes eight components and a score of 1 is assigned to beneficial food items including 
vegetables, legumes, fruits, cereal and ratio of monounsaturated fat to saturated fat for 
which the consumption is at or above the sex-specific median, and 0 is assigned to 
consumption of these foods below sex-specific median. For components presumed to be 
unhealthy (meat and meat products, milk and dairy products), people whose consumption 
is at or above the sex-specific median are assigned 0, and people with consumption below 
the sex-specific median are assigned a score of 1. For ethanol consumption, a score of 1 
is assigned for moderate ethanol consumption and 0 is assigned to heavy drinkers. The 
total score ranged from 0 (minimal adherence) to 8 (maximal adherence). Trichopoulou 
et al. later updated the original version of MDS to include fish intake and defined 
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moderate ethanol consumption as 10 to 50 grams per day for men and 5 to 25 grams for 
women, which made the total score between 0 to 9.169 Different definitions of moderate 
ethanol consumption were included in other studies.170,171  There were several 
Mediterranean dietary indices constructed based on the original MDS and used to 
evaluate their associations with health outcomes, such as the adapted composite 
Mediterranean diet score (MED) considering different health effects of cereal and grain 
products,172 the alternate MED (aMED) which was adapted to the American 
population,173 and the Mediterranean style-dietary pattern score (MSDPS).174,175 
Increasing evidence suggests that bioactive and nutrient-dense components contained in 
the Mediterranean diet are modulators of insulin resistance, can exert beneficial effects 
on blood pressure, improve atherogenic dyslipidemia, beneficially influence metabolic 
pathways or attenuate the inflammatory burden.176,177  The Mediterranean diet could 
protect against diseases associated with chronic inflammation, including metabolic 
syndrome,178,179 atherosclerosis and CVD, 180,181 cancers,182 diabetes,177 and obesity.183,184 
The MDS has been associated with lower chronic systemic inflammation markers, such 
as IL-6 and CRP. 7,185,186 A study to compare and evaluate the reliability of ten 
Mediterranean diet indices showed these indices had acceptable performance in 
measuring the adherence to the Mediterranean diet.187 The components that had strongest 
correlation with the core of Mediterranean diet were monounsaturated-to-saturated fatty 
acid ratio, fruit, and vegetables. In order to improve the concordance between the indices, 
further research was suggested to standardize the number of components and the scoring 
criteria.187 
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2.2.3.5 Dietary inflammatory index (DII)  
The development and construct validation of the DII have been described 
previously.22-24,26,27,29,30,188 In short, the 45 food parameters (i.e., DII components) were 
assigned inflammatory effect scores based on research summarizing findings from 1,943 
articles published through 2010 describing the relationship between the food parameters 
and six inflammatory markers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). A 
representative world database (i.e., dietary intake from 11 populations around the world) 
was created that provided a mean intake and standard deviation for each food parameter. 
To calculate an E-DII score, this global mean dietary intake after energy adjustment was 
subtracted from the actual food intake value from a specific study, and divided by its 
standard deviation. This z-score is then converted to a percentile (in order to minimize 
the effect of outliers or right-skewing) and centered by doubling the value and subtracting 
1. The product of the transformed z-score and inflammatory effect score for each DII 
component was calculated and summed across all components to create the overall E-DII 
score for an individual. The E-DII score characterizes an individual’s diet on a continuum 
from maximally anti-inflammatory to maximally pro-inflammatory, with a higher E-DII 
score indicating a more pro-inflammatory diet and a lower E-DII score indicating a more 
anti-inflammatory diet.  
The DII has been construct validated with dietary data from different dietary 
assessment tools, where higher DII scores were found to be positively associated with 
higher inflammatory biomarkers levels.23-27,29,30 Higher DII scores have previously been 
associated with some inflammation-related diseases such as colorectal cancer reported in 
the Iowa Women’s Health Study,33 NIH-AARP study,34 the Women’s Health Initiative,31 
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and the Bellvitge Colorectal Cancer Study;32 prostate cancer among French middle-aged 
adults189 and Jamaican men190 as well as Italian men;191 prostate cancer mortality among 
patients with aggressive cancer,192 esophageal squamous cell cancer,193,194 
gastroesophageal junctional adenocarcinoma,195 endometrial cancer,36 ovary cancer,196 
dyspnoea and radiological evidence of emphysema among heavy smokers,197 breast 
cancer death198 and incidence,193 myocardial infarction,199 ulcerative colitis,200 previously 
diagnosed circulatory conditions,201 hepatocellular cancer,202 metabolic syndrome and 
associated traits including higher blood pressure and triglycerides and lower HDL-
cholesterol,26,203 depression,204 asthma.205 Higher DII scores were more likely to be 
observed among shift workers especially rotating shift workers.206 The higher DII was 
also associated with larger BMI, waist circumference and waist to height ratio in a 
population sample at high CVD risk,207 lower scores on other dietary indices,208 
decreased cognitive functioning,196 lower fetal growth and breast feeding failure,209 lower 
bone mineral density,210 lower lung function,205 higher risk of incident cardiovascular 
diseases,211,212 higher CVD mortality,193,213,214 and higher cancer mortality and all-cause 
mortality.213-216 As mentioned previously, the DII has been associated with pancreatic 
cancer in two case-control studies.38,39 
2.3 Other inflammation-related lifestyle factors: Obesity, type-2 diabetes, 
smoking, NSAIDs use  
Obesity is an inflammatory condition, often associated with the development of 
adipose tissue inflammation, resulting in metabolic dysfunction and an increased risk for 
developing multiple chronic diseases.217 In addition to excess fat storage in adipose 
tissue, obesity is also associated with fat storage in other tissues including liver and 
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skeletal muscle, which may lead to insulin resistance and stimulate inflammation.218 On 
the other hand, obesity changes the type of chemicals that fat cells secrete which include 
several pro-inflammatory mediators, produced by macrophages resident in the adipose 
tissue.218 It has been demonstrated that healthy obese subjects have increased circulating 
levels of pro-inflammatory cytokines such as IL-6, TNF-α and CRP.219,220 Weight loss by 
hypocaloric diets or surgery reduced CRP levels in healthy middle-aged221 and 
postmenopausal obese women222 and obese men.223 
Chronic diabetic wounds are trapped in a persistent inflammatory state with 
elevated levels of pro-inflammatory cytokines and proteases together with impaired 
expression of growth factors.224 Recent data have demonstrated that the plasma 
concentration of inflammatory mediators, such as TNF-α and IL-6, are increased in the 
insulin-resistant states of obesity and type-2 diabetes. The first molecular link between 
inflammation and insulin resistance was established by observing the insulin resistance in 
obese mouse can be reduced through neutralization of TNF-α by soluble TNF- α 
receptors.225 In the Women’s Health Study, elevated CRP levels were associated with a 
four-fold increased risk to develop diabetes among healthy middle-aged women after 
follow up of 4 years.226  In addition, Dandona et al. demonstrated that insulin has an anti-
inflammatory effect that may inhibit atherogenesis in the long term.227  
Cigarette smoking has been shown to augment the production of pro-
inflammatory cytokines such as IL-1, IL-6 and IL-8 and to decrease the levels of anti-
inflammatory cytokines such as IL-10.228 One of the key mechanisms behind smoking-
induced inflammation activation is through the NF-kB pathway. In response to 
environmental stimuli including tobacco exposure, the inactive complex of NF-kB/ 
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intracellular inhibitor (IkB) is activated by phosphorylation of IkB, which leads to the 
poly-ubiquitination and subsequent degradation of IkB. Degradation of IkB induces 
transcription of various genes involved in immune regulation and inflammation.229  The 
pro-inflammatory impact of smoking on increased level of various inflammatory 
cytokines was confirmed in several epidemiological studies. The associations between 
cigarette smoking, years since quitting smoking and inflammatory markers were 
investigated among 2,920 British men and the result showed that current smokers had 
higher levels of the acute phase CRP compared to never smokers.230 Reduced levels of 
inflammatory markers were found in subjects who quit smoking for 5 years, and the 
levels of inflammatory markers were reverted to those found in never smokers only in 
subjects who quit smoking for 20 years or more.230 Serum levels of the key pro-
inflammatory mediator TNF-α were found to be highest among healthy subjects who 
smoked more than one pack of cigarettes per day, followed by smokers who smoked less 
than one pack per day and lowest in healthy nonsmokers, demonstrating a positive 
relationship between cigarette smoke and serum level of TNF-α.231 Also, significantly 
higher serum levels of IL-1β was found in healthy active smokers compared with 
nonsmokers.232  In a recent multi-ethnic study of atherosclerosis cohort of 6814 adults 
without prior CDV, a monotonic association was found between higher pack-year 
quartiles and increasing inflammatory markers including high sensitivity CRP (hsCRP), 
IL-6 and fibrinogen.233  
       NSAIDs which include aspirin, indomethacin, piroxicam, sulindac, ibuprofen and 
other COX-2 inhibitors, are a diverse group of similarly acting compounds that are used 
to treat the signs and symptoms of inflammation by primarily inhibiting the activity of the 
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COX enzymes and thereby affecting the synthesis of the prostaglandin signaling 
molecules, which are involved in a wide range of inflammation-related process.234  
NSAIDs have shown the ability to alter systemic inflammation, reduce tumor recurrence 
and improve moderate cancer cachexia (a multifactorial syndrome affecting almost 50% 
of all cancer patients, characterized by skeletal muscle wasting with or without loss of fat 
mass and is often associated with psychological distress and fatigue).235 A large body of 
evidence supports aspirin’s protective effect of reducing cancer incidence and cancer 
mortality. The beneficial effects are particularly large and consistent for colorectal, 
esophageal and gastric cancers, with smaller reductions seen on breast, prostate and lung 
cancer. 236 Data from 51 randomized controlled trials (RCTs) showed that aspirin use at 
doses between 75 and 100 mg/day reduced overall cancer incidence by 12%. This benefit 
was only noted apparently with a 24% reduction observed after 3 years of follow-up and 
beneficial effect became larger with increasing follow-up. The benefit was most evident 
in patients with a scheduled treatment duration of 5 years or longer.237  Reductions in 
cancer incidence were similar in men and women.237 Data from multiple RCTs showed 
that aspirin use can reduce total cancer death by 20% and the protective effect was only 
observed after 5 years of use. The magnitude of benefit became larger with longer 
duration of aspirin use, and it had similar benefit in men and women.238 
2.4 Risk factors for pancreatic cancer   
2.4.1 Selected individual dietary factors  
The following selected dietary factors and associated evidence are summarized 
based on the World Cancer Research Fund/American Institute for Cancer Research 2012 
Continuous Update Project (CUP) summary report for pancreatic cancer, which serves as 
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the most updated authoritative scientific resource generating evidence on food, nutrition 
and physical activity relating to the prevention of pancreatic cancer.239 This summary 
report updates the pancreatic cancer section of the Second Expert Report of Food, 
Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. 
Conclusions from the report were made based on the findings of the 2011 systematic 
literature review and the CUP Expert Panel discussion in June 2012. Evidence of this 
report was summarized based on literature review restricted to Medline and included only 
randomized controlled trials, cohort and case-control studies published up to September 
2011. Given that there is very little difference between pancreatic cancer incidence and 
mortality rates due to low survival rate, study results on incidence and mortality have 
been presented and analyzed together in the current report, unless there is large number 
of papers reporting pancreatic cancer incidence and mortality separately. I additionally 
include evidence from literature published after CUP.   
2.4.1.1 Red and processed meat intake  
    High intake of red meat may result in more absorption of heme iron, greater 
oxidative stress, and potential for DNA damage.240 It is also associated with the 
formation of N-nitroso compounds, which shares the same mechanisms for increasing 
risk with processed meat. Previous studies found inconsistent association for red meat 
and pancreatic cancer.241,242 CUP found three of seven studies on pancreatic cancer 
incidence that reported an increased risk when comparing the highest red meat intake 
group to the lowest, two of which were statistically significant. For pancreatic cancer 
mortality, two of three studies reported an increased risk and only one reached statistical 
significance. The dose–response meta-analysis showed a non-significant positive 
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association between red meat intake and pancreatic cancer risk [incidence and mortality 
combined, relative risk (RR)=1.19, 95% CI=0.98-1.45 per 100g/day with moderate 
heterogeneity (I2= 52%)] and the association was significant in men (RR=1.43, 95% 
CI=1.10-1.86) but not in women (RR=1.06, 95% CI=0.86-1.30). Results from two later 
published meta-analysis were similar to the CUP findings, both meta-analysis (one 
included 11 prospective studies through November 2011243 and the other included 10 
cohort studies and 11 case-control studies up to the end of 2010 244) reported a positive 
relationship. One meta-analysis reported an overall non-significant dose-response 
relationship (RR=1.13, 95% CI=0.93-1.39) and the association was significant in men 
although not in women.243 The other meta-analysis found a significant association in 
case-control studies (RR=1.48, 95% CI=1.25-1.76) but not in cohort studies (RR=1.14, 
95%CI=0.94-1.38).244 Five individual studies (two case-control studies245,246 and three 
prospective cohort studies247-249) reported on the red meat and pancreatic cancer 
relationship after the CUP summary report. All five studies reported positive associations 
between red meat and pancreatic cancer risk, among which three studies reported 
significant increased risk for the highest compared with the lowest group, one study 
reported significant association only in men, and one observed a non-significant positive 
dose-response relationship. A case-control study reported consumption of barbecuing red 
meat versus no consumption was associated with 67 % increased risk of pancreatic 
cancer risk.245 Results from the NIH-AARP study showed pancreatic cancer risk 
significantly increased with intake of high-temperature cooked meat, grilled/barbequed 
meat, or well/very well done meat, which suggested that meat cooking methods may be 
important in the association between red meat and risk of developing pancreatic 
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cancer.248  
Similarly, the association between processed meat and pancreatic risk was 
inconsistent. Overall, the CUP found four of six studies on pancreatic cancer incidence 
reported an increased risk comparing the highest intake group to the lowest, one of which 
was statistically significant. For mortality, one of two studies reported a non-significant 
increased risk and the other reported a non-significant decreased risk. Dose-response 
meta-analyses which included seven studies (incidence and mortality combined) found a 
17% increased risk associated with each 50g increase of processed meat per day, and this 
was statistically significant (RR=1.17, 95% CI=1.01-1.34) with no heterogeneity (I2=0). 
When stratified by sex, the effect was significant in men (RR= 1.21, 95% CI=1.01-1.45) 
but not in women (RR=1.09, 95% CI=0.69-1.73). The dose-response finding from CUP 
was consistent with a recent meta-analysis of prospective cohorts which also reported 
significantly positive associations.243 Two recent individual studies examining processed 
meat and pancreatic cancer risk both showed no associations.247,248 Limited evidence for  
nitrate/nitrite intake from processed meat in association with pancreatic cancer has been 
published but with inconsistent results.250-252  In summary, CUP concluded there was 
limited and inconsistent but suggestive evidence to implicate red and processed meat in 
pancreatic cancer etiology.  
2.4.1.2 Fat intake 
It is well established in animal models that total dietary fat plays a role in 
pancreatic carcinogenesis: long-term exposure to free fatty acids could result in 
pancreatic hypertrophy or hyperplasia, which in turn leads to uncontrolled growth of 
abnormal cells in the pancreas.253 Large amounts of fat intake may stimulate bile acid 
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secretion into the pancreatic duct and in turn stimulate the tumor promotor COX-2.254 In 
addition, the insulin resistance caused by high fat intake is another mechanism to increase 
pancreatic cancer risk through metabolic, immunological and hormonal alterations in the 
body.253  Several studies examined the association between total fat intake and pancreatic 
cancer risk with results being inconsistent. In a recent meta-analysis including 6 cohort 
and 13 case-control studies published up to February 2014 with total of 6,159 pancreatic 
canc cases, Shen et al. found a non-significant increased risk for the highest total fat 
intake group compared to the lowest group (pooled RR=1.04, 95%=0.90-1.20, I2=57.3%), 
with similar effects among case-control and cohort studies.  Furthermore, no significant 
associations were observed when stratifying by fat source.255 The CUP meta-analysis for 
total fat intake included 8 studies and showed a marginally significant positive 
association (RR=1.05, 95%CI=1.00-1.12) for the highest versus the lowest intake group, 
with no evidence of heterogeneity. In terms of saturated fatty acids, the CUP performed a 
dose-response meta-analysis including five studies and found an 11% statistically 
significant increased pancreatic cancer risk for each 10g saturated fatty acids intake per 
day (RR=1.11, 95% CI=1.01-1.21) with moderate heterogeneity observed. However, the 
evidence among individual studies is limited and inconsistent, with four of seven studies 
reporting a non-significant decreased risk and three reporting an increased risk (two of 
which were significant). In a recently published PLCO study with 411 pancreatic cancer 
cases, Arem et al. observed an inverse association between saturated fat, total fat intake 
and pancreatic cancer risk among subjects with less than four years of follow-up, and 
associations became weaker and nonsignificant after excluding these subjects, whereas 
intakes of monounsaturated and polyunsaturated fats and fats from animal or plant 
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sources showed no associations with pancreatic cancer.256 In another large cohort study 
(the NIH-AARP), researchers found that higher intake of total fat, saturated fat and 
monounsaturated fat all significantly increase pancreatic cancer risk, but there was no 
association with polyunsaturated fat and associations were strongest for saturated fat 
from animal food sources. The authors also examined individual fatty acids and found 
increased intake of two types of  saturated fatty acids (SFA) (palmitic acid and stearic 
acid), one monounsaturated fatty acids (MUFA) (palmitoleic acid), one n-6 
polyunsaturated fatty acid (PUFA) (arachidonic acid), and two n-3 PUFAs 
(eicosapentaenoic acid, docosahexaenoic acid) were associated with increased risk of 
pancreatic cancer.257 The trans fatty acids and pancreatic cancer relationship was 
examined in three studies, with two studies10,257 yielding non-significant positive 
associations and one study258  reporting a non-significant inverse association.  
2.4.1.3 Vegetable and fruit intake 
A large number of antioxidant vitamins and minerals rich in fruits and vegetables 
have been proposed to have many cancer-protective properties, including reducing 
oxidative DNA damage/mutations by reducing oxidative stress and inflammation, or 
stimulating glucose metabolism and/or insulin sensitivity.259,260 A recent meta-analysis 
summarizing available evidence (15 case-control studies, 8 prospective studies, and one 
pooled analysis) up to January 2015 found a significant reduction of pancreatic cancer 
risk for the highest versus lowest intake of vegetable and fruit combined (RR=0.73, 95% 
CI=0.53-1.00), fruit (RR=0.73, 95% CI=0.63-0.84), and vegetable (RR=0.76, 95% 
CI=0.69-0.83) with significant between-study heterogeneity (I2=70.5%, 55.7%, and 
43.0%, respectively).11 These inverse associations were borderline significant in 
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prospective studies.11 In a pooled analysis of 14 prospective cohort studies from North 
America, Europe, and Australia where primary data from these studies was used by 
standardizing the definitions of fruit and vegetable intake and covariate categories across 
studies, Koushik et al. found that for each 100g/day increase in intake of fruits and 
vegetables during adulthood there was a non-significant increased risk of pancreatic 
cancer with no statistically significant heterogeneity between studies (pooled 
multivariable RR=1.01, 95% CI= 0.99-1.03) for total fruits; RR=1.02, 95% CI= 0.99-
1.06 for total vegetables). Associations were similar for men and women.261  This lack of 
overall association was consistent regardless of whether intake was examined as a 
continuous measure or in categories based on absolute cut-points or study-specific 
quartiles. In the analyses of individual foods, statistically significant increased pancreatic 
cancer risks were observed for each 3-servings/week increment in intake of strawberries, 
fruit juice, brussels sprouts, green peppers, lettuce/salad, and tomatoes, although most of 
the positive associations became non-significant after adjustment for total fruit or 
vegetables. They also found each 100g/ day increment in intake of green leafy vegetables 
was associated with 17% increased risk with no significant between-study 
heterogeneity.261 These non-significant positive associations were not expected a priori 
and may have been due to chance. Some research has suggested that exposure to 
pesticides, which may be present on fruits and vegetables, may increase risk.262 Other 
research has suggested that indole-3-carbinol, which is found in cruciferous vegetables 
such as Brussels sprouts, may have some cancer-promoting effects, particularly when 
administered after carcinogen exposure.263,264 In addition, residual confounding from 
measurement error in the included covariates or uncontrolled covariates as well as 
 37 
 
misclassification in estimates of usual consumption due to only one time diet assessment 
may also contribute to the unexpected results, as suggested by authors of this paper.261 In 
the Multiethnic Cohort (MEC) Study with 529 pancreatic cancer cases, no association 
between total vegetable intake and vegetable subgroup intake and pancreatic risk was 
observed among the overall population, but an inverse association with total vegetables, 
light green vegetables, and legumes was observed in overweight/obese subjects.265 One 
case-control study looked at nutrient intake from fruits, vegetables, and supplements in 
association with pancreatic cancer incidence, and found a significant inverse association  
in a dose-dependent manner for magnesium, potassium, selenium, alpha-carotene, beta-
carotene, beta-cryptoxanthin, lutein and zeaxanthin, niacin, total alpha-tocopherol, total 
vitamin A activity, vitamin B6, and vitamin C.266 
2.4.1.4 Carbohydrate intake, glycemic load (GL), glycemic index (GI), dietary 
fructose and sucrose 
GI is a value assigned to foods based on how slowly or quickly those foods cause 
blood glucose levels to increase, while dietary GL, which reflects both the quality and 
quantity of carbohydrates ingested, is the product of the dietary GI and total dietary 
carbohydrates.267 Fructose can increase postprandial plasma glucose levels, and can 
increase risk of insulin resistance, type-2 diabetes and obesity, which may lead to higher 
pancreatic cancer risk.268 Results from a recent cohort study meta-analysis including 10 
cohort studies searching up to 2011 September revealed a significant increased risk with 
fructose intake (RR= 1.22, 95% CI=1.08–1.37, I2 = 0% per 25 g/day increase) but did not 
find an association of pancreatic cancer with dietary GI, GL, total carbohydrates and 
sucrose.268 Significantly higher risk of pancreatic cancer was reported to be associated 
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with higher GL only in a large population-based case-control study conducted in 
Canada.269  In the MEC Study, pancreatic cancer risk increased with higher intakes of 
total sugars, fructose, and sucrose in overweight or obese participants (RR=1.46, 95% 
CI=0.95–2.25; P for trend =0.04), but the association was not significant in normal-
weight participants.270 CUP conducted a dose-response meta-analyses which included six 
studies on dietary fructose and pancreatic cancer incidence and results showed a 22% 
statistically significant increased risk for each 25g increased intake of fructose per day 
(RR=1.22, 95% CI=1.08-1.37) with no heterogeneity observed and no differences of the 
association were observed between men and women. The CUP found that there were no 
clear associations between other related exposures (total carbohydrate, sucrose and soft 
drinks) and pancreatic cancer risk. Although there was ample consistent evidence, and 
some evidence for a dose-response relationship, fructose comes from many sources 
making the evidence difficult to interpret, so CUP concluded that the evidence suggesting 
that foods and beverages containing fructose are a cause of pancreatic cancer is limited. 
Increased carbohydrate intake during adolescence (age 12-13) and midlife could increase 
pancreatic cancer risk in later life.271 In a recently published meta-analyses, dietary fiber 
intake was found to be inversely associated with pancreatic cancer in case-control studies 
but not in cohort studies.12    
2.4.1.5 Coffee  
There was substantial evidence consistent with low heterogeneity, showing no 
effect of coffee intake on the risk of pancreatic cancer. The CUP dose-response meta-
analysis of 13 cohort studies found an overall non-significant positive association 
between each one cup of coffee increase per day and pancreatic cancer (incidence and 
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mortality combined, RR=1.02, 95% CI=0.95-1.09). When stratifying pancreatic cancer 
outcomes, meta-analysis of three studies on mortality showed no association (RR=0.99, 
95% CI=0.76-1.28), and non-significant positive association for incidence (RR=1.03, 
95% CI =0.95-1.11). The CUP finding is generally consistent with the other published 
meta-analyses: the Harvard pooing project of 14 prospective cohort studies revealed a 
similar pooled RR for each 237g/d of coffee (RR=1.01, 95% CI=0.97-1.04, I2=38);272 an 
updated meta-analysis including 20 cohort studies published up to November 2015 
reported the summary RR of pancreatic cancer risk for the highest category of coffee 
intake compared to lowest category was 1.06 (95% CI= 0.94-1.20, I2 = 38.5%) after 
removing one study which caused largest heterogeneity.273 In a large prospective study 
including the largest number of pancreatic cancer cases to date (NIH-AARP study), no 
associations between total, caffeinated, or decaffeinated coffee intake and pancreatic 
cancer risk were observed. 274  
2.4.1.6 Alcohol  
Heavy alcohol consumption might increase pancreatic cancer risk by promoting 
the effects of other risk factors such as tobacco smoking. Heavy alcohol consumption 
may also alter metabolic pathways involved in the inflammatory response and 
carcinogenesis (i.e. increased production of reactive oxygen species resulting in oxidative 
DNA damage and other independent genetic and epigenetic effects).275,276 Furthermore, 
alcohol use is the single most common cause of pancreatitis (its attributable risk is 
approximately 40%).277  It is thought that ethanol metabolites, such as acetaldehyde, 
might be important carcinogens for pancreatic cancer. 275 The dose-response meta-
analyses for total alcoholic drinks and pancreatic cancer (incidence and mortality 
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combined) conducted by CUP found a nonlinear association with significant risk starting 
from consuming 17.6 or more drinks per week. When stratifying analysis by sex for 
incidence and mortality combined, there was no clear linear association in women 
(RR=1.00, 95% CI: 0.98-1.01), but in men there was a marginally significant increased 
risk (RR 1.01, 95% CI= 1.00-1.02). When alcohol (as ethanol) was examined alone, CUP 
dose-response meta-analysis showed a nonlinear association. The risk was significant for 
those consuming 53.4g ethanol or more a day. Results from a published pooled 
analyses278 with a total of 14 cohort studies and a meta-analysis279 on alcohol (as ethanol) 
and pancreatic cancer risk consistently showed that daily consumption of 30g of alcohol, 
or the equivalent of >3 glasses of any alcoholic beverage per day, is associated with a 
22% increased risk of  pancreatic cancer. A statistically significant increase was only 
observed among men consuming 45 or more grams of alcohol from liquor per day in the 
Pancreatic Cancer Cohort Consortium (PanScan).280 CUP concluded that the increased 
pancreatic cancer risk was limited to those consuming more than about 3 alcoholic drinks 
per day.  
2.4.2 Dietary patterns  
Eleven published studies have investigated the dietary patterns and pancreatic 
cancer relationship, among them five studies examined a priori dietary patterns (HEI-
2005,281 aMDS,282  MDS17 and DII38,39), and the other six studies focused on a posteriori 
dietary patterns.15,16,18-21 Among the five a priori dietary pattern studies, in general, better 
dietary quality was associated with lower pancreatic cancer risk. Results were significant 
for studies examining HEI-2005281 and MDS score17 as well as DII,38,39 but not 
significant when using aMDS282 as the exposure. In the NIH-AARP with 2,383 incident 
 41 
 
exocrine pancreatic cancer cases, Arem et al. found the top quintile of HEI-2005 score 
was associated with a 15% decreased risk of pancreatic cancer compared to the lowest 
quintile (HRQ5vsQ1=0.85, 95% CI=0.74 -0.97, P-trend=0.003) for the overall study 
population, and the association was significant in men but not in women.281 In another 
NIH-AARP investigation which used aMDS as criteria to calculate the dietary score and 
categorized it to healthy and unhealthy diet, healthy diet was found to be associated with 
8% reduction in pancreatic cancer risk compared to unhealthy diet (HR=0.92, 95% 
CI=0.81-1.05).282 Based on aggregated primary data from two Italian case-control 
studies, Bosetti et al. found a significant reduction in risk with increased MDS score 
[(hazard ratio (HR) for a unit increase=0.85, 95% CI =0.80–0.91)] with significant 
inverse associations observed in each case-control study. Two case-control studies using 
the DII to examine its association with pancreatic cancer risk found subjects in the 
highest quintile of DII scores had a 2.48-fold (OR=2.48, 95% CI=1.50-4.10, P 
trend=0.002)38 and a  2.54-fold (OR=2.54, 95% CI=1.87-3.46, P trend<0.001)39 elevated 
odds of pancreatic cancer compared to those in the first quintile.  
The other six a posteriori studies identified food groups/dietary patterns based on 
dietary data using statistical analysis method which included the RRR and principal 
component analysis (PCA); factor score was calculated and assigned to each subject for 
each food item. Nothlings et al. reported in the MEC study that a food group pattern score 
which was predictive of flavonol intake (quercetin, kaempferol, and myricetin) was 
associated with lower risk, although the result was not significant (HRQ5vsQ1=0.88, 95% 
CI=0.67-1.15, P-trend=0.14).19 Three studies looked at Western dietary patterns and 
pancreatic cancer relationships,18,20,21 and only one case-control study found a significant 
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positive association among men only (ORQ5vsQ1=2.4, 95% CI=1.3-4.2, P-trend=0.008). 
This study also found a significant inverse association of a prudent dietary pattern 
characterized by greater intake of vegetables, fruit, fish, poultry, whole grains, and low-
fat dairy and pancreatic cancer.21 Results from the other two studies with the Western 
dietary pattern did not support an association of  prudent or Western patterns with 
pancreatic cancer risk,18,20  but a significant positive association for prudent dietary 
pattern score among men was observed in the Health Professionals Follow-Up Study 
(HPFS).18  A population-based, case-control study conducted in Canada between 1994 
and 1997 found “fruit and vegetable” dietary pattern was inversely associated with 
pancreatic cancer risk for men only (OR Q4vsQ1=0.51, 95% CI=0.29–0.90, P-trend<0.01) 
and “drinker” dietary pattern derived from this study had no association with pancreatic 
cancer.20 In the Iowa Women’s Health Study, Maki Inoue-Choi et al. used PCA method 
to derive several food patterns (“high vegetable”, “low fat”, Mediterranean, “high fiber” 
and “high fruit” food patterns) but none of the food patterns was associated with 
pancreatic cancer risk in the study.15 Using the same PCA method, another Italian case-
control study found compared to the lowest quartile of score, the highest quartile of 
“animal product” pattern score and “starch rich” pattern score had 2.03 folds and 1.69 
folds increased risk of pancreatic cancer, respectively and an inverse association emerged 
for the “vitamins and fiber” pattern.16 
2.4.3 Smoking  
Tobacco is the most well-established risk factor for pancreatic cancer, and with 
alcohol, they are cofactors to increase risk.277 Studies have consistently confirmed the 
relationship between smoking and pancreatic cancer, with smokers having about 2-fold 
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excess risk compared with nonsmokers. This increased risk is smaller for pancreatic 
cancer than for lung cancer, which could be because pancreas has indirect exposure to 
tobacco carcinogens, though as in lung cancer, the risk is proportional to the duration and 
the intensity of smoking.277  Predictably, the deleterious effect of smoking on the 
pancreas is caused by the release of or formation of carcinogens from tobacco. Several 
genes mediate the degradation of tobacco carcinogens but little is known how they 
function to affect risk.277  In a comprehensive meta-analysis of 47 case-control and 35 
cohort studies, Iodice et al. concluded that the overall risk of pancreatic cancer for current 
and former cigarette smokers was, respectively, 1.74 (95% CI=1.61-1.87) and 1.20 (95% 
CI=1.11-1.29) compared to non-smokers. For former cigarette smokers, the risk remains 
elevated for a minimum of 10 years after cessation.283 This study also found a linear 
increased trend of pancreatic cancer risk with increasing intensity (cigarette smoked per 
day), duration and cumulative dose with 1% increased risk per pack-year.283  Data from 
12 case-control studies within the International Pancreatic Cancer Case-Control 
Consortium (PanC4),284 pooled analysis of 30 cohort studies from the Asia-Pacific 
region,285  a meta-analysis of three case-control and four cohort studies conducted in 
Japan286 and a pooled analysis from the Pancreatic Cohort Consortium287 confirmed the 
positive link, with a summary RR between 1.6 and 2.2 for current cigarette smokers and 
between 1.1 and 1.7 for former cigarette smokers, compared to non-smokers. There are 
several other forms of tobacco besides cigarette; the PanC4 study found cigar-only users 
increased pancreatic cancer risk by 60% (OR=1.6, 95% CI=1.2-2.3) compared with never 
tobacco users and had higher risk than cigarette-only smokers, but pipe-smoking and 
smokeless tobacco such as chewing tobacco and snuff did not appear to increase the 
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risk.288 Some evidence also indicated increased risk with increasing amounts of cigars 
smoked per day although no association with duration.288 The recent meta-analysis found 
that current pipe and/or cigar smokers had 47% elevated pancreatic cancer risk compared 
to non-smokers, however, the association was not significant for former pipe and/or cigar 
smokers.283 Exposure to environmental smoking (passive smoking) during childhood or 
adulthood at home did not appear to be associated with pancreatic cancer risk.289  
Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, with 
multiple sequence variants may be genetic modifiers for smoking-related pancreatic 
cancer.290  Risk more than 15 years after smoking cessation was similar to that for never 
smokers. Estimates of excess odds ratio per pack-year declined with increasing intensity, 
suggesting greater risk for total exposure delivered at lower intensity for longer duration 
than for higher intensity for shorter duration. This finding and the decline in risk 
after smoking cessation suggest that smoking has a late-stage effect.287  
2.4.4 Adult attained height  
    The number of cell divisions in fetal life and childhood, health and nutrition status 
in childhood, and age of sexual maturity which will largely determine the adult height 
play a role in affecting the hormonal microenvironment and circulating levels of growth 
factors, insulin, and estrogens. Thus, taller adults are more likely to have error during 
DNA replication, which may result in cancer development.291 CUP identified 14 studies 
which examined the adult height and pancreatic cancer association, and the result was 
generally consistent with eight of 10 studies on incidence showing an increased risk 
(three of which were statistically significant) and one study on mortality showing a non-
significant increased risk when comparing the highest versus lowest groups. The CUP 
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meta-analysis showed a 7% statistically significant increased risk (incidence and 
mortality combined) per 5cm (RR=1.07, 95% CI=1.03-1.12) with considerable 
heterogeneity observed, which was consistent with the finding from most recent 
published meta-analysis including 12 cohort studies, showing the pooled RR per 5-cm 
increase in height was 1.07 (95 % CI=1.03-1.12, I2 =57%) and the association was 
similar among men and women.292   
2.4.5 Body fatness/obesity and physical activity  
There is an established connection between increasing BMI or body fatness and 
insulin resistance, which in turn increase pancreatic cancer risk via hyperinsulinemia.293 
Body fat also directly affects levels of a number of hormones and growth factors, such as 
insulin, insulin-like growth factor 1 (IGF-1), leptin, and estrogens, creating an 
environment that encourages carcinogenesis and discourages apoptosis.294 In addition, fat 
cell produces pro-inflammatory factors, which may contribute to the development of 
several cancers.295 Body fat is usually reflected by BMI, measures of abdominal girth 
such as waist circumstance and waist to hip ratio (WHR), and weight gain. For both 
pancreatic cancer incidence and mortality, CUP found a 10% statistically significant 
increased risk per 5 BMI units (RR=1.10, 95% CI=1.07-1.14 for incidence and RR=1.10, 
95% CI=1.02-1.19 for mortality) with lower between-study heterogeneity (I2=23%) and 
no difference between men and women in the dose-response meta-analysis. There was 
evidence of a nonlinear dose-response with an increased risk apparent for BMI of 25 
kg/m2 or higher. CUP findings on pancreatic cancer incidence are generally consistent 
with three large published pooled studies and a recent meta-analysis. The Harvard 
pooling project reported a linear increased trend of pancreatic cancer risk for each 5 BMI 
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units (RR=1.14, 95% CI=1.07–1.21), and reported a positive association for pancreatic 
cancer with higher BMI in early adulthood, and with greater than 10 kg/m2  BMI gain 
between early adulthood and baseline compared to individuals whose BMI remained 
stable.296 National Cancer Institute’s pooled analysis found that every 5kg/m2 increment 
of BMI was associated with a 1.08-fold increased pancreatic cancer risk for all 
participants, but the association was only significant for women, and only significant 
among never and former smokers, but not among current smokers.297 The PanScan 
pooling study reported pancreatic cancer risk increased by 13% for each 5 unit BMI 
increase (OR=1.13, 95% CI=1.11-1.14).298 The recent meta-analysis on BMI and PanC 
risk found a non-linear association between BMI and pancreatic cancer risk, with the 
lowest risk among persons with a BMI around 21 kg/m2 and with the most pronounced 
risk among persons with a BMI>35 kg/m2, however, among nonsmokers, there was a 
linearly increased risk.299 Data from the NIH-AARP study on lifetime adiposity and 
pancreatic cancer risk reported a higher risk for those being overweight or obese at ages 
18, 35, 50, or >50 years (baseline BMI) compared to normal weight. A longer duration 
of BMI>25 kg/m2 was significantly associated with pancreatic cancer risk, with 
individuals who reported diabetes having the greatest risk. They also found that a 
substantial gain in adiposity (>10 kg/m2) after age 50 years old was significantly 
associated with increased pancreatic cancer risk.300 A recently published pooled analysis 
with data combined from 20 prospective cohort studies which focused on pancreatic 
cancer mortality showed higher BMI during early adulthood (ages 18-21 
years) (HR=1.18, 95% CI=1.11-1.25 per 5 kg/m2) and  BMI gain after early adulthood 
(HR=1.05, 95% CI=1.01–1.10 per 5 kg/m2) was associated with increased mortality 
 47 
 
risk.301  
Five studies included in the CUP all found a non-significant increased pancreatic 
cancer incidence for highest waist circumference versus lowest category, and meta-
analysis using these five studies showed an 11% statistically significant increased risk per 
10cm waist circumference increase (RR=1.11,95% CI=1.05-1.18) with no heterogeneity. 
In a stratified analysis, the effect was statistically significant in women, but not in men. 
The CUP findings were consistent with findings from two published pooling 
studies.296,298 Higher waist circumference was also reported to be associated with 
increased pancreatic cancer mortality in a recent pooled analysis of 20 cohort studies 
(HR=1.07, 95% CI=1.00–1.14 per 10 cm).301  
Higher WHR was consistently associated with increased pancreatic cancer 
incidence and mortality.298,299,301 The CUP reported a 19% statistically significant 
increased risk of pancreatic cancer for each 0.1unit increase of the ratio. Others have 
suggested that overweight and obese individuals develop pancreatic cancer at a younger 
age than do patients with a normal weight, and that they also have lower survival rate 
once pancreatic cancer is diagnosed.302 Given ample and consistent evidence for the 
positive association between various measures of body fatness and pancreatic cancer 
incidence and mortality, the CUP concluded that the evidence that greater body fatness, 
including abdominal fatness and adult weight gain, was a cause of pancreatic cancer is 
convincing. 
    Physical activity can play a preventive role in pancreatic cancer development by 
regulating body weight and reducing insulin resistance, DNA damage, and chronic 
inflammation.303 In a recent meta-analysis comprising 30 studies with 10,501 pancreatic 
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cancer cases, results from cohort studies were homogeneous and indicated a weak, 
statistically significant inverse association between high versus low levels of total PA and 
pancreatic cancer (incidence and mortality combined, RR= 0.93, 95 % CI=0.88–0.98). 
Sub-analysis in the cohort studies showed that the protective effect appeared to be more 
pronounced for consistent PA over time (PA maintained for more than 10 years) (RR= 
0.86, 95% CI= 0.76–0.97) than for recent past PA (up to 3 years before baseline) or 
distant past PA (>=3 years prior to baseline). Occupational PA in the cohort studies had 
statistically significant inverse association with pancreatic cancer risk and appeared to 
generate a stronger risk reduction than did recreational activity, and that risk reduction 
was driven mainly by consistent activity over time. Stratified analysis on PA intensity 
showed null association for vigorous intensity, moderate intensity and low intensity PA 
in both case-control and cohort studies. The association was not modified by smoking 
status or BMI.303  Another meta-analysis examining leisure time PA and pancreatic 
cancer yielded a summary 11% significant reduction in risk comparing highest to lowest 
category, but the pooled association was only significant in case-control studies. They 
also found leisure time PA appeared to have the strongest effect among young 
populations.304  
2.4.6 Past medical history  
Several medical conditions are associated with pancreatic cancer risk, among 
them, diabetes has been investigated in the largest number of studies. Diabetes was 
associated with pancreatic cancer at the onset of symptoms in about 40 to 60% of 
patients, being a consequence or the cause of the disease, which is not fully known.305 
Five recent pooled analyses40,41,306-308 have concordant findings, showing that diabetics 
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had 40% to 90% increased pancreatic cancer risk compared to non-diabetics, and the RR 
decreased with duration of diabetes, but a significant excess risk was still evident 10 
years after diabetes diagnosis. Among diabetics, risk was higher in insulin ever users 
compared with nonusers, and insulin use of >10 years was associated with a reduced risk 
of pancreatic cancer (OR=0.5, 95% CI=0.3-0.9, P-trend< 0.001).40 Even in the absence of 
diabetes mellitus, higher fasting blood sugar and blood glucose or impaired glucose 
tolerance are associated with higher pancreatic cancer risk.285,309,310   
  The lag period between diagnosis of chronic pancreatitis and pancreatic cancer is 
usually one or two decades, whereas pancreatitis occurring a year or two before the 
diagnosis of pancreatic cancer is often because of tumor-related ductal obstruction.311 A 
comprehensive meta-analysis of 22 studies reported a statistically significant increase of 
pancreatic cancer risk associated with all types of pancreatitis, with summary RRs 
ranging from 5.1 for unspecified pancreatitis to 100 for tropical pancreatitis.311,312 Results 
from a pooled analysis of 10 case-control studies revealed ORs ranging from 3.4 (for an 
interval >25 years) to 21 (for an interval between pancreatitis and pancreatic cancer 
≤1 year) which probably reflected a combination of reverse causation and antecedent 
misdiagnosis of pancreas cancer as pancreatitis. The younger (<65 years) pancreatic 
cancer cases showed stronger associations with previous (>2 years) pancreatitis than the 
older (≥65 years) cases. 313 
Individuals with a history of gallstones and cholecystectomy were at 70% and 
31% increased risk of pancreatic cancer, respectively, reported by a recent meta-
analysis.314 The positive associations were observed among both Asian population and 
Whites.314  Diagnosis of gastric or duodenal ulcer within 2 years before pancreatic cancer 
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diagnosis increased cancer risk for 2.43 folds, but the significant positive association 
disappeared when ulcer duration persisted more than 2 years. Similarly, individuals with 
history of gastrectomy were at elevated pancreatic cancer risk but the excess risk was 
only limited to a gastrectomy within 2 years before cancer diagnosis. The increased risk 
for short-term history of ulcer and gastrectomy suggested that such association was due 
to reverse causality (i.e., underlying diseases) or increased cancer surveillance.315,316 No 
overall association was observed between Helicobacter pylori infection and risk 
of pancreatic cancer, but cytotoxin-associated gene A (CagA)-negative nonvirulent 
strains of Helicobacter pylori has been shown to increase pancreatic cancer risk, with 
findings confirmed in three recent published meta-analyses.317-319 
A positive association between periodontal disease (PD) and pancreatic cancer 
was reported in most studies performed on this topic.320 In a recent large cohort study in 
Taiwan, PD was found to be a risk factor for pancreatic cancer (HR=1.55, 95% CI=1.02-
2.33) independent of other comorbidities such as diabetes, and this positive association 
occurred predominantly among those aged 65 years or older.321  
      Venous thromboembolic events (VTE) was found to be associated with increased 
risk of pancreatic cancer in a meta-analysis comprising 12 studies but with significant 
between-study heterogeneity (RR= 6.1, 95%CI=3.8–9.7, P-heterogeneity<0.001).322 
Using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data of 
1.2 million cancer cases and 200,000 controls (66-99 years old, 1992-2005), Marks et al. 
found that VTE has been associated with an increased risk of pancreatic cancer among 
US elderly adults  (OR=1.53, 95% CI=1.43-1.64), with strongest risks observed within 1 
year of VTE diagnosis, but risks were still elevated more than 6 years after VTE.323 There 
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was consistent evidence showing that history of allergy, especially allergy to animal or 
allergy related to atopy and hay fever, reduced pancreatic cancer risk by 20–40%, based 
on evidence from PanScan pooling analysis324 and a meta-analysis.325  
       Finally, recent meta-analyses summarized the association with hepatitis B virus 
(HBV) infection.326-330  These reviews consistently reported a significant positive 
association between exposure to HBV infection and pancreatic cancer, but past exposure 
to HBV with natural immunity (anti-HB surface antibody positive) was not related 
to pancreatic cancer development, nor was the HBV active replication (hepatitis B e 
antigen positive status).329 Therefore, it is still unclear whether serological pattern of past 
exposure to HBV with or without natural immunity is associated with an enhanced risk of 
this malignancy. Results from two meta-analyses suggest a positive association between 
hepatitis C virus infection and pancreatic cancer risk328,329 but the same uncertainty as the 
HBV serological pattern was present for HCV.  
2.4.7 Demographic factors  
As for other cancers, less than 10% of pancreatic cancer cases occur at age 
younger than 55 years old, and the median age of onset is 71 years. In all race/ethnicity 
groups, men have higher incidence rates than women.277 Rates of pancreatic cancer are 
considerably higher in the African American population than in any other racial groups, 
although little is known about the reasons for the racial disparity.331 Males, Jewish 
descent and black ethnicity are associated with increased risk compared to their 
counterparts.332 No consistent relationship has been confirmed between development of 
the disease and socioeconomic status or immigration status. Finally, incidence rates of  
pancreatic cancer are highest in Western and industrialized countries and lowest in 
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underdeveloped nations.332 
2.4.8 Family history and genetic factors  
Several hereditary and genetic factors for pancreatic cancer have been identified. 
PanScan pooled analysis333 and a meta-analysis which included seven case-control and 
two cohort studies334 both observed that a family history of pancreatic cancer  in a parent, 
sibling or child was associated with about 80% increased risk of developing this 
malignancy. A family history of prostate cancer also was identified to increase pancreatic 
cancer risk (OR=1.45,95% CI=1.12–1.89).333  The ABO blood group has recently 
emerged as an important susceptibility factor for pancreatic cancer. Two recent meta-
analyses335,336 and a pooled PanScan analysis337 reported compared with blood type O, 
subjects with types A, AB, and B have a 23–53% increased risk of pancreatic cancer. In 
addition, compared with OO genotype, subjects with AO, AA, BO, BB genotypes 
significantly elevated the risk.337 Both inherited high-penetrant mutations in BRCA2, 
ATM, PALB2, BRCA1, STK11, CDKN2A and mismatch repair genes as well as low-
penetrant loci were associated with increased risk, and several previous genome-wide 
association study (GWAS) of pancreatic cancer with large numbers of cases and controls 
of European or North American populations revealed significant associations with single 
nucleotide polymorphisms (SNPs) at locations: 9q34.2(ABO)338, 13q22.1(KLF5)339, 
5p15.33 (TERT, CLPTM1)339,340, 13q12.2 (PDX1)340, 1q32.1(NR5A2)339, 7q32.3(LINC-
PINT)340, 16q23.1(BCAR1)340 and 22q12.1 (ZNRF3)340, 17q25.1 (LINC00673)341, 7p13 
(SUGCT)341, and 3q29 (TP63)341, 2p13.3 (ETAA1)341 , with odds ratio from 0.77 to 1.46.  
2.4.9 Drugs  
Many studies have assessed the effect of common drugs on pancreatic cancer, 
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such as NSAIDs (with most reports focusing on aspirin), statins and antidiabetic drugs 
such as metformin. Three most recent meta-analyses reported aspirin use was inversely 
associated with pancreatic cancer incidence,72,342,343 two of them found only high-dose 
aspirin use was associated with reduced pancreatic cancer,72,342only one study among 
them343 found risk decreased with increasing cumulative year of use of aspirin. Non-
aspirin NSAIDs was not associated with pancreatic cancer risk, supported by two meta-
analyses.72,342 A pooled analysis with eight clinical trials reported the latent period before 
a protective effect of daily aspirin use on pancreatic cancer death was about 5 years.238 
Statin use was not found to be associated with pancreatic cancer risk,344 while the 
association between metformin use and pancreatic cancer appeared to be inconsistent 345-
348 among diabetics. With regard to other anti-diabetic medications (ADMs), exogenous 
insulin use was investigated in many studies, with consistent findings that supported an 
increased pancreatic cancer risk with insulin use.40,346,349,350Although insulin, itself, can 
promote carcinogenesis either directly or indirectly by increasing insulin-like growth 
factor-1 activity, resulting in abnormal stimulation of multiple cellular signaling cascades 
and affecting cell metabolism,351 understanding the complex relationship between ADMs 
and pancreatic cancer risk is particularly difficult. Under a markedly diabetogenic state 
(normally found in pancreatic cancer patients), those with previously stable diabetes may 
experience worsening of their glycemic control and, hence, are more likely to require 
multiple ADMs, or require aggressive insulin therapy. The reverse causality, wherein the 
inherent nature of pancreatic cancer may have resulted in overestimation of the apparent 
carcinogenic effects of insulin, is difficult to measure.346 In a recent large prospective 
randomized trial, use of insulin glargine as compared with standard care was not 
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associated with an increased incidence of cancer, though pancreatic cancer was not 
independently evaluated in this study.352 
2.5 Summary of dietary factors and pancreatic cancer risk in the PLCO and 
NIH-AARP Studies 
     As reported above, several dietary factors have been examined with pancreatic 
cancer risk in the two prospective cohorts that are utilized in this dissertation (PLCO and 
NIH-AARP studies). Table 1 below summarizes the main findings with regard to 
associations between all dietary factors and pancreatic cancer identified from these two 
cohorts. Some dietary factors such as red meat which contained mostly pro-inflammatory 
components were associated with increased pancreatic cancer risk in the NIH-AARP,248 
whereas saturated fat was inversely associated with risk in the PLCO.256 Some anti-
inflammatory dietary factors such as fruits and vegetables were not associated with 
pancreatic cancer risk in the pooled cohort which included the PLCO .261 The different 
relationships between inflammation-modulated foods/nutrients and pancreatic cancer 
provide further justification for examining whole dietary patterns with regard to 
inflammation and pancreatic cancer risk in these two large, prospective cohort studies. 
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Table 2.1 Summary table for associations between dietary factors and pancreatic 
cancer in the PLCO and NIH-AARP 
 
Dietary 
factors 
PLCO NIH-AARP 
 Citation  Main findings Citation  Main findings 
Meat and 
associated 
products  
Anderson KE 
et al. (2012) 
Pancreatic 
cancer risk: 
associations 
with meat-
derived 
carcinogen 
intake in the 
Prostate, 
Lung, 
Colorectal, 
and Ovarian 
Cancer 
Screening 
Trial (PLCO) 
cohort. 
Molecular 
carcinogene45  
Pancreatic cancer 
risk comparing 
exposure Q5 vs 
Q1:  
Red meat intake 
with well to very 
well doneness 
level  
HR=1.6 (95%CI 
=1.01-2.54), P-
trend=0.04 
Red BBQ meat 
with well to very 
well doneness 
level  
HR=1.35 (95%CI 
=1.00-1.83) 
Mutagenic 
Activity Index 
(MAI)  
HR=1.87 
(95%CI=1.16, 
3.02), P-
trend=0.08 
Meat-derived 
mutagen 2-amino-
3,4,8-
trimethylimidazo[
4,5-f]quinoxaline 
(DiMeIQx)  
HR=1.81 
(95%CI=1.20, 
2.74), P-
trend=0.08 
Meat-derived 
mutagen 2-amino-
3,8-
dimethylimidazo[4
,5-f]quinoxaline 
(MeIQx) 
HR=1.75 
(95%CI=1.11, 
2.76), P-
trend=0.08  
Other mutagens 
including the 
benzo(a)pyrene 
Taunk P et al. 
(2016) Are 
meat and 
heme iron 
intake 
associated 
with 
pancreatic 
cancer? 
Results from 
the NIH-
AARP diet 
and health 
cohort. Int J 
Cancer248 
Pancreatic cancer risk 
comparing exposure Q5 vs 
Q1:  
Total meat 
HR = 1.20, 95%CI=1.02-
1.42, P-trend = 0.03 
Red meat 
 HR=1.22, 95%CI =1.01-
1.48, P- trend = 0.02 
High-temperature 
cooked meat  
HR=1.21, 95%CI=1.00-1.45, 
P-trend = 0.02  
Grilled/barbequed meat 
HR = 1.24, 95% CI=1.03-
1.50, P-trend = 0.007 
Well/very well done meat  
HR=1.32, 95% CI=1.10-
1.58, P-trend = 0.005 
Heme iron from red 
meat (Q4vsQ1) 
HR=1.21, 95% CI=1.01-
1.45, P- trend = 0.04 
 
All these significant 
associations above were 
observed among all 
population and among men 
only, but not among women.  
 
Meat types: White meat and 
processed meat were not 
associated with pancreatic 
cancer among all, but 
women had a significant 
association of white meat 
and pancreatic cancer  
HR=1.33, 95% CI=1.02-
1.74, P- trend =0.04 
 
Meat cooking methods: 
pan-fried meat, oven-broiled 
meat, sautéed, baked or 
microwaved meat were not 
risk factors for pancreatic 
cancer, but rare/medium 
done cooked meat was 
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(BaP) and one 
hydroxycitric acid 
[2-amino-1-
methyl-6-
phenylimidazo[4,5
-b]pyridine 
(PhIP)] were not 
associated with 
pancreatic cancer 
risk 
borderline associated with 
pancreatic cancer among all 
population 
 
Heme iron intake and meat-
derived mutagens were not 
found to be related to 
pancreatic cancer 
  Jiao L et al. 
(2015) 
Dietary 
consumption 
of advanced 
glycation end 
products and 
pancreatic 
cancer in the 
prospective 
NIH-AARP 
Diet and 
Health Study. 
Am J Clin 
Nutr249 
Pancreatic cancer risk 
comparing exposure Q5 vs 
Q1:  
Red meat 
Men: HR=1.35, 
95%CI=1.07-1.70, P-
trend=0.05  
Red meat cooked at high 
temperature 
Men: HR=1.29, 
95%CI=1.04-1.59, P 
trend=0.005 
Processed meat 
Men: HR=1.15, 95% 
CI=0.95-1.40, P trend=0.19 
N(ϵ)-(carboxymethyl)lysine 
(CML) Advanced glycation 
end products (AGEs):  
Men: HR=1.43, 95% 
CI=1.06-1.93, P trend = 
0.003  
Women: HR=1.14, 95% 
CI=0.76-1.72, P-trend = 0.42  
 
Meat consumption was not 
associated with risk of 
pancreatic cancer in women 
  Stolzenberg-
Solomon RZ 
et al. (2007) 
Meat and 
meat-
mutagen 
intake and 
pancreatic 
cancer risk in 
the NIH-
AARP 
cohort. 
Cancer 
epidemiology
, biomarkers 
Pancreatic cancer risk 
comparing exposure Q5 vs 
Q1:  
Total meat 
Men: HR=1.41, 
95%CI=1.08-1.83, P 
trend=0.001 
Red meat 
Men: HR=1.42, 
95%CI=1.05-1.91, P 
trend=0.01 
High-temperature 
cooked meat 
Men: HR=1.52, 
95%CI=1.12-2.06, P 
trend=0.005 
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& 
prevention353  
Grilled or barbecued meat 
Men: HR=1.46, 
95%CI=1.06-2.00, P 
trend=0.02 
Oven-broiled meat 
Men:HR=1.45 ,95%=1.12-
1.89, P trend=0.006 
Overall mutagenic activity 
(revertant colonies/1,000 
kcal) 
Men: HR=2.32,95%=1.52-
3.56, P trend=0.001 
Total DiMeIQx among all:  
HR=1.29 ,95%=1.01-1.64, P 
trend=0.006 
 
White meat and processed 
meat and other cooking 
methods and meat doneness 
were not associated with 
pancreatic cancer in men. No 
associations between meat 
and cooking methods among 
women were detected. 
 
  Aschebrook-
Kilfoy B et 
al. (2011) 
Pancreatic 
cancer and 
exposure to 
dietary nitrate 
and nitrite in 
the NIH-
AARP Diet 
and Health 
Study. 
American 
journal of 
epidemiology
250 
No association between total 
nitrate or nitrite intake 
and pancreatic cancer in men 
or women. 
 
Processed meat sources of 
dietary nitrate and nitrite  
Men: HR=1.18, 95% CI= 
0.95-1.47, P-trend=0.11  
Women: No association 
 
Nitrate/nitrite intake from 
processed meat at ages 12-
13 years  
Men: HR= 1.32, 95%CI= 
0.99-1.76; P-trend = 0.11 
Women: no association with 
adult or 
adolescent nitrate or nitrite i
ntake from processed meats 
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Fat and 
fatty acids  
Arem H et al 
(2013). 
Dietary fat 
intake and 
risk of 
pancreatic 
cancer in the 
Prostate, 
Lung, 
Colorectal 
and Ovarian 
Cancer 
Screening 
Trial. Annals 
of 
epidemiology
256 
Total fat  
HRQ5VSQ1=0.64, 
95% CI=0.39–
1.06, P-
trend=0.015 (<4 
years); 
HRQ5VSQ1=0.76, 
95% CI=0.51–
1.15, P-trend=0.35 
(>=4 years)  
 
Saturated fat 
intake  
HRQ5VSQ1=0.37, 
95% CI=0.21–
0.63, P-
trend<0.001 (<4 
years); 
HRQ5VSQ1=0.88, 
95% CI=0.58–
1.33, P-trend=0.49 
(>=4 years)  
 
Intakes of MUFA 
and PUFA and fats 
from animal or 
plant sources 
showed no 
associations with 
risk. Dietary 
changes due to 
undetected disease 
may explain the 
observed inverse 
associations 
Thiebaut AC 
et al. (2009) 
Dietary fatty 
acids and 
pancreatic 
cancer in the 
NIH-AARP 
diet and 
health study. 
J Natl Cancer 
Inst257 
Pancreatic cancer risk 
comparing exposure Q5 vs 
Q1:  
Total fat  
HR=1.23,95% CI=1.03-1.46, 
P-trend=0.03 
Saturated fat  
HR=1.36, 95%CI=1.14-1.62, 
P-trend<0.001  
Monounsaturated fat  
HR=1.22, 95%CI=1.02-1.46, 
P-trend=0.05 
Polyunsaturated fat 
HR=1.00, 95% CI=0.84-
1.18, P-trend=0.68  
food sources of fat:  
the positive association of 
total, saturated, and 
monounsaturated fat with 
pancreatic cancer was seen 
from food sources from 
animal foods 
(HR=1.23,1.19,1,22, 
respectively), especially red 
meat and dairy products and 
was not determined by 
vegetable food sources 
 
Individual fatty acids: 
Increased intake of two 
types of saturated fatty acids 
(palmitic acid and stearic 
acid), one MUFA-
Palmitoleic acid, one n-6 
PUFA-Arachidonic acid, and 
two n-3 PUFAs 
(Eicosapentaenoic acid, 
Docosahexaenoic acid) were 
associated with increased 
risk of pancreatic cancer 
with HR from 1.19 to 1.34.  
 
Total trans fatty acids:  
HR=0.99, 95% CI=0.83 to 
1.17, P-trend>0.99  
Carbohydr
ate intake, 
GL, GI, 
dietary 
fructose 
and 
sucrose 
Meinhold CL 
et al. (2010) 
Available 
carbohydrates
, glycemic 
load, and 
pancreatic 
cancer: is 
Pancreatic cancer 
risk comparing 
exposure 90th 
versus 10th 
percentile 
 
GL  
Jiao L et al. 
(2009) 
Glycemic 
index, 
carbohydrates
, glycemic 
load, and the 
risk of 
There were no associations 
between GI, total or 
available carbohydrates, GL, 
and pancreatic cancer risk.  
 
In terms of individual 
available carbohydrate 
constituents, only fructose 
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there a link? 
American 
journal of 
epidemiology
354 
HR=1.45, 95% 
CI=1.05-2.00 
GI  
HR=1.08, 95% 
CI=0.78-1.49 
Available 
carbohydrate 
HR=1.47, 95% 
CI=1.05-2.06 
Sucrose HR=1.37, 
95% CI= 0.99-
1.89  
 
GI and intakes of 
starch and fructose 
were not 
associated with 
pancreatic cancer.  
 
The positive 
association for 
available 
carbohydrate 
intake, glycemic 
load, sucrose, 
fructose, and 
inverse association 
with saturated fat, 
and total fat were 
strongest in the 
first 2 years and 
attenuated with 
subsequent follow-
up.  
pancreatic 
cancer in a 
prospective 
cohort study. 
Cancer 
epidemiology
, biomarkers 
& 
prevention355 
and glucose were associated 
with pancreatic cancer risk 
 
Free fructose 
HRQ5VSQ1=1.29, 95% 
CI=1.04-1.59, P trend=0.004 
Glucose (Q5 VS Q1) 
HRQ5VSQ1=1.35,95% 
CI=1.10-1.67, P trend=0.005 
 
  
Fruit and 
vegetable 
Koushik A et 
al. (2012) 
Intake of 
fruits and 
vegetables 
and risk of 
pancreatic 
cancer in a 
pooled 
analysis of 14 
cohort 
studies. 
American 
journal of 
epidemiology
261  
Pancreatic cancer 
risk comparing 
exposure of each  
100g/day 
increment in 
intake 
 
Total fruits and 
vegetables 
combined 
RR=1.01 (95% 
CI=0.99-1.03) 
Total vegetables  
RR=1.02 (95% 
CI=0.99-1.06) 
Total fruits  
RR=1.01 (95% 
CI=0.99-1.03) 
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Alcohol    Jiao L et al. 
(2009) 
Alcohol use 
and risk of 
pancreatic 
cancer: the 
NIH-AARP 
Diet and 
Health Study. 
American 
journal of 
epidemiology
356 
Total alcoholic drinks per 
day (>=6 drinks/day vs light 
drinkers who take 0-0.99 
drinks/ day)  
RR=1.55, 95% CI=1.13-
2.13, P-trend=0.004;  
Total alcoholic drinks >=3 
drinks/day vs 0-0.99 drinks/ 
day 
RR=1.45, 95% CI=1.17, 
1.80, P-trend = 0.002 
 
Liquor use (>=3 drinks/day 
vs >0-0.99 drinks/day) 
RR=1.62, 95% CI=1.24-
2.10, P trend=0.001 
 
Significant association 
between total alcohol and 
liquor drink was only 
observed among men not 
women.  
Beer or wine use was not 
associated with the risk.  
Coffee   Guertin KA 
et al. (2015) 
A prospective 
study of 
coffee intake 
and 
pancreatic 
cancer: 
results from 
the NIH-
AARP Diet 
and Health 
Study. Br J 
Cancer274 
 
No association between 
total, caffeinated, or 
decaffeinated coffee intake 
and pancreatic cancer, and 
the observed null association 
was consistent across all 
examined strata (sex, 
smoking status and prevalent 
diabetes)  
Dietary 
pattern  
  Arem H et al. 
(2013) The 
Healthy 
Eating Index 
2005 and risk 
for pancreatic 
cancer in the 
NIH-AARP 
study. J Natl 
Cancer Inst281 
  
 
Pancreatic cancer risk 
comparing exposure Q5 vs 
Q1:  
HEI-2005 
Men and women  
HR=0.85, 95% CI= 0.74-
0.97, P-trend=0.003  
Men and women had similar 
HR, but association was not 
statistically significant 
among women  
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Among men, P interaction 
by BMI=0.03 
HR=1.21, 95% CI=0.88 -
1.67, P-trend=0.23 (normal 
weight men 
HR= 0.72, 95% CI = 0.59-
0.88, P-trend<0.001 
(overweight/obese men) 
 
 
 
 
  
  Jiao L et al. 
(2009) A 
combined 
healthy 
lifestyle score 
and risk of 
pancreatic 
cancer in a 
large cohort 
study. 
Archives of 
internal 
medicine282 
Health diet quality vs. 
unhealthy diet quality (5–8 
points for aMDS excluding 
alcohol vs 0–4 points) 
HR=0.92, 95% CI=0.81-1.05 
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CHAPTER 3 
3  
METHODS 
3.1 Statement of research aims and hypotheses  
The overall aims of the dissertation were to examine the association between the 
inflammatory potential of diet measured by the DII and pancreatic risk in the PLCO and 
NIH-AARP cohorts, to assess effect measure modification by sex and inflammation-
related lifestyle factors including BMI, cigarette smoking, alcohol drinking, diabetes 
history and NSAIDs, as well as to investigate the mediated effect of type-2 diabetes in the 
association of E-DII and pancreatic cancer. Specifically, for Aim 1, we investigated if the 
inflammatory potential of diet impacted pancreatic cancer in the PLCO, and examined 
how sex and BMI modified the association. For Aim 2, we examined the association 
between E-DII and pancreatic cancer risk in the NIH-AARP, and examined effect 
modification by sex, BMI, smoking status, history of diabetes, alcohol drinking and 
NSAIDs use. With Aim 3, we conducted a causal mediation analysis to explore the 
mediated effect of type-2 diabetes in the association between E-DII to pancreatic cancer 
in the PLCO and NIH-AARP separately and in a pooled analysis after demonstrating that 
between-study heterogeneity was not significant.  
Our hypothesis was that greater inflammatory potential of diet would be 
associated with higher risk of pancreatic cancer in both studies, inflammation-related 
lifestyle conditions (overweight or obese individuals, individuals with previous smoking 
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history, high level of alcohol drinking, those who had presence of diabetes history, or less 
NSAIDs use frequency) could act jointly with E-DII to increase pancreatic cancer risk, 
and that type-2 diabetes mediated the E-DII and pancreatic cancer association (i.e., 
dietary inflammatory potential has indirect effect on pancreatic cancer through increasing 
risk of type-2 diabetes).  
3.2 Description of the study population  
3.2.1 Participants from PLCO Cancer Screening Trial   
PLCO is a large population-based randomized controlled trial with the aim to 
assess the effects of prostate, lung, colorectal and ovarian cancer screening tests on 
cancer-related mortality and secondary endpoints in men and women aged 55 to 74 years. 
A detailed description of the PLCO study design was published elsewhere.43 Briefly, a 
total of 154,897 eligible participants (76,682 men and 78,215 women), aged 55–74, were 
enrolled into the trial from 1993 to 2001 from ten screening centers across US and 
randomized based on sex and age group into either a control arm where usual care was 
received, or an intervention arm where screening exams for prostate, lung, colorectal or 
ovarian cancers were received. Participants included in the intervention arm received 
screening during their first 6 years in the trial: women had chest x-rays, flexible 
sigmoidoscopy, cancer antigen (CA)-125 blood tests, and transvaginal ultrasound and 
men received chest x-rays, flexible sigmoidoscopy, prostate-specific antigen (PSA) blood 
tests, and digital rectal exams and all the participants in the intervention arm were 
subsequently followed up for at least 7 additional years. The screening component of the 
trial was completed in 2006. Participants in the control arm were followed for 13 years 
after enrollment.44   
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Participants in PLCO were uncompensated volunteers recruited from the general 
population in the geographic area of each of the screening centers. They were excluded 
from the study if they met any of the following criteria44: (1) underwent cancer treatment 
at the time of randomization (excluding basal-cell and squamous-cell skin cancer); (2) 
had known prior cancer of the colon, rectum, lung, prostate (men only) or ovary (women 
only), including primary or metastatic PLCO cancers; (3) before October 1996, women 
with previous surgical removal of both ovaries were excluded from the trial, and 
beginning in October 1996, these women were not excluded; (4) participated in another 
cancer screening or cancer primary prevention trial; (5) males who had taken 
Proscar/Propecia/finasteride in the 6 months before randomization; (6) before April 1, 
1999, women were excluded from the trial if they currently took or had taken Tamoxifen 
or Evista\Raloxifene in the 6 months prior to randomization; after April 1, 1999, women 
who had been or currently took Tamoxifen or Evista\Raloxifene were not excluded; (7) 
males who had more than one PSA blood test in the three years prior to randomization; 
(8) individuals who had a colonoscopy, sigmoidoscopy, or barium enema in the three 
years prior to randomization; (9) individuals who were unwilling or unable to sign the 
informed consent form.  
In general, a majority of recruited participants were non-Hispanic white, married 
or living as married, had higher education level than some college, overweight at 
baseline, and above 85% of female participants were postmenopausal.45 A self-
administered baseline questionnaire, which included questions on demographic factors, 
medical history and health-related behaviors was collected from all subjects at the time of 
randomization. Dietary data were collected with the use of a self-administered FFQ, the 
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Diet History Questionnaire (DHQ), version 1.0 (National Cancer Institute, 2007), which 
was introduced to the intervention and control arms between 1998 and 2005.357 
Depending on the time a subject was recruited into study, only a small portion of subjects 
in the control arm completed DHQ at randomization while most subjects returned back 
the form at their third to five years after randomization.44 The DHQ queried frequency 
and portion size of 124 food items consumption during the past year.358 A supplemental 
questionnaire was introduced to all subjects in 2006 to update information that may have 
changed since completion of baseline questionnaire, which included medication use, 
demographic factors, and updated healthy history. The study was approved by the 
Institutional Review Boards of the National Cancer Institute and each of the centers that 
participated.  
3.2.2 Participants from NIH-AARP Diet and Health Study  
The NIH-AARP Diet and Health Study is the largest prospective cohort study of 
diet and health ever conducted in US and it was initiated in 1995 to 1996 when a baseline 
questionnaire asking information on demographic characteristics, medical history, dietary 
intake and health behaviors was mailed to 3.5 million AARP members with the goal to 
examine a number of important diet and cancer relationship hypotheses.359 The scientific 
rationale and study design of the cohort was described previously.46 The initial study 
population of this cohort was 617,119 females and males who responded to the baseline 
questionnaire with a response rate of 17.6%. Study exclusion criteria included: (1) 
responses on the questionnaire were not reliable (i.e., unknown sex, skipped everything, 
skipped facing page that provided personal information and date when they completed 
the questionnaire, deceased or proxy respondent, more than 10 recording errors and less 
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than 10 foods consumed); (2) respondents asked to be dropped from cohort; (3) died or 
moved before entry; (4) those with  duplicate representation of the questionnaire.46 
Participants in the NIH-AARP were 50 to 71 years old with mean age of 62 years at 
baseline and lived in one of six states (California, Florida, Pennsylvania, New Jersey, 
North Carolina, or Louisiana) or two metropolitan areas (Atlanta, Georgia or Detroit, 
Michigan).46 Participants were predominantly white, have higher education level and 
lower percentage of current smokers than the general US population.46,360 The self-
administered NCI-developed DHQ included in the baseline questionnaire assessed 
participants’ usual frequency of intake and portion size on 124 food items over the past 
year. It also included 21 additional questions on food choices and cooking practices, and 
four supplement intake questions.361 One year after the baseline questionnaire, a risk 
factor questionnaire was sent out in 1996 to 1997 to collect information of some common 
lifestyle or risk factors such as cooking practices in the past year, physical activity, family 
history of cancer, diet habit during young adulthood and other health behaviors. In 2004, 
a follow-up questionnaire was sent out to members to record their cancer status and other 
non-cancer endpoints as well as update medical use and other demographic 
information.359 The study was approved by the National Cancer Institute Special Studies 
Institutional Review Board.  
3.3 Diet assessment  
3.3.1 Diet data from PCLO and NIH-AARP  
The main exposure variable in this dissertation was the derived E-DII score 
calculated based on dietary responses from the DHQ in PLCO and NIH-AARP (both 
studies employed the NCI-developed DHQ but with different templates) with linkage to 
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the corresponding inflammatory effect score designated in the DII. The DHQ in both 
studies was used to assess the frequency and portion size of 124 food items during the 
past year among cohort participants. Participants in both studies were asked to choose 
from 10 frequency categories ranging from “never” to “>=6 times/d” for beverages, from 
“never” to “>=2 times/d” for solid foods and three categories of portion sizes.362,363 In the 
PLCO DHQ, from one to seven additional embedded questions are asked about related 
factors such as seasonal intake, food type (e.g., low fat, fat-free, lean, caffeine free), 
and/or fat uses or other additions use on 44 out of the 124 foods.362 Daily nutrient intake 
was calculated by the DietCalc software, which links responses of food frequency, 
portion size, and other relevant responses from the DHQ with a nutrient database based 
on national dietary data (USDA's 1994-96 Continuing Survey of Food Intakes by 
Individuals and supplemented by the Nutrition Data Systems for Research from the 
University of Minnesota).364 Three studies were conducted to evaluate the PLCO DHQ’s 
measurement performance. The first study used a checklist and showed that most of the 
cognitive improvements incorporated in the PLCO DHQ resulted in better measure of 
frequency than was 1992 NCI Block questionnaire.365 The second validation, which 
compared the DHQ to two widely used FFQs (the 1995 Block FFQ and the Willett FFQ), 
showed the DHQ performed best overall among the three instruments for estimating 
absolute intake of most nutrients.363 However, the third validation study, the Observing 
Protein and Energy Nutrition (OPEN) study, which compared intake of energy and 
protein estimated based on the DHQ with unbiased biomarkers, doubly labeled water for 
energy and urinary nitrogen for protein among 484 healthy adult men and women living 
in Maryland, suggested significant underreporting by both men and women for protein 
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and total energy366 and measurement error on the DHQ which may lead to severe 
attenuation in estimated disease relative risks.367 We obtained diet data of 35 food 
parameters out of the 45 food parameters in the DII from PLCO to calculate the E-DII 
score for each individual, which included alcohol, vitamin B12, vitamin B6, beta-
carotene, caffeine , carbohydrate , cholesterol, food energy, total fat, total dietary fiber, 
folate , iron, magnesium, monounsaturated fatty acids,  poly-unsaturated fatty acids, 
niacin, onions, protein, riboflavin, saturated fatty acids, selenium, thiamin, total trans-
fatty acids, vitamin A, vitamin C, vitamin E , vitamin D,  zinc, tea, flavan-3-ols, flavones, 
flavonones, anthocyanidin, isoflavone , and peppers.  
The DHQ used in the NIH-AARP allowed for variation in eating patterns in 
different parts of the country because it contained some regional and ethnic group-
specific foods. To assess relative validity and reliability, the baseline DHQ was compared 
to two nonconsecutive 24-hour dietary recalls (randomly assigned by day of the week 
with a median of 21 days apart) and a second FFQ among 1,415 participants who 
responded to baseline DHQ in the NIH-AARP. After adjusting for random within-person 
error, the energy-adjusted correlation coefficient ranged from 0.40 (vitamin E) to 0.76 
(saturated fat) among men, and from 0.36 (vitamin E) to 0.70 (vitamin B6) among 
women.361 NIH-AARP study respondents were found to consume less fat and red meat 
but more fruits and vegetables than comparably aged general US adults.353 Responses 
from the DHQ were linked to the US Department of Agriculture’s (USDA) Continuing 
Survey of Food Intakes of Individuals (CSFII) survey databases (1989–91 initially, and 
1994–96 as it became available), in order to estimate intake values of nutrients, foods, 
and food group intakes.364 Thirty-four out of the 45 food parameters were available in the 
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NIH-AARP dataset. These include the following: calories; carbohydrates; protein; total 
fat; saturated, monounsaturated, and polyunsaturated fat; trans-fat; alcohol; fiber; 
cholesterol; vitamins B1, B2, B6, B12, A, C, D, and E; niacin; iron; magnesium; zinc; 
selenium; folic acid; beta-carotene; anthocyanidins; flavan-3-ols; flavones; flavonones; 
isoflavones; caffeine; green peppers; and tea. To calculate flavonoid classes, DHQ-
derived daily fruits and vegetables intake in grams will be linked to the US Department 
of Agriculture (USDA)’s Database for Flavonoid Content from Selected Foods (Release 
3.1, December 2013) by matching foods with the USDA’s 5-digit nutrient database 
number. Once linked, the content levels of each flavonoid class will be applied to each 
fruit and vegetable in the DHQ and summed to provide a total value for each flavonoid 
class.34  
3.3.2 E-DII score calculation 
The DII is a literature-derived, population-based index used to measure individual’s diet 
in terms of inflammatory potential. The development22 and construct 
validation23,24,26,27,29,30,188 of the DII have been described previously. The goal in 
developing the DII was to create a score that could assess the overall quality of diet with 
regard to its inflammatory potential. A total of about 6,500 research articles published 
through December 2010 on the effect of dietary parameters on six well-established 
inflammatory markers (CRP, IL-1β, IL-4, IL-6, IL-10, TNF-α) were screened for 
inclusion in the DII scoring algorithm. CRP, IL-1β, IL-6 and TNF-α are considered pro-
inflammatory biomarkers while IL-4 and IL-10 are considered anti-inflammatory 
cytokines. A total of 1,943 research articles were reviewed and scored based on 45 pro- 
and anti-inflammatory food parameters identified in the search. One of three possible 
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values was assigned to each article based on the effect of the food parameter on 
inflammation: “+1” was assigned if the effects were pro-inflammatory (significantly 
increased IL-1 β, IL-6, TNFα, or CRP or decreased IL-4 or IL-10); “-1” if the effects 
were anti-inflammatory (significantly decreased IL-1β, IL-6, TNFα, or CRP or increased 
IL-4 or IL-10) and “0” if the food parameter had no relationship with the inflammatory 
marker. Sometimes, foods had differential effects in a study (have both anti-inflammatory 
and pro-inflammatory effects), then this article was scored separately, assigning ‘−1’ for 
its anti-inflammatory effect and ‘+1’ to the same article for its pro-inflammatory effect. 
Articles were first weighted by study design, with clinical trials receiving the highest 
weight and cell culture studies receiving the lowest weight. Using these weights, the pro- 
and anti-inflammatory fractions for each food parameter were calculated. The “food 
parameter-specific overall inflammatory effect score” was then calculated by: 1) dividing 
the weighted pro- and anti-inflammatory articles by total weighted number of articles and 
2) subtracting the anti-inflammatory fraction from the pro-inflammatory fraction. A cut 
point of 236, the median of the total weighted number of articles across all the food 
parameters, was chosen to indicate an optimally robust pool of literature. All food 
parameters with a weighted number of articles ≥236 were assigned the full value of the 
score which was regarded as the food parameter-specific raw inflammatory effect score. 
Foods and constituents with a weighted number of articles <236 were adjusted as 
follows: (1) number of weighted articles was divided by 236; (2) the fraction was then 
multiplied by the food parameter-specific raw inflammatory effect score.22 To avoid the 
arbitrariness as a result of simply using raw intake amounts, having consequence of 
different units of measurement for various nutrients which could exert large influences on 
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the overall score, the DII was standardized to a representative range of global dietary 
intake based on actual human consumption. This was accomplished by constructing a 
composite database representing a wide range of dietary intake consumed among 
populations living in countries in different regions in the world.22 Authors of articles 
reporting dietary data from nutrition surveys were contacted to request access to complete 
datasets. A total of 11 such datasets were identified and used in developing the composite 
worldwide dietary database with the detailed methods described in the reference.22 Thus, 
this representative world diet database provided an energy-adjusted mean intake and 
standard deviation for each food parameter as a reference to standardize the E-DII score. 
To calculate the overall E-DII score for each participant in a given study, dietary data 
from each study were first energy adjusted to take into account the difference in total 
energy intake and linked to the world composite database. By subtracting the standard 
global energy-adjusted mean from the energy-adjusted intake reported by the individual 
and dividing this value by its standard deviation, we obtained the multipliers to express 
an individual's exposure relative to the ‘global mean’ as a Z-score. To minimize the effect 
of “right skewing,” this value was converted to a percentile score. To achieve a 
symmetrical distribution with values centered on 0 (null) and bounded between -1 
(maximally anti-inflammatory) and 1 (maximally pro-inflammatory), each percentile 
score was doubled and then 1 was subtracted. The centered-percentile value for each food 
parameter was then multiplied by its respective food parameter-specific inflammatory 
effect score to obtain a food parameter-specific E-DII score. Finally, all of the food 
parameter-specific E-DII scores were summed to create the overall E-DII score for an 
individual.22 This approach both ‘anchors’ an individual's exposure to a robust range of 
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diet habits in a variety of countries and obviates completely the problem of non-
comparability of units because the Z-scores and percentiles are independent of the units 
of measurement (refer to Figure 3.1 for the E-DII score calculation flow chart). More 
positive scores represent a more pro-inflammatory diet, whereas more negative scores 
represent a more anti-inflammatory diet. When DII scores were calculated based on the 
composite global dietary database, the DII score was between +7.98 for maximally pro-
inflammatory diet, to −8.87 for the maximally anti-inflammatory diet and the median was 
+0.23.22 E-DII scores from food plus supplement were calculated as exposures in each 
cohort. The DII score, calculated from multiple different dietary assessment instruments, 
were found to be associated with higher levels of IL-6,24 TNF-α receptor 2,24 hsCRP23,27 
and homocysteine.25 
3.4 Covariates assessment 
Based on the comprehensive literature review about risk factors for pancreatic 
cancer stated in Chapter 2 and the directed acyclic graph (DAG) (Figure 3.2) which 
described the relationship among all the considered variables in the association between 
DII and pancreatic cancer, potential covariates to be included in both PLCO and NIH-
AARP studies were age at baseline (continuous), sex (male and female), race/ethnicity 
(Hispanic, Non-Hispanic Black, Non-Hispanic White, Others, missing), BMI 
(underweight, normal, overweight, obese, missing), alcohol consumption (continuous, 
grams/day), screening arm of PLCO (screening arm or control arm) , total energy intake 
(kcal/day, continuous), physical activity (never/rarely, 1–3times per month, 1–2times per 
week, 3–4times per week, or >=5times per week), past medical disease history including 
chronic pancreatitis, gallstone, cholecystectomy, gastric or duodenal ulcer, gastrectomy, 
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periodontal disease, venous thromboembolic events, HBV and HCV infection (yes or no), 
first-degree family history of pancreatic cancer  (yes/no), first-degree family history of 
prostate cancer (yes/no), cigarette smoking status (never smoker, former smoker, current 
smoker), pack-years of cigarette smoking (continuous), number of years of smoking 
cessation among former smokers since stopped smoking (1, 1–5, 5–10, or >10 years 
before baseline), ever used other tobacco products (yes or no), self-reported history of 
diabetes (yes or no), and NSAIDs use frequency (none,1-3times/month, 1-2times/week,3-
6 times/week, >=7 times/week). These covariates were all self-reported on baseline 
questionnaires in PLCO and NIH-AARP except that physical activity over the past year 
was not assessed at baseline in the PLCO but was assessed on the supplemental 
questionnaire and NSAIDs use information was collected from the risk factor 
questionnaire in the NIH-AARP. BMI was calculated as weight (kg)/height(m)2 and 
categorized based on the World Health Organization criteria.368  
3.5 Effect measure modifiers assessment  
Due to smaller case number in PLCO compared to NIH-AARP, in the NIH-
AARP, sex and inflammation-related lifestyle factors were examined as effect modifiers 
while sex, BMI, diabetes history and smoking status were examined as effect modifiers in 
the PLCO. As mentioned in section 3.5, these effect modifiers in both studies were all 
self-reported at baseline or close to baseline (NSAIDs use was assessed in the NIH-
AARP at one year after baseline). We categorized alcohol intake into high and low level 
by using 53.4g as the cut-off point in the interaction test in NIH-AARP given the 
evidence in the 2012 American Institute for Cancer Research (AICR) CUP report for 
pancreatic cancer that supported a nonlinear association between alcohol and pancreatic 
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cancer risk with increased risk observed among those consuming 53.4g alcohol or more a 
day.239 Based on previous evidence showing time may have a significant interaction with 
dietary factors in pancreatic cancer etiology using a cutoff of 4 years of follow-up, 256,354 
we also examined time (<4 and >=4 years) as effect modifier in both cohorts to be 
comparable to the two previous studies.    
3.6 Outcomes assessment  
  The outcome of interest for each aim was defined as incident adenocarcinoma of 
the exocrine pancreas: International Classification of Diseases for Oncology, Third 
Edition, codes C25.0-C25.3, C25.7- C25.9. In the PLCO, explicit diagnosis date with 
confirmed cancer status (rather than death) of incident exocrine pancreatic cancer was 
available, so we used this date as the outcome occurrence date. However, in the NIH-
AARP, they did not distinguish between pancreatic cancer death and incidence in the 
pancreatic cancer diagnosis status variable. Thus, pancreatic cancer date of death was 
compared to date of diagnosis to determine which subjects died of pancreatic cancer. A 
sensitivity analysis was conducted where date of pancreatic cancer diagnosis was 
imputed for those subjects who died from pancreatic cancer. Based on a literature review, 
the median survival time of exocrine pancreatic cancer after diagnosis is four months,369 
the value of date of diagnosis is the death date for pancreatic cancer minus four months, 
since the unit of time we used in the analysis was years, we did not impute the date of 
diagnosis using statistical method due to the very small values for the time variable. Our 
case definition in both studies excluded endocrine tumors (histology types 8150–8155, 
8240, 8246, and 8502) and some other rare histology types such as islet cell adenoma, 
carcinoid tumor, sarcoma because these types and exocrine pancreatic cancer may have 
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different disease mechanisms and etiology.370 In the PLCO, pancreatic cancer cases were 
ascertained through a mailed annual questionnaire in which subjects were asked if they 
had been diagnosed with cancer by a health care provider. They were then asked to 
provide information on the type of cancer.371 Additional sources for identification of 
pancreatic cases included state registries, death certificates, physician reports, and reports 
from next of kin (for deceased subjects).371 These cases were then confirmed by 
abstraction from medical records.371 We calculated the person-years of follow up for each 
individual from the date of DHQ to the date of first incident pancreatic cancer diagnosis, 
to censoring at the date of death, study withdrawal or the end of data collection for the 
study which was the first of either 13 years after randomization or 12/31/2009, whichever 
came first.44   
In the NIH-AARP, participants were followed up yearly by using the National 
Change of Address database (U.S. Postal Service) and MaxCoA (Anchor Computer Inc.). 
Approximately 4% of participants were lost to follow-up.249 Vital status was ascertained 
by annual linkage to the Social Security Administration Death Master File.249 Incident 
pancreatic cancer cases were identified by linkage to 11 state cancer registries (the 8 
original states where participants were recruited as well as Arizona, Nevada, and Texas), 
and mortality cases were identified by linkage to the National Death Index.249 Similar to 
PLCO, the person-years of follow up for each individual was calculated from the date of 
response to baseline questionnaire to the date of first incident exocrine pancreatic cancer 
diagnosis, or to censoring at the date of death, or move out from the study area, or the end 
of study which was December 31, 2011, whichever came first.    
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3.7 Statistical analysis      
3.7.1 Statistical methods for specific aim 1 and 2  
3.7.1.1 Primary aim analysis: relationship between E-DII and pancreatic cancer risk 
Among the eligible study population in each study, we further excluded participants with 
any cancer history at baseline and with extreme total energy intake and those with 
implausible BMI. E-DII score was adjusted for total energy intake using the energy 
density model372 and categorized to various quantiles (tertiles, quartiles, quintiles, and 
deciles) first to examine the trend. The decision of which quantile to use in final models 
was made based on the trend results and distribution of E-DII and case number in each 
category, as well as the result after examination of the proportional hazards assumption. 
In both studies, we categorized E-DII into quintiles, and the trend in other quantiles were 
similar with quintiles of E-DII. In the NIH-AARP, we treated E-DII as both a categorical 
and a continuous variable. The lowest E-DII category served as the referent group. 
Potential confounding variables in our analysis include those listed in section 3.5 above. 
Confounding variables were assessed using two methods: (1) 10% rule method where 
covariates were added to the crude model individually and ≥10% changes in the risk 
estimate for the highest compared to lowest E-DII quintile was regarded as confounding; 
(2) covariates which were both related to E-DII (categorical or continuous) and 
pancreatic cancer risk were regarded as confounders. Covariates determined to be 
confounders using either aforementioned method and effect modifiers were retained in 
the final multivariable-adjusted models. 249 We checked the Spearman rank correlation 
coefficient between each two continuous variables included in the final model to make 
sure there was no collinearity indicated by statistically significant large coefficient 
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(>=0.7) and P value<=0.05.373  Descriptive baseline demographic and lifestyle 
characteristics of the study population were generated, including means and standard 
errors (SE) for the continuous variables and frequencies and proportions for the 
categorical variables. Analysis of variance (ANOVA) was used to test the difference 
across E-DII quintiles for continuous variables, and Chi-square test was performed to test 
the difference for categorical variables. To estimate and compare the risk of pancreatic 
cancer by quintiles of E-DII score, multivariable Cox proportional hazards regression 
with person-year as the underlying time metric was fitted to estimate the age- and energy-
adjusted and multivariable-adjusted hazard ratios HRs and 95% CIs with subjects in the 
lowest E-DII quintile (the most anti-inflammatory score) as the referent. Proportional 
hazard (PH) assumption was examined using the Schoenfeld residual test.374 
Stratification or interaction of time and covariate was used for those covariates that did  
not meet the PH assumption. Linear trend test was performed by using the continuous E-
DII variable and in the multivariable-adjusted models. Continuous HR and 95% CIs also 
were calculated and reported for each one unit of standard deviation increase of E-DII 
score after the restricted cubic spline test indicated the linear assumption was sufficient in 
the NIH-AARP.375 In the NIH-AARP, we presented sex-specific E-DII and pancreatic 
cancer association given that men and women had different distributions of the E-DII 
score and other covariates, although the interaction by sex was not statistically  
significant.  
All data analyses were conducted using SAS statistical software (SAS Institute, 
Cary, NC). All statistical tests were two-sided, and P values less than 0.05 were 
considered as statistically significant.  
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3.7.1.2 Secondary aim analyses: effect modification examination 
Interaction tests were conducted to examine if the association between E-DII and 
pancreatic cancer risk was consistent among strata of variables including sex and BMI in 
the PLCO, and sex and inflammation-related lifestyle factors in the NIH-AARP. An 
interaction test was performed by including each interaction term (product of quintile E- 
DII score and categorical effect modifier) one at a time in the final multivariable-adjusted 
model and conducting -2 log likelihood ratio test. If any interaction was significant (P 
value from -2 log likelihood ratio test <=0.1),376 we stratified the effect modifier and 
reported the E-DII and pancreatic cancer association in each stratum of the effect 
modifier separately, otherwise, we only reported the combined result.   
3.7.1.3 Sensitivity analyses  
Several sensitivity analyses to examine the robustness of our results under 
different scenarios were conducted. In the first sensitivity analysis, we excluded 
participants with follow-up<5 years to avoid potential subclinical disease which may 
affect usual diet habit to result in reverse causality. A second sensitivity analysis was 
conducted to exclude all the participants who self-reported history of diabetes because 
there was evidence showing diabetes may be a preclinical indictor of pancreatic 
cancer.377 We also restricted the outcome to primary pancreatic cancer only, and in the 
NIH-AARP, we added pancreatic cancer death cases to both primary pancreatic cancer 
outcomes and the total incident outcomes using the imputed incidence time. We 
performed the main analysis and the interaction analyses described in section 3.7.1 in 
these sensitivity analyses.  
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3.7.2 Statistical methods for specific aim 3  
Based on the analytical cohort of PLCO and NIH-AARP, we further excluded 
participants who did not have valid supplemental questionnaire in PLCO or follow-up 
questionnaire in NIH-AARP, which contained follow-up data on diabetes, and those who 
had baseline diabetes, the remaining subjects constituted the mediation cohort for PLCO 
and NIH-AARP separately. Causal mediation analysis approach under the counterfactual 
framework was used to first assess the study-specific mediated effect of type-2 diabetes 
in the association between E-DII and pancreatic cancer.378 A SAS macro developed by 
Valeri and Vanderweele379 was used to calculate the study-specific mediation parameters: 
natural direct effect (NDE), natural indirect effect (NIE), and marginal total effect (MTE) 
of E-DII on pancreatic cancer risk with type-2 diabetes as a mediator. Briefly, mediation 
parameter estimates were obtained in three steps: 1) type-2 diabetes (mediator variable) 
was regressed on E-DII using the logistic regression with inclusion of the study-specific 
set of confounding variables except that diabetes history at baseline was removed; 2) 
pancreatic cancer was regressed on type-2 diabetes and E-DII with inclusion of the E-DII 
and type-2 diabetes interaction and the same set of confounders as in 1) using a logistic 
regression model, if the interaction was not statistically significant, it was then be 
removed from the model; 3) based on the specified comparison levels of exposure, 
parameters derived from these two logistic models gave way to essential mediator 
parameters through a series of mathematical calculations.379  
The incident follow-up type-2 diabetes data was retrieved from the supplemental 
questionnaire in the PLCO and from the follow-up questionnaire in the NIH-AARP. Both 
questionnaires asked participants whether they have been diagnosed with diabetes and the 
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timing when they were diagnosed (choices were several categories of years of diagnosis 
or age ranges at diagnosis). Because we excluded participants with baseline diabetes in 
the mediation analysis, the study-specific responses to the two above-mentioned diabetes 
questions could be used to identify incident diabetes that occurred during follow-up. The 
mediator subsequently was coded as a categorical variable with three levels: “yes”, “no” 
and “missing” using the following method: 1) if subjects answered they were never 
diagnosed with diabetes on the study-specific follow-up questionnaire, these subjects 
were assigned “no”; 2) if subjects reported they were ever diagnosed with diabetes, we 
further compared their ages at first diagnosis of diabetes using the median value of each 
category of the variable indicating diabetes occurrence time on the study-specific follow-
up questionnaires, with their ages at pancreatic cancer diagnosis, and coded mediator as 
“yes” if diabetes occurred before pancreatic cancer or no pancreatic cancer occurred, 
“no” if diabetes occurred after pancreatic cancer (because mediator as defined should 
occur before the occurrence of outcome of interest), or “missing ” if no information on 
age at first diagnosis of diabetes; and 3) if subjects did not report whether they were 
diagnosed with diabetes, these subjects were assigned “missing” as their mediator level. 
In the study-specific mediation analysis, we calculated the NDE, NIE, and MTE 
of E-DII on pancreatic cancer risk for subjects in each higher E-DII quintile (i.e., quintile 
2, quintile 3, quintile 4, quintile 5) compared to those in the lowest quintile with type-2 
diabetes as mediator. We also centered each E-DII value to the mean to report the 
mediation effect of a one-unit increase in centered E-DII on pancreatic cancer with type-2 
diabetes as mediator. The Z-score of E-DII was calculated by dividing the centered value 
by the standard deviation, and used in the mediation model to report the mediation effect 
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of type-2 diabetes on the association of one standardized unit increment of E-DII with 
pancreatic cancer risk. For all these mediation analysis, we also calculated the mediation 
proportion by type-2 diabetes using the equation as follows: proportion of mediation by 
type-2 diabetes= NDE x (NIE – 1)/ (NDE x NIE – 1) 
A random effects model was used to pool each study-specific mediation effect 
(i.e., NDE, NIE, MTE) on pancreatic cancer comparing each higher E-DII quintile to the 
lowest quintile, and the study-specific mediation effect on pancreatic cancer associated 
with each one unit increment of centered E-DII value and z-score of E-DII, across two 
studies. Between-studies heterogeneity was evaluated using the Q statistic 380,381 and I2 
statistic.382 If between-study heterogeneity was not significant, we combined primary data 
from two cohorts into one dataset by harmonizing categories for the categorical 
covariates which were shared in both studies as potential confounders and performed the 
mediation analyses as stated above in the pooled mediation cohort of PLCO and NIH-
AARP. We reassessed the confounders in the pooled cohort using the two methods as 
stated in the section 3.7.1.1 and used these confounders in the mediation analysis 
procedures.  
All statistical tests were two-sided and all data analyses were conducted using 
SAS statistical software (SAS Institute, Cary, NC).  
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Figure 3.1: Sequence of steps to calculate the energy-adjusted DII score in the 
PLCO Cancer Screening Trial and NIH-AARP Diet and Health Study. (Adapted from 
Shivappa, N., Steck SE, Hurley TG, Hussey JR, Hebert JR, Designing and Developing a 
Literature-derived, Population-based Dietary Inflammatory Index. Public Health Nutr, 2013: p. 1-
8.) Abbreviations: DII, dietary inflammatory index; PLCO, the Prostate, Lung, Colorectal and 
Ovarian; NIH-AARP, the National Institute of Health Association of Retired Persons 
 
 
1)1943 articles identified on 45 food 
parameters, reviewed and scored 
based on inflammation effect  
 
2) Weight articles by study design and 
calculate pro- and anti-inflammation 
fractions 
3) Adjust scores if total weighted 
articles are<236 
4) Calculate food parameter-specific 
overall inflammatory effect score 
 
7) Multiply centered percentile by the inflammatory 
effect score for each food parameter and sum across 
all 45 food parameters to obtain overall E-DII score  
5) Calculate energy-adjusted world 
mean and standard deviation for each 
of the 45 food parameters using the 
world composite database for 
45 food parameters based on diet 
data from 11 countries 
Energy-
adjusted 
dietary 
intake 
calculated 
from a 
given study 
6) Calculate z-scores and 
centered percentiles for each of the 
food parameters for each individual 
in the study, based on the energy-
adjusted dietary data and world 
mean and standard deviation. 
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Figure 3.2 DAG that describes the relationships of each covariate with exposure DII 
and with outcome pancreatic cancer in the PLCO Cancer Screening Trial and NIH-
AARP Diet and Health Study. Abbreviations: DAG, directed acyclic graph; DII, dietary 
inflammatory index; PLCO, the Prostate, Lung, Colorectal and Ovarian; NIH-AARP, the 
National Institute of Health Association of Retired Persons 
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4.1 Abstract  
Background: Inflammation plays a central role in pancreatic cancer etiology and 
can be modulated by diet. We aimed to examine the association between the 
inflammatory potential of diet, assessed with the Dietary Inflammatory Index (DIITM), 
and pancreatic cancer risk in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial prospective cohort. Methods: Our study included 101,449 participants 
aged 52 to 78 years at baseline who completed both baseline questionnaire and a diet 
history questionnaire. Energy-adjusted DII (E-DII) scores were computed based on food 
and supplement intake. Cox proportional hazards models were used to estimate hazard 
ratios (HRs) and 95% confidence intervals (CIs) with participants in the lowest E-DII 
quintile (most anti-inflammatory scores) as referent. Results: After a median 8.5 years of 
follow-up, 328 pancreatic cancer cases were identified. E-DII scores were not associated 
with pancreatic cancer risk in the multivariable model (HRQ5vsQ1 =0.99; 95% CI=0.69-
1.40; P-trend=0.31). Time significantly modified the association (P-interaction=0.02). 
Among subjects with follow up <4 years, there was an inverse association between E-DII 
and pancreatic cancer (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15) while there was 
a positive trend among those with ≥4 years of follow-up (HRQ5vsQ1 =1.36; 95% CI=0.85-
2.17; P-trend=0.03). Similar results were observed for E-DII from food only. 
Conclusion: Our study does not support an association between inflammatory potential 
of diet and pancreatic cancer risk; however, heterogeneous results were obtained with 
different follow-up times. Reverse causality owing to undetected disease may account for 
the inverse association observed in the first four years of follow-up.  
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4.2 Introduction  
Pancreatic cancer, the majority (~90%) of which is ductal adenocarcinoma of the 
exocrine pancreas, has the highest case-fatality rate of any major cancer.1,383 Despite low 
incidence, it is the fourth leading cause of cancer death among both men and women in 
the United States, with a 5-year relative survival rate of only 8% for all stages combined.1 
Although the etiology of pancreatic cancer is not fully understood, inflammation may 
play a pivotal role in the pathogenesis of this malignancy, as manifested by the fact that 
inflammatory states are etiologically linked to well-recognized risk factors for pancreatic 
cancer, including chronic pancreatitis, cigarette smoking, obesity, and diabetes.58,384  
Dietary factors could affect cancer risk through modulation of inflammation,385,386 
realized mainly by dietary impact on visceral obesity,387 oxidative damage78 and insulin 
resistance.387 Therefore, understanding the effect of dietary inflammatory potential on the 
development of pancreatic cancer may guide dietary intervention strategies aimed at the 
primary prevention of this lethal malignancy. A number of epidemiological studies have 
reported inconsistent results regarding the relationship between pancreatic cancer risk and 
inflammation-modulating nutrients or foods, such as fruits and vegetables and associated 
vitamins,388,389 fat and fatty acids,390  fiber,391 whole grains,392  and flavonols.393,394   
A typical human diet consists of both pro-inflammatory and anti-inflammatory 
foods and nutrients. Therefore, a dietary pattern approach, which takes into account the 
complex interactions among dietary components, has advantages over individual foods or 
nutrients when being studied for associations with disease risk.13 Assessing the overall 
inflammatory potential of the diet may provide better insight on the effect on pancreatic 
cancer risk than assessing only a select set of nutrients or individual foods. To date, two 
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case-control studies have used the DII to assess the association between dietary 
inflammatory potential and pancreatic cancer risk; both studies reported a significant >2-
fold increased risk in the most pro-inflammatory diet group.38,39 However, case-control 
studies are susceptible to recall and selection biases, which may distort the true 
associations.395 Therefore, a large prospective cohort study in which exposure 
information has been collected before the cancer diagnosis is advantageous for examining 
the role of diet in pancreatic cancer etiology. The objective of this study was to examine 
the association between inflammatory potential of diet, assessed using the DII, and 
pancreatic cancer risk with data from the PLCO Cancer Screening Trial prospective 
cohort.  
4.3 Materials and methods  
4.3.1 Study design  
The PLCO was a multi-center population-based randomized trial designed to 
assess effects of screening tests for prostate, lung, colorectal and ovarian cancers on 
mortality and secondary endpoints. Details of this study have been described elsewhere.43 
Briefly, between 1993 and 2001, a total of 154,897 eligible participants (76,682 men and 
78,215 women), aged 55–74 years, were enrolled into the trial from ten screening centers 
across the United States. Participants were randomized by sex and age group into a 
control arm, where usual medical care was received, or intervention arm where screening 
exams for PLCO cancers were received.44 PLCO eligibility criteria excluded a previous 
personal history of PLCO cancers, ongoing cancer treatment (excluding basal-cell and 
squamous-cell skin cancer), participation in another cancer screening or cancer primary 
prevention trial, and a recent screening test for prostate or colorectal cancer.43,358 
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Participants in the intervention arm received their screening tests during their first six 
years in the trial and were subsequently followed up for at least seven additional years; 
participants in the control arm also were followed for 13 years after enrollment.44  
4.3.2 Study population 
In our analyses, we further excluded 11,874 participants who had a cancer (except 
non-melanoma skin cancer) diagnosed before completing the DHQ; 4,920 participants 
who did not return baseline questionnaires; 36,268 participants who did not have valid 
DHQ responses (i.e., valid DHQ responses were defined as having DHQ completion 
date; alive at DHQ completion; <8 missing DHQ responses; and plausible caloric intake 
defined as within the sex-specific first and last percentiles of total energy); 220 
participants who reported  unreasonable BMI (i.e., BMI was considered unreasonable if 
one of  the followings occurred: weight<60 pounds; height<48 inches;  height>78 inches 
for females; height>84 inches for males; BMI<15 kg/m2)  and 166 participants without 
follow-up data. After these exclusions, the analytical cohort included 101,449 
participants (49,347 men and 52,102 women). The study was approved by the 
institutional review boards of the National Cancer Institute and each of the centers that 
participated. Informed consent was obtained from each eligible participant in the study.  
4.3.3 Dietary assessment 
Diet was assessed by a self-reported FFQ, the DHQ version 1.0 (National Cancer 
Institute, 2007), which was introduced in 1998 to both control and intervention arms 
within a median of three years after randomization in the trial.396 On the DHQ, 
participants reported their frequency of intake and portion size of 124 food items and 
supplement use over the previous year.396 Daily nutrient intake was calculated by the 
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DietCalc software, which links responses of food frequency, portion size, and other 
relevant responses from the DHQ with a nutrient database based on national dietary data 
(USDA's 1994-96 Continuing Survey of Food Intakes by Individuals and supplemented 
by the Nutrition Data Systems for Research from the University of Minnesota).364 The 
DHQ has been validated against four 24-hour dietary recalls (one in each season) among 
1,640 nationally representative participants in the Eating at America's Table Study where 
the energy-adjusted correlation coefficients for dietary factors ranged from 0.51 for 
vitamin E to 0.78 for magnesium among women and from 0.41 for sodium to 0.83 for 
thiamin among men.363 
4.3.4 Energy-adjusted DII score calculation  
The E-DII score for each participant was calculated based on the reported nutrient 
and food intake from the DHQ with linkage to the corresponding inflammatory effect 
scores designated in the DII.22 The DII is a literature-derived, population-based index 
designed to estimate the overall inflammatory potential of an individual’s diet. The 
details of the development of the DII have been published previously.22 Briefly, 1,943 
eligible peer-reviewed primary research articles published through 2010 on the effect of 
dietary factors on six inflammatory markers (IL-1β, IL-4, IL-6, IL-10, tumor necrosis 
TNF-α, and CRP) were identified and scored to derive the component-specific 
inflammatory effect scores for 45 dietary factors (i.e. components of DII), which 
comprised macronutrients, micronutrients and some foods or bioactive components such 
as spices and tea.22  
Ten DII components including ginger, turmeric, garlic, oregano, rosemary, 
eugenol, saffron, n-3 fatty acids, n-6 fatty acids and flavonols were not available from the 
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DHQ. Therefore, the remaining 35 components were used for E-DII score calculation in 
our analysis. The food and nutrient consumption estimated from the DHQ was first 
adjusted for total energy per 1000 calories to account for the difference in individual 
energy intake. To avoid the arbitrariness as a result of simply using raw intake amounts, 
the energy-adjusted dietary intake was subsequently standardized to a composite dietary 
database representing energy-adjusted dietary intake from 11 populations living in 
different countries across the world.22 The energy-adjusted standardized dietary intake 
was then multiplied by the literature-derived inflammatory effect score for each DII 
component, and summed across all components to obtain the overall E-DII score.22 
Higher E-DII scores represent more pro-inflammatory diets while lower (i.e., more 
negative) E-DII scores indicate more anti-inflammatory diets. The DII score has been 
construct-validated and found to be associated with higher levels of inflammatory 
biomarkers including IL-6,24 TNF-α receptor 2,24 and hsCRP.23 Because a majority of the 
partipants (79%) in the PLCO consumed supplements, and many dietary factors used in 
supplements have anti-inflammatory properties,397 we reported E-DII scores from food 
plus supplements and E-DII scores from food only as exposures to quantify the 
association between the inflammatory potential of diet, with and without supplements, in 
relation to pancreatic cancer risk.  
4.3.5 Assessment of other covariates  
Baseline characteristics, which included demographic information, personal 
medical history, family history, and health behaviors, were self-reported through the 
baseline questionnaire within three months of randomization in the PLCO. BMI was 
calculated as weight (kg)/height(m)2 and categorized based on the World Health 
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Organization criteria.368  Information on physical activity over the past year was not 
assessed at baseline, but was assessed on the supplemental questionnaire which was 
introduced at a median of nine years after randomization in the trial.    
4.3.6 Pancreatic cancer case ascertainment   
Incident pancreatic cancer cases were identified through an annual study update 
questionnaire in which participants reported if they had been diagnosed with any cancer 
by a healthcare provider, the type of cancer, date of diagnosis, and location of diagnosis. 
State registries, death certificates, and physician reports also were used as additional 
sources for identification of pancreatic cancer cases. All reports of pancreatic cancer were 
followed-up and medical records were abstracted and reviewed for case ascertainment. In 
this analysis, pancreatic cancer case was defined as primary incident adenocarcinoma of 
the exocrine pancreas (International Classification of Diseases for Oncology, Third 
Edition, codes C25.0-C25.3, C25.7- C25.9). Our case definition excluded  pancreatic 
endocrine tumors and other rare histology types of pancreatic cancer (histology type 
8150, 8154, 8240,8245, 8246, 8550) as etiology may differ,248,370 and we censored these 
types of pancreatic cancer at the date of diagnosis.  
4.4 Statistical analysis  
The baseline characteristics of the study population were presented by quintiles of 
E-DII from food plus supplements with cut-off points determined from the distribution of 
the entire cohort.  Means and SE for continuous variables and frequencies and 
percentages for categorical variables were calculated. Participants were followed up from 
the date of DHQ completion to the date of diagnosis of pancreatic cancer, death from any 
cause, study withdrawal, or the end date of study follow-up (the first of either 13 years 
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after randomization or 12/31/2009), whichever came first. Cox proportional hazards 
regression, with person-year as the underlying time metric, was used to estimate the HRs 
and 95% confidence intervals (CIs) for higher E-DII quintiles compared to the lowest E-
DII quintile (the most anti-inflammatory score) as referent. To test the linear trend of 
pancreatic cancer risk across E-DII score, a continuous E-DII variable was used. 
Variables were considered as confounders if they were associated with both pancreatic 
risk and E-DII (in either continuous or categorical format), or they changed the crude risk 
estimate by more than 10% in bivariate analyses. Although BMI did not meet these 
criteria, we included it as a confounder because BMI is an established risk factor for 
pancreatic cancer and is also related to diet.239 In the multivariable models, we adjusted 
for age at DHQ completion, sex (male or female), BMI (underweight, normal, 
overweight, obese, missing), pack-years categories within smoking status (never smoker, 
former smoker with<18 pack-years, former smoker with 18-41 pack-years, former 
smoker with >41 pack-years, current smoker with <18 pack-years, current smoker with 
18-41 pack-years, current smoker with >41 pack-years, missing), history of diabetes (yes, 
no, missing), and total energy intake (kcal/day).  The proportional hazards (PH) 
assumption was examined using the Schoenfeld residual test.374 There was no evidence 
that E-DII or any covariate violated the PH assumption. 
Effect modifications by sex, BMI, history of diabetes, smoking status were 
examined by adding the cross-product of each effect modifier with E-DII quintile in the 
multivariable-adjusted model with P value smaller or equal to 0.10 as an indicator of 
significant interaction.376 We also examined effect modification by follow-up time in our 
analysis given the possibility of latent pancreatic cancer affecting recent dietary intake.354 
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Previous PLCO analyses with diet and pancreatic cancer suggested significant time 
interaction with dietary fat and available carbohydrate using a cutoff of 4 years of follow-
up.256,354 Among the effect modifiers of interest, only follow-up time was found to be 
significant. Therefore, we performed the stratified analyses by two distinct time intervals, 
with cut-off point at 4 years of follow-up, to be comparable with the other PLCO 
analyses.256,354   
Two sensitivity analyses were performed. First, subjects who self-reported 
diabetes history at baseline were removed from analyses because diabetes may be a 
preclinical indictor of pancreatic cancer and diet modification may have occurred after 
diagnosis of diabetes.377,398 Secondly, as we excluded a large number of participants, we 
compared the demographic characteristics and pancreatic cancer risk factors between our 
included sample and excluded subjects to examine how results could have been affected 
by excluding these subjects in our analyses. 
Identical analyses, including sensitivity analyses, were performed for E-DII from 
food only in relation to pancreatic cancer risk. All statistical analyses were conducted 
using SAS® (version 9.4, Cary, NC). All tests were two-sided, with p values <0.05 
considered statistically significant unless otherwise noted. 
4.5 Results  
After a median of 8.5 years of follow-up, 328 incident pancreatic cancer cases 
occurred. E-DII scores from food and supplements ranged from -8.43 to 6.38. Compared 
to participants who had the most anti-inflammatory E-DII scores from food and 
supplement (i.e., E-DII quintile 1), participants consuming a more pro-inflammatory diet 
had higher BMI and who smoked more heavily at baseline, were younger at the time of 
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DHQ completion, consumed more alcohol and total calories, and were more likely to be 
male, Black non-Hispanic or Hispanic, current smokers,  have below-college education 
level, a family history of pancreatic cancer in a first-degree relative, and have a personal 
history of diabetes (Table 4.1).  
HRs for pancreatic cancer risk across E-DII quintiles from food plus supplement 
are presented in Table 4.2. After controlling for confounders, there was no significant 
association between E-DII scores and pancreatic cancer risk (HRQ5vsQ1 =0.99, 95% 
CI=0.69-1.40, P-trend=0.31). After excluding subjects with a history of diabetes at 
baseline (n=7,319), the multivariable-adjusted HRs changed only slightly.  
In stratified analyses by sex, BMI category, history of diabetes, smoking status, 
and follow-up time (<4 and >=4 years), only follow-up time had a statistically significant 
interaction with E-DII scores (P-interaction=0.02). Analyses stratified by follow-up time 
of <4 years and ≥4 years produced divergent results (Table 4.3). Among 8,977 
individuals with <4 years of follow-up, those consuming the most pro-inflammatory diets 
had a statistically significant 45% lower risk of pancreatic cancer compared with 
individuals with the most anti-inflammatory diets although the trend was not significant 
(multivariable HRQ5vsQ1 =0.55, 95% CI=0.32-0.95, P-trend=0.15). However, a significant 
positive trend was seen among individuals with follow-up time of ≥4 years, although the 
HR comparing two extreme quintiles was not statistically significant (multivariable 
HRQ5vsQ1 =1.36, 95% CI=0.85-2.17, P-trend=0.03). We performed the stratified 
association by follow-up time <4years and ≥4 years in the sensitivity analysis (i.e., 
excluding subjects with diabetes history), and the results did not change (data not shown).   
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Similar patterns of associations were observed when analyses were performed 
with E-DII from food only. In the multivariable analyses, E-DII from food only was not 
associated with pancreatic cancer risk and similar HRs were observed in the sensitivity 
analyses (Table 4.4). None of the covariates, except follow-up time, significantly 
modified the observed results (data not shown). A similar but nonsignificant association 
was observed for E-DII from food only among subjects with less than four years of 
follow up (HRQ5vsQ1=0.60, 95% CI=0.33-1.07, P-trend=0.30) and there was a borderline 
significant positive trend among those with longer follow-up (HRQ5vsQ1=1.28, 95% 
CI=0.80-2.06, P-trend=0.05) (Table 4.5).  
Compared to subjects included in analyses, excluded subjects tended to have less 
healthy behaviors or characteristics that are likely associated with increased risk of 
pancreatic cancer, including male, Black or Hispanic, heavier smoking, a more pro-
inflammatory diet, older age, diabetes history, lower education attainment (Table 4.6).  
4.6 Discussion  
This is the first prospective cohort study investigating the association between 
dietary quality with respect to inflammatory potential and pancreatic cancer risk. Overall, 
no association was found between inflammatory potential of diet and pancreatic cancer 
risk. However, there was significant effect modification by follow-up time. In the 
stratified analysis, we observed a significant increased trend of risk associated with a pro-
inflammatory diet among those with follow-up longer than four years, whereas evidence 
of risk reduction was seen among subjects diagnosed with pancreatic cancer in the first 
four years of follow-up. These divergent results may indicate the presence of reverse 
causality in the short-term, where decreases in dietary inflammatory potential may be a 
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consequence, rather than a cause, of pancreatic cancer or a well-known precursor 
condition, pancreatitis.399  We observed similar results for E-DII from food plus 
supplements and E-DII from food only. Because supplements may be the preferred 
choice for people with subclinical disease, this also may reflect issues of appetite control. 
Two case-control studies, with one conducted in the U.S.39 and the other in 
Italy,38 previously reported positive associations between E-DII scores from food and 
pancreatic cancer risk. Both studies found an approximate 2.5-fold increased risk of 
pancreatic cancer in the highest compared to the lowest quintile of the E-DII group (U.S.: 
ORQ5vsQ1 =2.54, 95% CI=1.87-3.46, P-trend<0.0001;39 Italy: ORQ5vsQ1=2.48, 95% 
CI=1.50-4.10, P-trend=0.00238). Evidence of effect modification by smoking status and 
BMI was documented in the Italian case-control study where a significant positive 
association was observed among never and past smokers but not among current smokers, 
and among normal and overweight rather than obese subjects, respectively.38 In the  U.S. 
case-control study using a joint effect approach, Antwi et al. demonstrated that dietary 
inflammatory potential may act synergistically with cigarette smoking and diabetes to 
increase the risk of pancreatic cancer beyond the risk of any of these factors alone.39 
Compared to these two case-control studies, a significant association was not observed in 
the PLCO and the magnitude of the association was much weaker, even after excluding 
the subjects who may have changed diet due to symptoms associated with latent 
pancreatic cancer in the early follow-up period. There are differences between the 
prospective cohort design we utilized and a case-control design which are important to 
note. Differential misclassification of exposure is minimized in a cohort design because 
exposure is measured before the outcome develops, but after the outcome has occurred in 
 97 
 
a case-control design, possibly resulting in differential recall. In addition, there may be 
biased selection of cases and controls in a case-control study which may induce selection 
bias and thus biased associations.400  
We did not observe evidence of effect modification in our study except for 
follow-up time which, as noted above, may reflect subclinical disease. Although many 
pancreatic cancer studies have performed lag time analysis by excluding subjects with 
short follow-up time in order to alleviate concerns about changes in diet driven by pre-
clinical symptoms of pancreatic cancer (or precursor conditions, especially pancreatitis), 
few studies have examined the time interaction with dietary exposure. Our study finding 
of significant time interaction with E-DII were consistent with two previous analyses of 
diet and pancreatic cancer in the PLCO cohort, of which both found time was the only 
significant effect modifier.256,354 In the study by Arem et al, higher total fat and saturated 
fat intake (both strongly pro-inflammatory) were associated with significant reduced 
pancreatic cancer risk among subjects with less than four years of follow-up, and 
associations became weaker and nonsignificant after excluding these subjects.256 In the 
other PLCO study examining dietary glycemic load and available carbohydrates as well 
as fat (also pro-inflammatory), the positive association of pancreatic cancer with 
glycemic load and available carbohydrate and inverse association with saturated fat were 
observed only in the first four years, but not subsequently.354 Pancreatic cancer patients 
may present with severe, though nonspecific symptoms such as impaired glucose control, 
fatigue, jaundice, abdominal pain, nausea, blunted appetite, and vomiting before actual 
diagnosis, which is usually at a late stage because there exists no accurate method for 
early detection.401 Thus, assessment of dietary intake in pancreatic cancer studies, which 
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typically query diet in the past 12 months, may capture disease-related diet changes (or 
those related to precursor conditions), rather than intake prior to cancer symptoms.354 In 
our study, subjects may choose to eat healthier or more anti-inflammatory food or less 
amount of total food (i.e., fewer calories) due to symptoms associated with latent diseases 
in the early time period, which resulted in lower E-DII scores. Although prospective 
studies are less susceptible to reverse causation bias, such bias can occur in prospective 
studies of pancreatic cancer, given the cancer's unknown latency and the fact that it and 
its precursor conditions have profound effects on digestion. Differences in associations 
by follow-up time should be considered in future prospective studies assessing dietary 
intake and pancreatic cancer. Unlike the previous PLCO studies on fat intake, we 
observed a significant positive trend among subjects with longer follow up. Differences 
in results between these investigations may be explained by the different exposure we 
used that measured the total inflammatory potential from multiple foods and nutrients 
rather than dietary intake of a single macronutrient.  
Five studies investigating a priori dietary patterns other than DII in relation to 
pancreatic cancer risk have been published, including variants of MDS,17,282,402 the HEI-
2005,48 and dietary total antioxidant capacity score.403 Results from these studies all 
suggested better diet quality, was associated with lower pancreatic cancer risk, with effect 
estimates ranging from 0.4417 to 0.92282  comparing the highest with the lowest dietary 
quality group. However, our study suggested a nonsignificant association with total 
inflammation potential of diet. The different findings may be, to some extent, explained 
by the differences in dietary patterns under study, the nature of FFQs, study design, study 
population, sample size, or timing from dietary data collection to diagnosis.   
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It is well-recognized that pro-inflammatory states foster a cellular environment 
that supports the development of genetic mutations and the initiation of pancreatic 
carcinogenesis.58 Inflammation associated with diet may contribute to pancreatic 
malignancy through the increased level of inflammatory cytokines (e.g., TNF-α; IL-6, IL-
8 and interferon-γ), reactive oxygen species and mediators in the inflammatory pathway 
(e.g., NF-кB and cyclooxygenase-2), leading to increased cell cycling, loss of tumor 
suppressor function, and stimulated oncogene expression, all of which may induce 
modifications of key cancer-related proteins, and ultimately, tumorigenesis.57,58  
  Major strengths of our study include its prospective cohort design, which 
conceptually minimizes the possibility of recall bias. The long follow-up in the PLCO 
cohort among a large study population allowed for an in-depth evaluation of effect 
modification by time from the DHQ to cancer diagnosis. Detailed information on a 
comprehensive list of covariates allowed for careful adjustment in the analyses. The E-
DII, a construct-validated tool which takes into account the whole diet instead of single 
nutrients or foods and is based on the entire literature on inflammation, provided a 
comprehensive assessment of dietary inflammatory potential. It has major advantages 
over other a priori dietary patterns as it was developed specifically to reflect diet’s effect 
on inflammation that plays a central role in pancreatic cancer etiology. In addition, the 
use of a validated FFQ which covered major foods and nutrients consumed by 
Americans, and application of majority of DII components to calculate the E-DII scores 
helped to create a large contrast of E-DII scores in this study population. This is the first 
study to investigate whether dietary inflammatory potential is associated with pancreatic 
cancer risk in a prospective manner. The significant time interaction identified in our 
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study and the inverse association between proinflammatory diet and pancreatic cancer 
within <4 years of follow up, confirmed the previous PLCO findings on diet and 
pancreatic cancer.  
This study also presents several limitations. First, it is likely the case number was 
not large enough in some stratified analyses so that we lacked statistical power to observe 
significant associations. Exclusion criteria resulted in exclusion of over 50,000 subjects, 
and differences were noted between excluded and included participants by various 
pancreatic cancer risk factors. This may have introduced selection bias and resulted in 
underestimation of the association. The FFQ is prone to response set bias, including 
social approval and social desirability, leading to measurement error in FFQ data as 
another unavoidable limitation, which may have resulted in some misclassification of the 
E-DII score.404Although follow-up data were available on most covariates, the large 
amount of missing information impeded our ability to use these data.  Evaluation of the 
E-DII at a single time point could result in non-differential misclassification of exposure 
given diet may change over time. However, we previously found DII scores were 
relatively stable over a long timeframe in postmenopausal women who were of 
comparable ages as ours.405 Another limitation of the study is that data were only 
available on 37 out of the 45 DII components used to calculate the E-DII scores; 
however, the range of DII scores may rely more on the amount of foods actually 
consumed rather than the number of available DII components.406 While we adjusted for 
important potential confounders, residual or unmeasured confounding  
cannot be ruled out.  
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4.7 Conclusion  
In conclusion, this study does not support an association between inflammatory 
potential of diet and pancreatic cancer risk in the PLCO cohort. However, time 
significantly modified the association. There was evidence of an inverse association 
between E-DII and pancreatic cancer in the first four years of follow up, suggesting 
dietary changes due to undiagnosed disease (or a precursor condition) might affect 
appetite and food choices to lower the E-DII scores in the early stage, while a positive 
association was suggested by a significant trend after excluding subjects with follow-up 
time <4years. Future prospective cohort studies assessing dietary factors and pancreatic 
cancer risk should consider differences in associations by follow-up time. Additional 
cohort studies with large number of cases are warranted to examine effect modification of 
E-DII and pancreatic cancer by important lifestyle risk factors.  
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Table 4.1 Baseline characteristics of 101,449 subjects in the PLCO Cancer 
Screening Trial cohort by quintiles of E-DII from food plus supplement 
 
 Most anti-
inflammatory 
diet  
   Most pro-
inflammatory 
diet  
 E-DII 
Quintile 1 
(-8.43, -5.32) 
E-DII 
Quintile 2 
(-5.31, -
4.26) 
E-DII 
Quintile 3 
(-4.25, -
3.03) 
E-DII 
Quintile 4 
(-3.02, - 
1.22) 
E-DII 
Quintile 5 
(-1.21, 6.38) 
N 20290 20290 20290 20290 20289 
 
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
Age at DHQ 
completion (y) 
65.8 (0.04) 65.8 (0.04) 65.6 (0.04) 65.5 (0.04) 64.9 (0.04) 
BMI at baseline 
(kg/m2)  
26.4 (0.03) 27.0 (0.03) 27.3 (0.03) 27.7 (0.03) 28.1 (0.03) 
Pack-years of 
cigarette at 
baseline 
13.5 (0.2) 14.8 (0.2) 16.5 (0.2) 19.5 (0.2) 25.0 (0.2) 
Alcohol 
consumption 
(g/d) 
8.2 (0.1) 7.1 (0.1) 7.7 (0.1) 9.9 (0.2) 14.8 (0.3) 
 N (%)a N (%)a N (%)a N (%)a N (%)a 
Sex       
Male  6476 (31.9) 7653 (37.7) 9505 (46.9) 11531 (56.8) 14182 (69.9) 
Female  13814 (68.1) 12637 
(62.3) 
10785 
(53.1) 
8759 (43.2) 6107 (30.1) 
Trial arm       
Intervention  10361 (51.1) 10253 
(50.5) 
10302 
(50.8) 
10460 (51.6) 10290 (50.7) 
Control  9929 (48.9) 10037 
(49.5) 
9988 (49.2) 9830 (48.4) 9999 (49.3) 
Race/ Ethnicity      
White non-
Hispanic 
18124 (89.3) 18413 
(90.8) 
18615 
(91.8) 
18655 (91.9) 18452 (91.0) 
Black non-
Hispanic  
525 (2.6) 618 (3.0) 674 (3.3) 651 (3.2) 873 (4.3) 
Hispanic 239 (1.2) 290 (1.4) 278 (1.4) 316 (1.6) 367 (1.8) 
Others 1402 (6.9) 969 (4.8) 723 (3.5) 668 (3.3) 597 (2.9) 
Education level       
High school or 
below 
4291 (21.1) 5328 (26.3) 5736 (28.3) 6471 (31.9) 7867 (38.8) 
Post high school 
training other 
than college   
2267 (11.2) 2554 (12.6) 2648 (13.1) 2760 (13.6) 2887 (14.2) 
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Some college 4482 (22.1) 4419 (21.8) 4466 (22.0) 4273 (21.0) 4112 (20.3) 
College 4134 (20.4) 3778 (18.6) 3564 (17.6) 3401 (16.8) 2922 (14.4) 
Postgraduate 5077 (25.0) 4154 (20.5) 3850 (19.0) 3349 (16.5) 2457 (12.1) 
Missing 39 (0.2) 57 (0.3) 26 (0.1) 36 (0.2) 44 (0.2) 
Smoking status 
at baseline 
     
Never smoked 10396 (51.2) 10357 
(51.0) 
10175 
(50.2) 
9357 (46.1) 8116 (40.0) 
Past smoker 8916 (44.0) 8667 (42.7) 8484 (41.8) 8822 (43.5) 8770 (43.2) 
Current smoker 978 (4.8) 1260 (6.2) 1627 (8.0) 2107 (10.4) 3399 (16.8) 
First-degree 
pancreatic 
cancer family 
history 
     
Yes  562 (2.8) 569 (2.8) 496 (2.4) 514 (2.5) 450 (2.2) 
No  19194 (94.6) 19134 
(94.3) 
19138 
(94.3) 
19044 (93.9) 18949 (93.4) 
Probable 389 (1.9) 431 (2.1) 516 (2.5) 560 (2.8) 724 (3.6) 
Missing  145 (0.7) 156 (0.8) 140 (0.7) 172 (0.9) 166 (0.8) 
History of 
diabetes 
     
Yes  1160 (5.7) 1313 (6.5) 1481 (7.3) 1532 (7.5) 1299 (6.4) 
No  19025 (93.8) 18869 
(93.0) 
18711 
(92.2) 
18631 (91.8) 18894 (93.1) 
Missing  105 (0.5) 108 (0.5) 98 (0.5) 127 (0.6) 96 (0.5) 
Abbreviations: SE, standard error  
 a Sum of percentages may not add up to 100% because of rounding or missing.   
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Table 4.2 Association between E-DII from food plus supplement and pancreatic 
cancer risk among 101,449 subjects in the PLCO Cancer Screening Trial cohort   
 
 Most anti-
inflammatory 
diet   
   Most pro-
inflammatory 
diet 
 
 E-DII  
Quintile 1 
(-8.43, -5.32) 
E-DII 
Quintile 
2 
(-5.31, -
4.26) 
E-DII 
Quintile 
3 
(-4.25, -
3.03) 
E-DII 
Quintile 
4 
(-3.02, - 
1.22) 
E-DII 
Quintile 5 
(-1.21, 6.38) 
P-
trenda 
Cases (n) 67 56 59 71 75  
Sample size 20290 20290 20290 20290 20289  
Age and 
energy- 
adjusted HR 
(95% CI) 
1.00 0.85 
(0.60-
1.22) 
0.92 
(0.65-
1.30) 
1.12 
(0.80-
1.57) 
1.25 (0.89-
1.76) 
0.01 
Multivariable-
adjusted HR 
(95% CI)b 
1.00 0.82 
(0.57-
1.17) 
0.83 
(0.58-
1.18) 
0.97 
(0.69-
1.36) 
0.99 (0.69-
1.40) 
0.31 
After excluding subjects with diabetes history at baseline 
Multivariable- 
adjusted HR 
(95% CI)c 
1.00 0.83 
(0.56-
1.23) 
0.93 
(0.64-
1.37) 
1.10 
(0.76-
1.59) 
1.07 (0.73-
1.56) 
0.18 
a Continuous DII score was used to determine P for trend 
b Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline 
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes, missing), packyears 
within smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 
18-41 pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current 
smoker with 18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d)  
c Model included 94,130 subjects and was adjusted for covariates listed in b.  
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Table 4.3 Stratified analyses of E-DII from food plus supplement and pancreatic 
cancer risk by follow-up time (i.e. <4 and >=4 years) among 101,449 subjects in the 
PLCO Cancer Screening Trial cohort  
 
 Most anti- 
inflammat
ory diet   
   Most pro-
inflammato
ry diet  
  
 E-DII  
Quintile 1 
(-8.43, -
5.32) 
E-DII 
Quintile 2 
(-5.31, -
4.26) 
E-DII 
Quintile 3 
(-4.25, -
3.03) 
E-DII 
Quintile 4 
(-3.02, - 
1.22) 
E-DII 
Quintile 5 
(-1.21, 
6.38) 
P-
trend
a 
P-
inter
actio
nb 
Participants with follow-up time<4 years 
Cases (n) 34 25 24 30 25  
Sample size 1539 1711 1768 1903 2056   
 
 
 
 
 
0.02 
 
Age and 
energy-
adjusted HR 
(95% CI) 
1.00 0.66 (0.40-
1.11) 
0.58 (0.34-
0.98) 
0.69 
(0.42-
1.13) 
0.58 (0.34-
0.98) 
0.16 
Multivariabl
e-adjusted 
HR (95% 
CI)c 
1.00 0.65 (0.39-
1.09) 
0.56 (0.33-
0.95) 
0.65 
(0.39-
1.09) 
0.55 (0.32-
0.95) 
0.15 
Participants with follow-up>=4 years 
Cases (n) 33 31 35 41 50  
Sample size 18757 18579 18522 18387 18233   
Age and 
energy- 
adjusted HR 
(95% CI) 
1.00 0.96 (0.59-
1.57) 
1.11 (0.69-
1.79) 
1.33 
(0.84-
2.10) 
1.70 (1.08-
2.67) 
0.001 
Multivariabl
e-adjusted 
HR (95% 
CI)c 
1.00 0.93 (0.57-
1.52) 
1.03 (0.64-
1.66) 
1.17 
(0.73-
1.87) 
1.36 (0.85-
2.17) 
  0.03 
a Continuous DII score was used to determine P for trend 
b  P-value for interaction was calculated by adding the cross-product of the E-DII quintiles and binary variable of time 
(<4 years and >=4 years) in the multivariable-adjusted model 
c Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline 
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes), packyears within 
smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 18-41 
pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current smoker with 
18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d) 
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Table 4.4 Association between E-DII from food only and pancreatic cancer risk 
among 101,449 subjects in the PLCO Cancer Screening Trial cohort  
 
 Most anti-
inflammatory 
diet 
   Most pro-
inflammatory 
diet 
 
 
P-
trenda  E-DII Q1 
(-7.58, -3.82) 
E-DII Q2 
(-3.81, -
2.60) 
E-DII Q3 
(-2.59, -
1.30) 
E-DII Q4 
(-1.29, 
0.37) 
E-DII Q5 
(0.38, 6.89) 
Cases (n) 64 52 65 78 69  
Sample size 20291 20289 20290 20289 20290  
Age and 
energy- 
adjusted HR 
(95% CI) 
1.00 0.82 (0.57-
1.19) 
1.06 (0.75-
1.49) 
1.32 (0.94-
1.84) 
1.22 (0.86-
1.73) 
0.009 
Multivariable-
adjusted HR 
(95% CI)b 
1.00 0.79 (0.55-
1.14) 
0.97 (0.68-
1.37) 
1.13 (0.81-
1.59) 
0.97 (0.67-
1.39) 
0.26 
After excluding subjects with diabetes history at baseline 
Multivariable- 
adjusted HR 
(95% CI)c 
1.00 0.70 (0.47-
1.06) 
0.90 (0.61-
1.32) 
1.21 (0.84-
1.73) 
0.97 (0.66-
1.43) 
0.17 
a Continuous DII score was used to determine P for trend 
b Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline 
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes, missing), packyears 
within smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 
18-41 pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current 
smoker with 18-41 pack-years, current smoker with>=41 pack-years, missing), total energy intake (kcal/d) 
c Model included 94,130 subjects and was adjusted for covariates listed in b  
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Table 4.5 Association between E-DII from food only and pancreatic cancer risk by 
follow-up time (i.e. <4 and >=4 years) among 101,449 subjects in the PLCO Cancer 
Screening Trial cohort  
 
 Most anti-
inflammato
ry diet   
   Most pro-
inflammat
ory diet 
  
 E-DII Q1 
(7.58, -
3.82) 
E-DII Q2 
(-3.81, -
2.60) 
E-DII Q3 
(-2.59, -
1.30) 
E-DII Q4 
(-1.29, 
0.37) 
E-DII Q5 
(0.38,6.89) 
P-
trend
a 
P-
intera
ctionb 
 
Subjects with follow up <4 years 
Cases (n)  31 20 35 30 22   
Sample size 1563 1651 1825 1959 1979   
 
 
 
 
 
 
       
Age and 
energy-
adjusted  
HR (95% CI) 
1.00 0.64 (0.36-
1.12) 
0.98 
(0.61-
1.60) 
0.77 
(0.46-
1.28) 
0.60 (0.34-
1.05) 
0.29 
Multivariabl
e-adjusted 
HR (95% 
CI)c 
1.00 0.63 (0.36-
1.10) 
0.96 
(0.58-
1.56) 
0.76 
(0.45-
1.28) 
0.60 (0.33-
1.07) 
0.30 
Subjects with follow up>=4 years 
Cases (n) 33 32 30 48 47  0.01 
Sample size  18728 18638 18465 18330 18311   
Age and 
energy-
adjusted  
HR (95% CI) 
1.00 0.98 (0.61-
1.60) 
0.95 
(0.58-
1.55) 
1.57 
(1.01-
2.46) 
1.61 (1.02-
2.54) 
0.002 
Multivariabl
e-adjusted 
HR (95% 
CI)c 
1.00 0.95 (0.59-
1.55) 
0.88 
(0.54-
1.45) 
1.38 
(0.87-
2.17) 
1.28 (0.80-
2.06) 
0.05 
a Continuous DII score was used to determine P for trend 
b  P-value for interaction was calculated by adding the cross-product of the E-DII quintiles and binary variable of time 
(<4 years and >=4years) in the multivariable-adjusted model 
c Adjusted for age at time of DHQ completion, sex (male and female), body mass index at baseline 
(underweight, normal, overweight, obesity and missing), history of diabetes (no, yes), packyears within 
smoking status at baseline (never smoker, former smoker with<18 pack-years, former smoker with 18-41 
pack-years, former smoker with>=41 pack-years, current smoker with<18 pack-years, current smoker with 
18-41 pack-years, current smoker with>=41 pack-years, missing),  total energy intake (kcal/d) 
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Table 4.6 Comparison of important demographic and lifestyle characteristics 
between study sample and excluded sample in the PLCO Cancer Screening Trial 
cohort 
 
 Study population 
(n=101,449) 
Excluded subjects  
(n=53,448) 
P-valuea 
 Mean (SE) Mean (SE)  
Age at DHQ (years) 65.5 (0.02) 66.8 (0.04) <.0001 
Pack-years of cigarette at 
baseline 
17.8 (0.08) 21.8 (0.1) <.0001 
E-DII from food and 
supplement  
-3.2 (0.01) -3.0 (0.02) <.0001 
E-DII from food only  -1.7 (0.01) -1.5 (0.02) <.0001 
 N (%)b N (%)b  
Sex   <.0001 
Male  49347 (48.6) 27335 (51.1)  
Female 52102 (51.4) 26113 (48.9)  
Trial Arm     
Intervention  51666 (50.9) 25778 (48.2) <.0001 
Control  49783 (49.1) 27670 (51.8)  
Race/Ethnicityc   <.0001 
White non-Hispanic 92259 (90.9) 40320 (83.2)  
Black non-Hispanic  3341 (3.3) 4367 (9.0)  
Hispanic 1490 (1.5) 1328 (2.7)  
Others 4359 (4.3)  2477 (5.1)  
Education levelc    <.0001 
High school or below 29693 (29.3)  15782 (32.7)  
Post high school training 
other than college   
13116 (13.0) 5711 (11.8)  
Some college  21752 (21.5) 10940 (22.6)  
College 17799 (17.6) 7545 (15.6)  
Postgraduate 18887 (18.6) 8341 (17.3)  
Smoke status at baselinec     <.0001 
Never smoked   48401 (47.7) 20871 (43.0)  
Past smoker  43659 (43.0) 20958 (43.2)  
Current smoker 9371 (9.2) 6684 (13.8)  
First-degree pancreatic 
cancer family historyc 
  <.0001 
Yes   2591 (2.6) 1208 (2.5)  
No   95459 (94.8) 45308 (94.1)  
Probable  2620 (2.6) 1616 (3.4)  
History of diabetesc    <.0001 
Yes   6785 (6.7) 4744 (9.9)  
No 94130 (93.3) 43364 (90.1)  
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a P value was calculated from independent t-test for continuous variables and from Chi-Square test for 
categorical variables. 
b The sum of percentages for some categorical variables may not add up to 100% because of rounding.  
C the proportion was calculated after excluding missing because there were 9% excluded participants did 
not return baseline questionnaire which contained these variables 
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CHAPTER 5 
5  
INFLAMMATORY POTENTIAL OF DIET, INFLAMMATION-
RELATED LIFESTYLE FACTORS AND RISK OF PANCREATIC 
CANCER: RESULTS FROM THE NIH-AARP DIET AND HEALTH 
STUDY
5.1 Abstract  
Background: Chronic inflammation is an underlying pathophysiological 
foundation for many cancers, including pancreatic cancer. Diet is a strong moderator of 
chronic inflammation. Other inflammation-related lifestyle factors such as smoking and 
obesity may act synergistically with inflammatory potential of diet, to affect pancreatic 
cancer risk. We aimed to use data from NIH-AARP Diet and Health Study which 
includes so far the largest number of pancreatic cancer cases in the US, to prospectively 
examine the association between dietary inflammatory potential and pancreatic cancer 
and the association by cancer severity, and also examine the effect modifications by 
important inflammation-related lifestyle factors including body mass index, cigarette 
smoking, diabetes history, alcohol drinking and frequency of use of non-steroidal anti-
inflammatory drugs. Methods: Our final analytical cohort consisted of 533,286 
participants (314,162 men and 219,124 women) aged between 50 to 71 at baseline. 
Energy-adjusted DII (E-DII) scores were computed based on food and supplement intake. 
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Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% 
confidence intervals (CIs) with participants in the lowest E-DII quintile (most anti-
inflammatory scores) as referent. Effect modifications were examined by adding cross-
product of each effect modifier as a categorical variable with E-DII quintile in the 
multivariable-adjusted model. Results: After a median 13.4 years of follow-up, a total of 
3,338 pancreatic cancer cases occurred. After controlling for confounders, there was no 
significant association between E-DII scores and pancreatic cancer risk among both men 
and women. Inflammatory potential of diet was not associated with pancreatic cancer by  
cancer stage or grade. The E-DII and pancreatic cancer association was not modified by 
any of the inflammation related lifestyle factors. Conclusion: Our study did not support 
an association between inflammatory potential of diet and pancreatic cancer and no 
significant effect modifications between diet-associated inflammation and other lifestyles 
related to inflammation on pancreatic cancer etiology were detected.  
5.2 Introduction  
Inflammation, a critical function of the innate immune system, protects against 
pathogens and initiates specific immunity.49 Acute inflammation is not regarded as a risk 
factor for the development of neoplasia, but frequent acute inflammation results in 
unresolved wound healing with consequent chronic inflammation.50 Chronic 
inflammation has been identified as an underlying  pathophysiological foundation for 
many chronic diseases, including cancers.407,408 Chronic inflammation also plays a pivotal 
role in the development of pancreatic cancer, as exemplified by the fact that both 
hereditary and sporadic forms of chronic pancreatitis are associated with an increased risk 
of pancreatic cancer.57,59,409,410 Due to lack of early detection approaches and limited 
 112 
 
effective treatments, pancreatic cancer has the highest case-fatality rate of any major 
cancer.1,370,411 It is the fourth leading cause of cancer death among both men and women 
in the United States, even with low incidence rates.1  
Diet is a strong moderator of chronic inflammation, mainly through its impact on 
visceral obesity,387 oxidative damage,78 and insulin resistance.387 The DII was developed 
to assess the inflammatory potential of diet.22 The use of a dietary index or patterns 
approach has advantages over the use of individual inflammation-modulating nutrients or 
foods, given the complex interaction and correlation among various dietary 
components.412,413 Besides diet, other lifestyle factors are known to be associated with 
inflammation, such as obesity, diabetes, smoking, alcohol intake, and frequency use of 
NSAIDs.  
To date, two case-control studies have examined the association between the DII 
and pancreatic cancer risk with both studies reporting a more than 2-fold increased risk 
among individuals consuming a pro-inflammatory diet. Both studies examined the 
interaction between DII and some inflammation-related factors but with inconsistent 
results.38,39 However, a cohort study using data from the PLCO Cancer Screening Trial 
did not find an association between DII and pancreatic cancer, except when stratified by 
follow-up time where a pro-inflammatory diet was associated with increased risk only in 
those subjects with >4 years of follow-up (Zheng et al. unpublished data in chapter 4). 
Therefore, the NIH–AARP Diet and Health Study, one of the largest diet and health 
prospective cohort studies in the US (approximately 500,000 US adults), provides an 
invaluable opportunity to examine and verify the relationship between the DII and 
pancreatic cancer risk with a large number of cases. We also explored if important 
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inflammation-related lifestyle factors including BMI, cigarette smoking, alcohol 
drinking, NSAIDs use frequency, and history of diabetes modified the DII and pancreatic 
cancer association. Additionally, the study examined the association between dietary 
inflammatory potential and severity of pancreatic cancer (cancer grade and cancer stage).   
5.3 Methods  
5.3.1 Study population 
The NIH-AARP Diet and Health Study is the largest prospective cohort study of 
diet and health ever conducted in US with the goal to examine a number of important diet 
and cancer hypotheses. Baseline data collection was initiated between 1995 and 1996 
when a baseline questionnaire asking information on demographic characteristics, 
medical history, dietary intake and health behaviors was mailed to 3.5 million AARP 
members.359 The scientific rational and study design of the cohort was described 
previously.46 The initial study population of this cohort was 617,119 females and males 
who responded to the baseline questionnaire with a response rate of 17.6%. Subjects were 
50 to 71 years old with mean age of 62 years at baseline and lived in one of six states 
(California, Florida, Pennsylvania, New Jersey, North Carolina, or Louisiana) or two 
metropolitan areas (Atlanta, Georgia or Detroit, Michigan).46 After excluding respondents 
whose responses on the baseline questionnaire were not reliable with the following 
reasons: 1) unknown sex, 2) skipped substantial portions of the questionnaire, 3) skipped 
facing page that provided personal information and date when they completed the 
questionnaire, 4) indicated they were not the intended respondent and did not complete 
the rest of the questionnaire, 5) more than 10 recording errors and less than 10 foods 
consumed, and respondents who asked to be dropped from cohort, who died or moved 
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before entry and those with  duplicate representation of the questionnaire, there remained 
566,398 eligible study participants (339,666 men and 226,732 women).46  From the 
eligible participants, we further excluded 15,760 subjects whose baseline questionnaires 
were filled out by proxy, 8,828 subjects who had any registry-confirmed cancer diagnosis 
at baseline (except for non-melanoma skin cancer), 4,261 subjects who had extreme daily 
energy intake [i.e., 2 interquartile ranges (IQRs) below the sex-specific 25th percentile or 
above the 75th percentile of log-transformed energy intake], 49 subjects who moved out 
of the study area or died at or before processing of the baseline questionnaire, and 4,214 
subjects who had implausible body mass index (BMI) values (2 IQRs below the sex-
specific 25th percentile or above the 75th percentile of log-transformed BMI). Our final 
analytical cohort consisted of 533,286 participants (n=314,162 men and n=219,124 
women).  The NIH–AARP Diet and Health Study was approved by the National Cancer 
Institute Special Studies Institutional Review Board, and all participants gave informed 
consent by virtue of completing and returning the questionnaire. 
5.3.2 Dietary assessment and E-DII score calculation  
The self-administered NCI-developed FFQ included in the baseline questionnaire 
assessed participants’ usual frequency of intakes and portion sizes on 124 food items over 
the past year, using 10 frequency categories ranging from “never” to “>=6 times/d” for 
beverages and from “never” to “>=2 times/d” for solid foods. Each item has 3 options of 
portion size.48 The FFQ also included 21 additional questions on food choices and 
cooking practices, and four supplement intake questions.361 In the calibration study, the 
performance of baseline FFQ was evaluated using two nonconsecutive 24-hour dietary 
recalls by telephone which were randomly assigned by day of the week with a median of 
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21 days apart among 1,953 subsample participants who responded to at least a baseline 
FFQ and one 24-hour recall.361 After adjusting for random within-person error, the 
energy-adjusted correlation coefficient ranged from 0.40 (vitamin E) to 0.76 (saturated 
fat) among men, and from 0.36 (vitamin E) to 0.70 (vitamin B6) among women.361 
Responses from the FFQ were linked to the USDA’s CSFII survey databases (1989–91 
initially, and 1994–96 as it became available), in order to estimate individuals’ nutrients, 
foods, and food group intakes.364 
The DII is a literature-derived, population-based index designed to assess the 
overall inflammatory potential of an individual’s diet. The details of the development of 
the DII have been published previously.22 Briefly, 1,943 eligible peer-reviewed primary 
research articles published up to 2010 on the effect of dietary factors on six inflammatory 
markers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP) were identified and scored to derive 
the component-specific inflammatory effect scores for 45 dietary factors (i.e. components 
of DII), which comprised macronutrients, micronutrients and some bioactive components 
such as spices and tea.22 Thirty-four baseline FFQ-derived food parameters in the NIH-
AARP study were used to calculate the E-DII score. These included the following: 
calories; carbohydrates; protein; total fat; saturated, monounsaturated, and 
polyunsaturated fat; trans-fat; alcohol; fiber; cholesterol; vitamins B1, B2, B6, B12, A, C, 
D, and E; niacin; iron; magnesium; zinc; selenium; folic acid; beta-carotene; 
anthocyanidins; flavan-3-ols; flavones; flavonones; isoflavones; caffeine; green peppers; 
and tea. To calculate flavonoid classes, daily fruits and vegetables intakes in grams were 
linked to the USDA’s Database for Flavonoid Content from Selected Foods (Release 3.1, 
December 2013) by matching foods with the USDA’s 5-digit nutrient database number. 
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The content levels of each flavonoid class from each fruit and vegetable were calculated 
and summed to provide amount of consumption for each flavonoid class.48  
The food and nutrient consumption estimated from the FFQ was first adjusted for 
total energy per 1000 calories. The energy-adjusted dietary intake was subsequently 
standardized to a composite dietary database representing average worldwide energy-
adjusted dietary intake from 11 populations in the world, to avoid the arbitrariness of 
simply using raw intake amounts.22 The energy-adjusted standardized dietary intake was 
then multiplied by the literature-derived inflammatory effect score for each of 34 DII 
components, and summed across all components to obtain the overall E-DII score.22 
Higher E-DII scores represent more pro-inflammatory diets while lower (i.e., more 
negative) E-DII scores indicate more anti-inflammatory diets. The DII score, calculated 
from multiple different dietary assessment instruments, has been construct validated and 
found to be associated with  higher levels of IL-6,24 TNF-α receptor 2,24 hsCRP23,27 and 
homocysteine.25 
A majority of the partipants (68%) in the NIH-AARP Study consumed 
supplements, and most dietary supplements contain components which have anti-
inflammatory properties. Thus, we utilized intake data from food and supplements to 
calcuate the E-DII and quantify the association between the inflammatory potential of 
overall dietary exposures and pancreatic cancer risk.  
5.3.3 Assessment of other covariates  
Baseline characteristics, which included demographic information, personal 
medical history, family history, and health behaviors such as smoking, alcohol drinking, 
and physical activity were self-reported through the baseline questionnaire. BMI was 
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calculated as weight (kg)/height(m)2 and categorized based on the World Health 
Organization criteria.368 NSAIDs use information was collected from a risk factor 
questionnaire which was sent to participants in 1996 to 1997.414  
5.3.4 Cohort follow-up and pancreatic cancer case ascertainment   
The NIH-AARP cohort are followed annually for change of address by matching 
the cohort database to that of the National Change of Address (U.S. Postal Service). Vital 
status was ascertained by annual linkage of the cohort to the Social Security 
Administration Death Master File (SSA DMF) on deaths in the U.S., follow-up searches 
of the National Death Index (NDI) for subjects that match to the SSA DMF, cancer 
registry linkage, questionnaire responses and responses to other mailings. Incident cases 
of pancreatic cancer were identified through linkage between the NIH-AARP cohort 
membership and eight state cancer registry databases which are estimated to be 95% 
complete within two years of cancer incidents. Uncertain matches underwent a final 
manual review. A follow-up questionnaire sent out in 2004 to record participants’ cancer 
status and other non-cancer endpoints was used as an additional resource. Mortality cases 
were identified by linkage to the NDI. In our analysis, pancreatic cancer case was defined 
as incident adenocarcinoma of the exocrine pancreas (International Classification of 
Diseases for Oncology, Third Edition, codes C25.0-C25.3, C25.7- C25.9) and our case 
definition excluded pancreatic endocrine tumors and other rare histology types (histology 
type 8150, 8151, 8154, 8155,8160, 8240,8245, 8246, 8430, 8440, 8453, 8470, 8471, 
8520, 8550, 8800, 8980) because they may differ etiologically from adenocarcinoma of 
exocrine pancreas.248,370,383 We treated these cases as censored at the date of diagnosis. 
Secondary pancreatic cancer cases (i.e., non-primary pancreatic cancer) were excluded 
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from outcome in the sensitivity analysis. There were cases who had pancreatic cancer 
diagnosis at the time of death (diagnosis date=death date), so we imputed their diagnosis 
date by subtracting 4 months from the death date (4 months is the median survival time 
for exocrine pancreatic cancer) and we included these people in the outcome in one of the 
sensitivity analyses.369     
5.4 Statistical analysis  
The baseline characteristics of the study population by quintiles of E-DII from 
food plus supplement, with quintile cut-off points determined from the distribution of the 
entire cohort, was described by calculating means and SE for continuous variables and 
frequencies and percentages for categorical variables. ANOVA test was used to test the 
difference across E-DII quintiles for continuous variables, and Chi-square test was 
performed to test the difference for categorical variables. Participants were followed up 
from the baseline questionnaire completion to the date of diagnosis of pancreatic cancer, 
death from any cause, moved out of the study’s ascertainment area, or the end date of 
study follow-up (12/31/2011), whichever came first. Multivariable Cox proportional 
hazards regression with person-year as the underlying time metric was fitted to estimate 
the age- and energy-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% 
confidence intervals (CIs) with subjects in the lowest E-DII quintile (the most anti-
inflammatory score) as the referent. Proportional hazard (PH) assumption was examined 
using the Schoenfeld residual test.374 Only baseline age (continuous format) violated PH 
assumption, so we fitted a stratified COX model by binary age group using the median 
age of the cohort. To test the linear trend of pancreatic cancer risk across quintiles of E-
DII score, a continuous E-DII variable was used.415 We considered all variables in Table 
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5.1 as potential confounders during model building and created parsimonious 
(multivariable-adjusted) models that included variables if they were associated with both 
pancreatic risk and E-DII (in either continuous or categorical format), or changed the 
crude risk estimate by more than 10%. In the multivariable-adjusted models, we adjusted 
for age group at entry (<62 or >=62 years old), sex (male and female), BMI 
(underweight; normal; overweight; obese; missing), smoking status  (nonsmoker; 
quit>=10 years,<=20 cigs/day; quit>=10 years,>20 cigs/day; quit 5-9 years,<=20 
cigs/day; quit 5-9 years,>20 cigs/day; quit 1-4 years,<=20 cigs/day; quit 1-4 years,>20 
cigs/day; quit<1 year or current,<=20 cigs/day; quit<1 year or current,>20 cigs/day; 
missing), alcohol intake (g/d), education levels (<=11 years; 12 years or completed high 
school; post-high school, some college, college or post graduate; unknown), medical 
history of diabetes (yes; no), and total energy intake (kcal/day). Continuous HR and 95% 
CIs also were calculated for each one unit of standard deviation increase of E-DII score 
after the restricted cubic spline test indicated the linear assumption was sufficient.375 
Since men and women had different distributions of the E-DII score and other covariates, 
we present the associations between E-DII and pancreatic cancer by sex using sex-
specific E-DII quintile cut-off points, and among combined men and women.    
Effect modifications by inflammation-related lifestyle factors including BMI, 
smoking status, alcohol drinking , NSAIDs use frequency (i.e., aspirin and ibuprofen 
products), and diabetes history were examined by adding cross-product of each effect 
modifier as a categorical variable with E-DII quintile in the multivariable-adjusted model 
with a P value ≤0.1 as an indicator of significant interaction.376 HRs and 95% CIs 
comparing subjects in each higher E-DII group with lowest E-DII were reported for each 
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stratum of a given effect modifier. According to the American Institute for Cancer 
Research Continuous Update Project 2012 report  for pancreatic cancer, there was 
evidence of a nonlinear association between alcohol (as ethanol) and pancreatic cancer 
risk with increased risk observed among those consuming 53.4g alcohol or more a day.239 
Thus, we categorized alcohol intake into high and low level by using 53.4g as the cut-off 
point in the interaction test. We did not find any difference in the significance of 
interactions between males and females; thus, we presented the results of interactions 
without stratifying by sex.  
To examine whether associations varied by pancreatic cancer severity, we also 
performed separate association analysis among cancer cases with different cancer stages 
and cancer grades.  
Multiple sensitivity analyses were performed. First, to alleviate concerns 
regarding reverse causality (i.e., a biased association attributed to diet or a lifestyle 
change as a result of latent pancreatic cancer), lag time analysis was performed by 
excluding study subjects with follow-up <5 years as previously reported. Secondly, 
subjects who self-reported diabetes history at baseline were removed from analysis as 
diabetes may be a preclinical indictor of pancreatic cancer, and diet modification may 
have occurred after diagnosis of diabetes.307,354,377,398 We also restricted the outcome to 
primary pancreatic cancer only, and added death cases of pancreatic cancer to both 
primary pancreatic cancer outcomes and the total incident outcomes using the imputed 
incidence time.   
All statistical analyses were conducted using SAS® (version 9.4, Cary, NC). All 
tests were two-sided with p values<0.05 considered to be statistically significant if not 
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otherwise noted. 
5.5 Results  
After a median 13.4 years of follow up, a total of 3,338 pancreatic cancer cases 
occurred. E-DII scores ranged from -7.91 to 6.66, which was comparable to other US 
cohorts.193,406 As shown in Table 5.1, compared to participants who had the most anti-
inflammatory E-DII scores (i.e. E-DII quintile 1), participants consuming a more pro-
inflammatory diet (i.e., higher E-DII scores) were younger at baseline but with larger 
BMI, consumed more alcohol and energy, and were more likely to be males, current 
smokers or former smoker who smoked more than 20 cigarettes per day, Black non-
Hispanic or Hispanic race/ethnicities, have below-college education level, have history of 
diabetes, but be less physically active, and report less frequent use of NSAIDs.  
HRs for pancreatic cancer risk according to E-DII quintiles and continuous E-DII 
are presented in Table 5.2. In the age- and energy-adjusted model, significantly increased 
pancreatic cancer risk with E-DII quintile and continuous E-DII was seen among males 
and among all subjects combined, but not among females. After controlling for 
confounders, there was no significant association between E-DII scores and pancreatic 
cancer risk among men (HRQ5vsQ1=1.03, 95% CI=0.89-1.18, P-trend=0.69), women 
(HRQ5vsQ1= 0.98, 95% CI=0.82-1.17, P-trend=0.98), or all subjects combined 
(HRQ5vsQ1=0.97, 95% CI=0.87-1.09, P-trend=0.87, P-interaction by sex=0.63) 
Continuous HRs also were not significant among men or women or all (Table 5.2).  
The E-DII and pancreatic cancer association was not modified by any of the 
inflammation related lifestyle factors which consisted of BMI, smoking status, alcohol 
drinking, NSAIDs use (i.e. aspirin and ibuprofen products), and diabetes history (Table 
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5.3). Stratified by any effect modifier, no significant association was detected in any of 
the strata comparing the highest to lowest E-DII group.  
Stratified by cancer stage, localized pancreatic cancer made up the least 
proportion, followed by regional and distant metastasized pancreatic cancers. However, 
inflammatory potential of diet was not associated with pancreatic cancer in any cancer 
stage (Table 5.4). Similarly, when stratified by cancer grade, the largest proportion of 
pancreatic cancer was poorly differentiated or moderately well differentiated. We did not 
identify any significant association with pancreatic cancer in any cancer grade (Table 
5.5).    
After excluding subjects with follow-up <5 years, the multivariable HRs did not 
change materially (Table 5.6). Similar HRs were observed when primary pancreatic 
cancer was treated as the outcome. After we added pancreatic cancer death cases to 
outcomes (i.e., total incident pancreatic cancer cases and primary pancreatic cancer cases) 
by using the imputed incidence time, results did not change (Table 5.7 and 5.8).  
5.6 Discussion  
The current analyses represent the largest cohort to date to examine the 
association between dietary inflammatory potential and pancreatic cancer in a prospective 
manner. No association was observed between the E-DII and pancreatic cancer risk. We 
also did not observe evidence of effect modification by inflammation-related lifestyle 
factors including BMI, smoking status, alcohol drinking, NSAIDs use, or history of 
diabetes. Due to the large sample size, we were able to examine associations by disease 
severity, but found no evidence of increased risk of pancreatic cancer with a more pro-
inflammatory diet among different cancer stages or grades.  
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Two case-control studies and one cohort study previously investigated the E-DII 
and pancreatic cancer association. The finding of the present analysis was consistent with 
our previous work where an overall null association was reported among 101,449 US 
participants in the PLCO cohort (Zheng et al. unpublished data in Chapter 4). In the two 
case-control studies from the US39 and Italy,38 both reported a more than 2-fold 
significant increased risk of pancreatic cancer in the highest compared to the lowest 
quintile of the E-DII group (US: OR Q5vsQ1 =2.54, 95% CI=1.87-3.46, P trend<0.000139; 
Italy: OR Q5vsQ1=2.48, 95% CI=1.50-4.10, P-trend=0.00238). The different results between 
our analysis and the case-control studies may be explained by the different study designs. 
The prospective design utilized in the two studies with null associations serves to 
minimize differential misclassification of exposure which can be present in case-control 
studies due to  recall bias.400,416 On the other hand, it is possible that a one-time dietary 
assessment many years prior to diagnosis in cohort studies is not the most etiologically-
relevant timeframe for assessing exposure. Of note, however, our group has reported 
significant associations between the DII and colorectal cancer, another cancer 
substantially influenced by inflammation, within the NIH-AARP Study.34 While there 
was no evidence of a follow-up time interaction in the current study, previous analyses of 
the PLCO cohort indicated the association between diet and pancreatic cancer may differ 
by follow-up time. In that study, decreased risk with a more pro-inflammatory diet was 
observed with shorter follow-up time, and increased risk was observed for longer follow-
up time (Zheng et al. unpublished data in Chapter 4). Thus, the effect of preclinical 
disease on dietary intake and recall should be further explored in cohort studies.  
Previous studies of dietary indices other than the DII using a priori or data-driven 
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methods for deriving dietary patterns have generally suggested healthier dietary quality 
characterized by high consumption of fruit, vegetables, whole grains, white meat, fiber, 
low-fat dairy products was associated with reduced pancreatic risk while patterns 
characterized by greater intake of animal foods, refined grains, high-fat dairy products, 
sweets and desserts were associated with increased risk of pancreatic 
cancer,16,17,20,21,48,402,403 although the associations were stronger in case-control than 
cohort studies.417 The differences in dietary patterns of interest, dietary assessment 
instruments, study design and study population, number of cases or timing from dietary 
data collection to diagnosis are important factors that may explain the different results 
across studies.  
No evidence of effect modification by inflammation-related lifestyle factors was 
identified in the study and no significant association appeared in any stratum of an effect 
modifier, which was consistent with our findings in the PLCO cohort where BMI, history 
of diabetes, and smoking status were not effect modifiers. The Italian case-control study 
reported effect modification by smoking status and BMI where a significant positive 
association was observed among never smokers (OR Q5vsQ1=2.32, 95% CI=1.08-4.99; P-
trend=0.01) and past smokers (ORQ5vsQ1= 3.37, 95 % CI=1.22-9.35; P-trend=0.07), but 
not among current smokers. Positive associations were observed among normal weight 
(ORQ5vsQ1 =2.24, 95 % CI=1.03-4.86; P-trend=0.16) and overweight (ORQ5vsQ1=2.32, 
95% CI=1.03- 5.21; P-trend=0.005), but not among obese subjects (P-interactions by 
BMI and by smoking status were not reported in the study).38 In the US case-control 
study, Antwi et al. did not find significant interaction between DII and BMI,  diabetes 
history or cigarette smoking using the statistical test for multiplicative interaction. 
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However, the quantitative additive and multiplicative interactions calculated by 
comparing the observed and expected ORs suggested that diet-associated inflammation 
may act synergistically with cigarette smoking and diabetes to increase the risk of 
pancreatic cancer beyond the risk of any of these factors alone.39   
This is one of the first cohort studies to examine the association between a dietary 
index and pancreatic cancer severity. Similar to the overall null association, we did not 
find a differential association between inflammatory potential of diet and pancreatic 
cancer in any cancer stage or grade. The only other study to examine DII in relation to 
pancreatic cancer stage at diagnosis was the case-control study in the US which found a 
positive association overall. They also did not find differential effects by stage, reporting 
increased risk for cancers presenting with resectable (ORQ5vsQ1 = 2.36, 95% CI = 1.48–
3.75), locally advanced (ORQ5vsQ1 = 2.21, 95% CI = 1.41–3.46) or metastatic (ORQ5vsQ1 = 
3.13, 95% CI = 1.85–5.29) tumors.39 Due to the rapid fatality rates of pancreatic cancer, 
case-control studies are especially prone to biases with frequent proxy responses used 
among cases, which in turn may produce more measurement error among cases than 
controls.   
Although no association was found between a pro-inflammatory diet and 
pancreatic cancer, there is mechanistic support for the hypothesis. It is well accepted that 
inflammatory states foster a cellular environment that supports the development of 
genomic mutations and the initiation of pancreatic carcinogenesis.58 Dietary factors can 
modify inflammation through multiple mechanisms including regulation of the pro-
inflammatory cytokines, NF-κB pathway activation, changes in DNA methylation, and 
influence on the antioxidant defense.79,73 Pro-inflammatory diets can increase insulin 
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resistance, increase  reactive oxygen species and mediators in the inflammatory pathway 
(e.g., NF-kB and COX-2), leading to increased cell cycling, loss of tumor suppressor 
function, and stimulated oncogene expression, genetic alterations and modifications of 
key cancer-related proteins and ultimately cause malignancy.57,58,418,419 Anti-
inflammatory diets can have strong antioxidant and carcinogenesis-inhibition properties, 
owing to healthy fatty acid profiles, large fiber content, high antioxidants and 
phytochemicals from vegetables and fruits which help to reduce insulin resistance, 
oxidative stress and damage, and inhibit tumor initiation and promotion.182,420  
This study has several strengths. The NIH-AARP Diet and Health Study is a large 
well- established prospective cohort study with diet and lifestyle factors assessed before 
cancer diagnosis, which minimized the recall bias and selection bias that may be found in 
a typical case-control study. A large number of pancreatic cancer cases has provided 
sufficient statistical power to detect the main association and interaction by several 
important inflammation-related lifestyle factors. Detailed information on a 
comprehensive list of covariates allowed for careful adjustment in the analyses. This is 
the first cohort study to examine whether inflammatory potential of diet could act 
synergistically with other inflammation-related lifestyle factors to influence pancreatic 
cancer risk. It is also the first cohort study to examine the association between a dietary 
index and pancreatic cancer severity. The use of the DII, a construct-validated 
measurement tool which takes into account the whole diet to assess dietary inflammatory 
potential has major advantage over other a priori dietary patterns as it was developed 
specifically for inflammation mechanism,22 which plays a central role in the pancreatic 
cancer carcinogenesis.58,59 
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Despite these strengths, study limitations also are noted. The number of cases in 
certain cancer stage (localized pancreatic cancer) and grade (well-differentiated 
pancreatic cancer and undifferentiated/anaplastic pancreatic cancer) categories and some 
other stratified analyses was not large enough to infer valid associations. Measurement 
error in FFQ data and other covariates is another unavoidable limitation, and a measure 
of social desirability was not obtained in this study.421,422 Although follow-up data on 
covariates were available in the risk factor or follow-up questionnaires, the large missing 
percentage impeded the possibility to use these data. Diet was only assessed at baseline, 
therefore, any changes in diet over follow up were not captured, which could result in 
non-differential misclassification of exposure. However, we previously found DII scores 
were relatively stable over a long timeframe in postmenopausal women where the study 
participants were of comparable age as the NIH-AARP study.405 Another possible 
limitation in our study was that only data on 34 components of the DII were available to 
calculate the E-DII scores. However, the range of DII scores may rely more on the 
amount of foods actually consumed rather than on the number of available DII 
components.406 Although important potential confounders were adjusted for in our 
analyses, residual or unmeasured confounding may still be a possibility.  
5.7 Conclusion 
In conclusion, there was no association between dietary inflammatory potential 
and pancreatic cancer risk in this large cohort among both men and women. 
Inflammation-related lifestyle factors including BMI, smoking status, alcohol drinking, 
NSAIDs use, and history of diabetes did not modify the association. Dietary 
inflammatory potential was not associated with pancreatic cancer risk by cancer stage or 
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grade. Future large cohort studies are warranted to test the effect modification of E-DII 
and cancer by inflammation-related lifestyle factors and test the association between E-
DII and severity of pancreatic cancer to confirm our findings. Future cohort studies 
should also examine the difference in associations by follow-up time.  
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Table 5.1 Baseline characteristics of 533,286 subjects in the NIH-AARP Diet and 
Health Study by quintiles of E-DII  
 
 Most anti-
inflammato
ry diet  
   Most pro-
inflammato
ry diet  
 
 
 
 
     P-
valuea 
 E-DII Q1 
(-7.91,-5.61) 
E-DII Q2 
(-5.60,-
4.51) 
E-DII Q3 
(-4.50,-
3.29) 
E-DII Q4 
(-3.28,-1.51) 
E-DII Q5 
(-1.50,6.66) 
N 106658 106657 106657 106655 106659  
 
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)  
Age at 
baseline (y) 
62.0 (0.02) 61.9 (0.02) 61.8 (0.02) 61.6 (0.02) 61.1 (0.02) <.0001 
Total energy 
intake 
(kcal/d) 
1564.7 (1.8) 1722.9 (2.2) 1817.2 (2.4) 1937.7 (2.6) 2180.1 (3.1) <.0001 
BMI at 
baseline 
(kg/m2)  
26.3 (0.01) 26.8 (0.01) 27.1 (0.01) 27.4 (0.01) 27.6 (0.01) <.0001 
Alcohol 
consumption 
(g/d) 
8.9 (0.05) 9.1 (0.06) 10.1 (0.07) 12.5 (0.1) 22.7 (0.2) <.0001 
 n (%)b n (%)b n (%)b n (%)b n (%)b  
Sex       <.0001 
Male  48772 (45.7) 56695 
(53.2) 
62315 
(58.4) 
69005 (64.7) 77375 
(72.5) 
 
Female  57886 (54.3) 49962 
(46.8) 
44342 
(41.6) 
37650 (35.3) 29284 
(27.5) 
 
Race/ 
Ethnicity 
     <.0001 
White non-
Hispanic 
98311 (92.2) 97681 
(91.6) 
97094 
(91.0) 
97170 (91.1) 97249 
(91.2) 
 
Black non-
Hispanic  
3249 (3.1) 3915 (3.7) 4359 (4.1) 4319 (4.1) 4532 (4.3)  
Hispanic 1675 (1.6) 1901 (1.8) 2114 (2.0) 2195 (2.1) 2015 (1.9)  
Other races  2170 (2.0) 1873 (1.8) 1709 (1.6) 1457 (1.4) 1353 (1.3)  
Unknown  1253 (1.2) 1287 (1.2) 1381 (1.3) 1514 (1.4) 1510 (1.4)  
Education 
level  
     <.0001 
less than or 
equal to 11 
years  
3689 (3.5) 5050 (4.7) 6106 (5.7) 7429 (7.0) 9593 (9.0)  
       
High school 
completion  
16655 (15.6) 19182 
(18.0) 
20309 
(19.0) 
22155 (20.8) 25819 
(24.2) 
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Post high 
school 
training other 
than college  
9548 (9.0) 10032 (9.4) 10336 (9.7) 10810 (10.1) 11630 
(10.9) 
 
Some college 25274 (23.7) 25051 
(23.5) 
24514 
(23.0) 
24577 (23.0) 24331 
(22.8) 
 
College and 
postgraduate  
48561 (45.5) 44210 
(41.5) 
42193 
(39.6) 
38555 (36.2) 32090 
(30.1) 
 
Missing 2931 (2.8) 3132 (2.9) 3199 (3.0) 3129 (2.9) 3196 (3.0)  
Smoking 
status and 
dose 
combined 
       
<.0001 
Never 
smoked 
41415 (38.8) 40371 
(37.9) 
38425 
(36.0) 
35937 (33.7) 29965 
(28.1) 
 
Quit, <=20 
cigs/d 
33914 (31.8) 31148 
(29.2) 
29957 
(28.1) 
28543 (26.8) 24776 
(23.2) 
 
Quit, >20 
cigs/d  
20853 (19.6) 21904 
(20.5) 
22738 
(21.3) 
23947 (22.5) 25782 
(24.2) 
 
Current 
smoker, 
<=20 cigs/d 
5219 (4.9) 6790 (6.4) 7870 (7.4) 9070 (8.5) 12256 
(11.5) 
 
Current 
smoker, >20 
cigs/d 
1443 (1.4) 2615 (2.5) 3621 (3.4) 5182 (4.9) 9571 (9.0)  
Unknown  3814 (3.6) 3829 (3.6) 4046 (3.8) 3976 (3.7) 4309 (4.0)  
Physical 
activity 
frequency in 
the past year  
       
<.0001 
Never 2379 (2.2) 3493 (3.3) 4402 (4.1) 5529 (5.2) 8127 (7.6)  
Rarely  9316 (8.7) 12124 
(11.4) 
13962 
(13.1) 
16348 (15.3) 20676 
(19.4) 
 
1-3 time per 
month 
11280 (10.6) 13170 
(12.4) 
14412 
(13.5) 
15631 (14.7) 17353 
(16.3) 
 
1-2 times per 
week  
21867 (20.5) 23070 
(21.6) 
23192 
(21.7) 
23503 (22.0) 22817 
(21.4) 
 
3-4 times per 
week 
34950 (32.8) 31369 
(29.4) 
28947 
(27.1) 
26253 (24.6) 21085 
(19.8) 
 
5 or more 
times per 
week 
25974 (24.4) 22408 
(21.0) 
20555 
(19.3) 
18184 (17.1) 15213 
(14.3) 
 
Unknown 892 (0.8) 1020 (1.0) 1187 (1.1) 1207 (1.1) 1388 (1.3)  
History of 
diabetes 
      
<.0001 
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No  98693 (92.5) 96906 
(90.9) 
96102 
(90.1) 
95788 (89.8) 97567 
(91.5) 
 
Yes  8019 (7.5) 9751 (9.1) 10555 (9.9) 10867 (10.2) 9092 (8.5)  
Aspirin 
products use 
frequency  
      
<.0001 
No use  17070 (16.0) 16650 
(15.6) 
16996 
(15.9) 
16914 (15.9) 16801 
(15.8) 
 
1-3 
times/month 
19527 (18.3) 19139 
(17.9) 
19267 
(18.1) 
19542 (18.3) 20165 
(18.9) 
 
1-6 
times/week 
11384 (10.7) 11272 
(10.6) 
10466 (9.8) 10226 (9.6) 9259 (8.7)  
>=1 time/day 17982 (16.9) 17057 
(16.0) 
16267 
(15.3) 
14956 (14.0) 12750 
(12.0) 
 
Unknown  40695 
(38.15) 
42539 
(39.9) 
43661 
(40.9) 
45017 (42.2) 47684 
(44.7) 
 
Ibuprofen 
products use 
frequency 
     <.0001 
No use  26408 (24.8) 26659 
(25.0) 
27366 
(25.7) 
27690 (26.0) 27911 
(26.2) 
 
1-3 
times/month 
22739 (21.3) 21333 
(20.0) 
20563 
(19.3) 
19646 (18.4) 18403 
(17.3) 
 
1-6 
times/week 
9463 (8.9) 9033 (8.5) 8339 (7.8) 8057 (7.6) 6957 (6.5)  
>=1 time/day 7133 (6.7) 6899 (6.5) 6519 (6.1) 5994 (5.6) 5459 (5.1)  
Unknown 40195 (38.4) 42733 
(40.1) 
43870 
(41.1) 
45268 (42.4) 47929 
(44.9) 
 
Abbreviations: SE, standard error  
a  Statistical analyses were performed by ANOVA test for continuous variables and by Chi-Square test for 
categorical variables. 
b Sum of percentages may not add up to 100% because of rounding or missing.   
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Table 5.2 Hazard ratios of pancreatic cancer by quintiles of E-DII score among 
533,286 subjects in the NIH-AARP Diet and Health Study 
  
 E-DII 
Q1 
 
E-DII 
Q2 
 
E-DII 
Q3 
E-DII 
Q4 
 
E-DII 
Q5 
 
P-
trend
a 
Continuous 
HR and 
95%CIb 
P-
interactio
nc 
Total subjects   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.63 
Total sample  10665
8 
10665
7 
10665
7 
10665
5 
10665
9 
  
Number of 
cases  
666 618 683 660 711   
Age and 
energy- 
adjusted 
model HR 
(95% CI)  
1.00 0.94 
(0.84-
1.05) 
1.05 
(0.95-
1.17) 
1.03 
(0.92-
1.15) 
1.14 
(1.02-
1.27) 
0.001 1.06 (1.03-
1.10) 
Multivariable
- adjusted 
model HR 
(95% CI)d 
1.00  0.91 
(0.81-
1.01) 
0.99 
(0.89-
1.10) 
0.94 
(0.84-
1.04) 
0.97 
(0.87-
1.09) 
0.78 1.01 (0.97-
1.04) 
Males  
Total sample 62833 62833 62833 62830 62833   
Number of 
cases 
422 413 435 407 448   
Age and 
energy- 
adjusted 
model  
HR (95% CI) 
1.00 1.00 
(0.87-
1.14) 
1.07 
(0.93-
1.22) 
1.01 
(0.88-
1.16) 
1.15 
(1.01-
1.32) 
0.02 1.05 (1.01-
1.10) 
Multivariable
- adjusted 
model HR 
(95% CI)d 
1.00 0.97 
(0.85-
1.12) 
1.02 
(0.89-
1.17) 
0.95 
(0.83-
1.09) 
1.03 
(0.89-
1.18) 
0.69 1.01 (0.97-
1.06) 
Females  
Total sample  43826 43822 43827 43824 43825   
Number of 
cases 
254 237 211 253 258   
Age and 
energy- 
adjusted 
model HR 
(95% CI) 
1.00 0.94 
(0.79-
1.13) 
0.85 
(0.71-
1.02) 
1.04 
(0.87-
1.23) 
1.09 
(0.92-
1.30) 
0.16 1.04 (0.98-
1.10) 
Multivariable
- adjusted 
model HR 
(95% CI)d 
1.00 0.93 
(0.78-
1.11) 
0.82 
(0.68-
0.98) 
0.98 
(0.82-
1.17) 
0.98 
(0.82-
1.17) 
0.98 1.00 (0.94-
1.06) 
a.P-trend was calculated using the continuous E-DII score in the model  
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b.The continuous HR and associated 95% CI for one standard deviation increase of E-DII score 
c.P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted 
COX model  
d. Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index 
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined 
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day, 
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or 
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing),  total energy(kcal/day), alcohol from 
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high 
school, post-high school, some college, college and post graduate, unknown).  
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Table 5.3 Hazard ratios* of pancreatic cancer by quintiles of E-DII score among 
533,286 subjects in the NIH-AARP Diet and Health study, stratified by 
inflammation-related lifestyle factors 
 Q1  Q2  Q3  Q4  Q5 P-
trenda 
P-
interactionb 
  HR  HR    
95%CI 
 HR    
95%CI 
 HR    
95%CI 
 HR    
95%CI 
  
BMI           0.29 
  
Underweight  
1.00  1.60 
(0.46-
5.53) 
 1.95 
(0.59-
6.43) 
 0.41 
(0.07-
2.29) 
 0.84 
(0.21-
3.36) 
0.50  
  Normal  1.00  0.91 
(0.76-
1.10) 
 1.09 
(0.91-
1.31) 
 0.86 
(0.71-
1.05) 
 0.94 
(0.77-
1.15) 
0.73  
  Overweight  1.00  0.89 
(0.75-
1.05) 
 1.01 
(0.86-
1.19) 
 0.95 
(0.80-
1.12) 
 1.01 
(0.85-
1.19) 
0.54  
  Obese 1.00  0.86 
(0.67-
1.09) 
 0.75 
(0.59-
0.97) 
 0.88 
(0.70-
1.12) 
 0.86 
(0.67-
1.09) 
0.53  
            
Smoking 
status  
          0.48 
   Never 
smokers 
1.00  0.81 
(0.68-
0.98) 
 0.84 
(0.70-
1.01) 
 0.86 
(0.71-
1.04) 
 0.88 
(0.72-
1.07) 
0.59  
  Former 
smokers 
1.00  0.96 
(0.82-
1.12) 
 1.04 
(0.89-
1.22) 
 1.03 
(0.88-
1.21) 
 1.05 
(0.89-
1.24) 
0.26  
  Current 
smokers 
1.00  0.95 
(0.67-
1.34) 
 1.18 
(0.85-
1.63) 
 0.88 
(0.63-
1.23) 
 1.09 
(0.80-
1.49) 
0.61  
            
Alcohol 
level  
          0.92 
   Low 1.00  0.90 
(0.81-
1.01) 
 0.98 
(0.88-
1.09) 
 0.93 
(0.83-
1.04) 
 0.96 
(0.86-
1.08) 
0.89  
   High  1.00  0.95 
(0.50-
1.77) 
 1.22 
(0.68-
2.19) 
 1.10 
(0.62-
1.95) 
 1.14 
(0.66-
1.96) 
0.74  
            
Frequency 
of use of 
aspirin 
products 
          0.23 
  No use 1.00  0.78 
(0.59-
1.03) 
 0.95 
(0.73-
1.23) 
 0.87 
(0.66-
1.14) 
 0.99 
(0.76-
1.31) 
0.53  
Monthly use 1.00  0.84 
(0.64-
1.11) 
 1.15 
(0.90-
1.49) 
 0.97 
(0.75-
1.27) 
 0.89 
(0.68-
1.17) 
0.42  
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*The model was adjusted for age group, sex, body mass index category, smoking status with quit and dose 
combined, total energy(kcal/day), alcohol intake (g/d), diabetes history, education level while adding the 
cross-product term of the quintile E-DII and each effect modifier in the model.  
a. P-trend was calculated using the continuous E-DII score in the model  
b. P-interaction was calculated with the cross-product of the effect modifier and E-DII quintile in the 
multivariable-adjusted COX model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Weekly 
and daily    
use  
1.00  1.07 
(0.87-
1.31) 
 1.01 
(0.82-
1.25) 
 0.93 
(0.75-
1.16) 
 1.21 
(0.97-
1.51) 
0.10  
            
Frequency  
of use of 
ibuprofen 
products 
          0.92 
  No use  1.00  0.97 
(0.78-
1.20) 
 1.15 
(0.93-
1.41) 
 0.98 
(0.79-
1.21) 
 1.09 
(0.88-
1.36) 
0.71  
  Monthly 
use  
1.00  0.88 
(0.69-
1.13) 
 1.03 
(0.81-
1.31) 
 0.93 
(0.72-
1.19) 
 1.07 
(0.82-
1.38) 
0.20  
  Weekly 
and daily use 
1.00  0.90 
(0.68-
1.20) 
 0.87 
(0.65-
1.17) 
 0.86 
(0.63-
1.16) 
 0.94 
(0.68-
1.29) 
0.93  
            
Self-
reported 
diabetes 
history 
          0.50 
  No  1.00  0.92 
(0.82-
1.04) 
 1.02 
(0.91-
1.14) 
 0.93 
(0.83-
1.05) 
 0.99 
(0.88-
1.11) 
0.83  
  Yes 1.00  0.79 
(0.57-
1.09) 
 0.79 
(0.58-
1.09) 
 0.93 
(0.68-
1.26) 
 0.86 
(0.62-
1.21) 
0.90  
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Table 5.4 The association between E-DII quintiles and risk of pancreatic cancer by 
cancer stage in the NIH-AARP Diet and Health Study 
  
 Q1 Q2 Q3 Q4 Q5 P-
trenda 
Localized pancreatic cancer  
Sample size  106658 106657 106657 106655 106659  
Number of cases  25 33 31 22 37  
Age and energy 
adjusted model 
HR (95% CI)  
1.00 1.35 (0.80-
2.27) 
1.29 (0.76-
2.20) 
0.94 (0.53-
1.67) 
1.66 (0.98-
2.79) 
0.03 
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00 1.31 (0.78-
2.21) 
1.23 (0.72-
2.09) 
0.87 (0.49-
1.57) 
1.48 (0.86-
2.53) 
0.11 
Regional pancreatic cancer 
Number of cases 137 126 136 123 138  
Age and calorie 
adjusted model 
HR (95% CI) 
1.00 0.93 (0.73-
1.19) 
1.02 (0.81-
1.30) 
0.94 (0.73-
1.20) 
1.10 (0.86-
1.40) 
0.30 
Multivariable- 
adjusted model  
HR (95% CI)b 
1.00 0.91 (0.71-
1.16) 
0.97 (0.76-
1.23) 
0.87 (0.68-
1.11) 
0.96 (0.75-
1.24) 
0.91 
Distant metastasized pancreatic cancer 
Number of cases 214 180 200 215 227  
Age and energy 
adjusted model 
HR (95% CI) 
1.00 0.85 (0.70-
1.03) 
0.95 (0.79-
1.16) 
1.03 (0.85-
1.25) 
1.12 (0.92-
1.36) 
0.01 
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00 0.81 (0.66-
0.99) 
0.87 (0.72-
1.06) 
0.91 (0.75-
1.10) 
0.90 (0.74-
1.10) 
0.82 
a. P-trend was calculated using the continuous E-DII score in the model 
b. Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index 
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined 
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day, 
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or 
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing),  total energy(kcal/day), alcohol from 
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high 
school, post-high school, some college, college and post graduate, unknown).  
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Table 5.5 The association between E-DII quintiles and risk of pancreatic cancer by 
cancer grade in the NIH-AARP Diet and Health Study 
 
 Q1 Q2 Q3 Q4 Q5 P-
trenda 
Grade 1 or well-differentiated pancreatic cancer  
Sample size  106658 106657 106657 106655 106659  
Number of cases  35 31 29 37 24  
Age and energy- 
adjusted model 
HR (95% CI) 
1.00 0.91 (0.56-
1.48) 
0.87 (0.53-
1.43) 
1.13 (0.71-
1.81) 
0.77 (0.45-
1.32) 
0.69 
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00  0.86 (0.53-
1.40) 
0.79 (0.48-
1.31) 
0.99 (0.62-
1.59) 
0.64 (0.37-
1.10) 
0.25 
Grade II or moderately well differentiated pancreatic cancer  
Number of cases 105 94 106 93 112  
Age and energy-  
adjusted model 
HR (95% CI) 
1.00 0.91 (0.69-
1.20) 
1.04 (0.80-
1.37) 
0.93 (0.70-
1.23) 
1.16 (0.88-
1.52) 
0.26 
Multivariable- 
adjusted model  
HR (95% CI)b 
1.00 0.89 (0.67-
1.17) 
0.99 (0.76-
1.31) 
0.86 (0.65-
1.14) 
1.00 (0.75-
1.33) 
0.99 
Grade III or poorly differentiated pancreatic cancer  
Number of cases 121 103 110 123 123  
Age and energy- 
adjusted model 
HR (95% CI) 
1.00 0.86 (0.66-
1.12) 
0.94 (0.72-
1.21) 
1.06 (0.82-
1.36) 
1.09 (0.85-
1.42) 
0.08 
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00 0.83 (0.64-
1.08) 
0.88 (0.68-
1.14) 
0.97 (0.75-
1.25) 
0.94 (0.72-
1.23) 
0.60 
Grade IV or undifferentiated/anaplastic pancreatic cancer 
Number of cases 9 6 7 10 9  
Age and energy- 
adjusted model 
HR (95% CI) 
1.00 0.67 (0.24-
1.90) 
0.79 (0.29-
2.14) 
1.14 (0.46-
2.85) 
1.06 (0.41-
2.74) 
0.79 
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00 0.64 (0.23-
1.79) 
0.72 (0.27-
1.95) 
0.99 (0.39-
2.51) 
0.86 (0.32-
2.32) 
0.87 
a. P-trend was calculated using the continuous E-DII score in the model 
b. Model was adjusted for age group(<62 and >=62 years old), sex (male or female), body mass index 
category (underweight, normal, overweight, obese, missing), smoking, quit and dose combined 
(nonsmoker, quit>=10 years,<=20 cigs/day, quit>=10 years,>20 cigs/day, quit 5-9 years,<=20 cigs/day, 
quit 5-9 years,>20 cigs/day, quit 1-4 years,<=20 cigs/day, quit 1-4 years,>20 cigs/day, quit<1 year or 
current,<=20 cigs/day, quit<1 year or current,>20 cigs/day, missing),  total energy(kcal/day), alcohol from 
alcoholic drinks(g/d), diabetes history(yes/no), education level (<=11 years, 12 years or completed high 
school, post-high school, some college, college and post graduate, unknown).  
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Table 5.6. Multivariable-adjusted HRs of lag time analysis of DII and pancreatic 
cancer risk after excluding subjects with follow-up<5 years  
 
 Q1 Q2 Q3 Q4 Q5 P-trenda 
Subjects with follow-up >=5 years (N=489,744) 
Sample size  99008 98407 97799 97694 96836  
Number of cases 515 489 514 495 539  
Multivariable- 
adjusted model 
HR (95% CI)b 
1.00 0.94 
(0.83-
1.06) 
0.98 
(0.86-
1.11) 
0.93 (0.82-
1.05) 
0.98 (0.86-
1.11) 
0.75 
a.P-trend was calculated using the continuous E-DII score in the model  
b.The model was adjusted for age group, sex, body mass index category, smoking status with quit and dose 
combined, total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level 
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Table 5.7 Multivariable-adjusted HRs of sensitivity analysis of adding pancreatic 
cancer death cases with imputed incident time to the first incident pancreatic cancer  
 
 Q1 
 
Q2 
 
Q3 Q4 
 
Q5 
 
P-
trenda  
Continuous 
HR (95% 
CI)b 
P-
interaction 
by sexc 
Total subjects   
 
 
 
 
 
 
 
 
 
0.34 
 
 
 
 
 
 
 
Sample size 10665
8 
10665
7 
10665
7 
10665
5 
10665
9 
  
Number of 
cases  
803 759 804 791 843   
Multivariabl
e-adjusted 
modeld 
1.00 0.92 
(0.84-
1.02) 
0.97 
(0.87-
1.07) 
0.93 
(0.84-
1.03) 
0.96 
(0.86-
1.06) 
0.84 1.00 (0.96-
1.03) 
Males 
Sample size  62833 62833 62833 62830 62833   
Number of 
cases 
533 502 513 489 535   
Multivariabl
e-adjusted 
modeld 
1.00 0.94 
(0.83-
1.06) 
0.95 
(0.84-
1.08) 
0.90 
(0.79-
1.02) 
0.97 
(0.85-
1.10) 
0.72 0.99 (0.95-
1.04) 
 
Females 
Sample size 43826 43822 43827 43824 43825   
Number of 
cases 
289 289 253 295 302   
Multivariabl
e-adjusted 
modeld 
1.00 1.00 
(0.85-
1.18) 
0.87 
(0.73-
1.03) 
1.02 
(0.87-
1.21) 
1.03 
(0.87-
1.22) 
0.84 1.01 (0.95-
1.06) 
a.P-trend was calculated using the continuous E-DII score in the model  
b.The continuous HR and associated 95% CI for one standard deviation increase of E-DII score 
c.P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted 
COX model  
d. Model was adjusted for age group, sex, body mass index category, smoking, quit and dose combined, 
total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level  
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Table 5.8 Multivariable-adjusted HRs of sensitivity analysis of adding pancreatic 
cancer death cases with imputed incident time to incident primary pancreatic 
cancer  
 
 Q1 
 
Q2 
 
Q3 Q4 
 
Q5 
 
P-
trend
a 
Continuous 
HR (95% 
CI)b 
P-
interacti
on by 
sexc 
Total subjects   
 
 
 
 
 
 
 
 
 
 
 
0.56 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size  10665
8 
10665
7 
10665
7 
10665
5 
10665
9 
  
Number of 
cases  
638 599 645 627 672   
Multivariable
- adjusted 
modeld 
1.00 0.92 
(0.82-
1.03) 
0.98 
(0.88-
1.10) 
0.94 
(0.84-
1.05) 
0.98 
(0.87-
1.10) 
0.70 1.01 (0.97-
1.05) 
Males 
Sample size  62833 62833 62833 62830 62833   
Number of 
cases 
410 385 412 375 416   
Multivariable
- adjusted 
modeld 
1.00 0.94 
(0.81-
1.08) 
1.00 
(0.87-
1.15) 
0.90 
(0.78-
1.04) 
0.99 
(0.86-
1.15) 
0.92 1.00 (0.96-
1.05) 
Females 
Sample size  43826 43822 43827 43824 43825   
Number of 
cases 
237 240 205 244 257   
Multivariable
- adjusted 
modeld 
1.00 1.01 
(0.84-
1.21) 
0.86 
(0.71-
1.03) 
1.02 
(0.85-
1.23) 
1.05 
(0.87-
1.26) 
0.55 1.02 (0.96-
1.08) 
a.P-trend was calculated using the continuous E-DII score in the model  
b.The continuous HR and associated 95% CI for one standard deviation increase of E-DII score 
c.P-interaction was calculated with the cross-product of sex and E-DII quintile in the multivariable adjusted 
COX model  
d. Model was adjusted for age group, sex, body mass index category, smoking, quit and dose combined, 
total energy(kcal/day), alcohol from alcoholic drinks(g/d), diabetes history, education level  
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CHAPTER 6 
6  
MEDIATION EFFECT OF TYPE-2 DIABETES IN THE ASSOCIATION 
BETWEEN DIETARY INFLAMMATORY POTENTIAL AND 
PANCREATIC CANCER RISK: A POOLED ANALYSIS OF THE PLCO 
CANCER SCREENING TRIAL AND NIH-AARP DIET AND HEALTH 
STUDY 
6.1 Abstract  
Background: inflammation plays an important role in pancreatic cancer 
pathogenesis and can be modulated by diet. Two case-control studies have reported a 
significant positive association between dietary inflammatory index and pancreatic 
cancer risk. However, little is known about the mechanism underlying the pathway from 
dietary inflammatory potential to pancreatic cancer development. Given type-2 diabetes 
is an inflammatory disease and a large amount of biological and epidemiological 
evidence have suggested a strong positive association between type-2 diabetes and 
pancreatic cancer, we aimed to investigate whether type-2 diabetes mediated the 
association between dietary inflammatory potential and pancreatic cancer risk in a pooled 
cohort of two similar large prospective cohorts in the US (PLCO Cancer Screening Trial 
and NIH-AARP Diet and Health Study). Methods: A total of 74,826 participants from 
the PLCO and 194,815 subjects from the NIH-AARP with age range from 50 to 74 years 
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at baseline comprised the pooled mediation cohort which included a total of 269,641 
subjects (144,999 men and 124,642 women). E-DII scores from food plus supplement 
were calculated based on study-specific baseline diet questionnaire. Information on 
incident diabetes occurrence status (i.e., mediator) during follow-up and the age/year of 
first diagnosis was obtained through the follow-up questionnaires of both studies. Study-
specific primary incident adenocarcinoma of the exocrine pancreas was regarded as the 
outcome of interest. Causal mediation approach under the counterfactual concept, was 
used to calculate the study-specific natural direct effect (NDE), natural indirect effect 
(NIE), and marginal total effect (MTE) on pancreatic cancer risk with type-2 diabetes as 
a mediator by quintile E-DII while treating the lowest quintile as the reference.  
Mediation effects of type-2 diabetes also were calculated for pancreatic cancer associated 
with each unit increment of centered E-DII value and z-score of E-DII. Random effects 
model was used to pool each mediation effect together, and since there was no significant 
between-study heterogeneity, we further calculated and reported the pooled mediation 
results using same approach. Results: In the pooled cohort, incident type-2 diabetes 
significantly mediated associations between both categorical and continuous E-DII and 
pancreatic cancer although the mediated effect was small. The overall effect of E-DII on 
pancreatic cancer, averaged over direct and indirect effect with type-2 diabetes as a 
mediator was not statistically significant. Conclusion: Incident type-2 diabetes may play 
a mediator role in the association between dietary inflammatory potential and pancreatic 
cancer development.  
6.2 Introduction  
Pancreatic cancer, the majority (~90%) of which is ductal adenocarcinoma of the 
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exocrine pancreas, is one of the most rapidly fatal malignancies with the highest case 
fatality rate among any major cancers.1,383 Despite its low incidence rate, pancreatic 
cancer is the fourth leading cause of cancer mortality in the United States among both 
men and women.4 Inflammation plays a critical role in the pathogenesis of this 
malignancy, as manifested by the fact that inflammatory states are etiologically linked to 
well-recognized risk factors for pancreatic cancer, including chronic pancreatitis, 
cigarette smoking, obesity, and diabetes.58,384 Diet, an important modifiable lifestyle 
factor, can modulate inflammation through its effect on visceral obesity,387 oxidative 
damage,78 and insulin resistance.387 The DIITM was developed to assess the inflammatory 
potential of an individual’s diet,22 which has the advantage over individual foods or 
nutrients when being studied for associations with disease risk as it takes into account the 
complex interactions among dietary components.13  
To date, the association between the inflammatory potential of diet and pancreatic 
cancer risk has been investigated and reported in two case-control studies and two cohort 
studies. Both case-control studies identified a significant more than 2-fold increased risk 
among individuals consuming a pro-inflammatory diet.38,39 As described in this 
dissertation, no associations were observed overall in the two cohort studies (Zheng et al., 
unpublished data). Little is known about the mechanism underlying the pathway from 
dietary inflammatory potential to pancreatic cancer development. Enhancing knowledge 
about potentials in the pathway could provide scientific evidence for identifying 
intermediate biomarkers to screen high risk populations for pancreatic cancer. It also 
helps with the design and guidance of an effective dietary intervention to reduce risk of 
pancreatic cancer.  Given the large amount of biological and epidemiological evidence 
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that suggests a strong positive association between type-2 diabetes and pancreatic cancer 
and the inflammatory nature of diabetes, we hypothesized that type-2 diabetes may play a 
role as a mediator linking dietary inflammatory potential to increased pancreatic cancer 
risk.  
Causal mediation analysis, under the counterfactual concept, could discover the 
causal role of a mediator underlying the relation between an exposure and outcome by 
quantifying the extent to which this relationship is mediated by the mediator.423 The 
conventional mediation analysis approach proposed by Baron and Kenny424 could give 
rise to biased estimates if there is any uncontrolled mediator-outcome confounding or if 
an interaction between exposure and mediator exists, and could not be used to obtain 
causal inference of the mediated effect. In contrast, causal mediation analysis, with the 
clear no-unmeasured-confounding assumption, is able to be used to obtain unbiased 
casual inference of direct and indirect effects under the counterfactual framework.    
Therefore, we aimed to investigate whether the associations between dietary 
inflammatory potential and pancreatic cancer are mediated by incident type-2 diabetes by 
using the causal mediation approach, in the pooled analysis of two large, well-established 
cohorts in the U.S., the PLCO Cancer Screening Trial and NIH-AARP Diet and Health 
Study.  
6.3 Methods  
6.3.1 Study population  
The PLCO is a population-based randomized trial aimed to assess the effects of 
screening tests for prostate, lung, colorectal, and ovarian cancers on mortality and 
secondary endpoints. A total of 154,897 eligible participants (76,682 men and 78,215 
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women) with age range from 55 to 74 years, were enrolled into the trial at baseline 
between 1993 to 2001 from different centers spanning across the United States.43 
Participants were randomized into either a control arm, where usual medical care was 
received, or intervention arm where PLCO cancers screening tests were received. The 
whole PLCO cohort was followed up for 13 years after enrollment, and participants in the 
intervention arm received their screening tests during their first six years in the trial.44 
The NIH-AARP Diet and Health Study is the largest prospective cohort study of diet and 
health ever conducted in the US with the goal to examine a number of important diet and 
cancer hypotheses. The details of the study design were described previously.46 Briefly, 
566,398 eligible AARP members living across the country (339,666 men and 226,732 
women) with age of 50 to 71 years old, who responded to the baseline questionnaire, 
were enrolled between 1995 and 1996. NIH-AARP participants were followed until the 
end of 2011 for the current analysis. In general, although the NIH-AARP had 
approximately 3.6 times more participants and slightly longer follow-up than PLCO, 
these two cohorts share substantial similarities in terms of the characteristics of study 
population, with similar age ranges at enrollment and similar proportions of racial/ethnic 
groups and other health behavior factors. In addition, the two studies were initiated 
during similar time periods and utilized similar diet questionnaires which included 
similar lists of food items (diet questionnaires in both studies were developed based on 
the NCI-developed DHQ but with different templates and a few different questions),396,361 
and included comprehensive information on covariates and cancer outcomes.  
Study-specific exclusions included 1) cancer (except non-melanoma skin cancer) 
diagnosed before dietary measurement; 2) participants did not return diet questionnaire or 
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did not have valid responses; 3) participants reported unreasonable BMI (in the PLCO, 
BMI was considered unreasonable if one of  the followings occurred: weight<60 pounds; 
height<48 inches;  height>78 inches for females; height>84 inches for males; BMI<15 
kg/m2 ; in the NIH-AARP, implausible BMI was defined as 2 IQRs below the sex-
specific 25th percentile or above the 75th percentile of log-transformed BMI) or calorie 
intake (unreasonable calorie intake was defined as sex-specific first and last percentiles of 
total energy in the PCLO and 2 IQRs below the sex-specific 25th percentile or above the 
75th percentile of log-transformed energy intake in the NIH-AARP ); or 4) no follow-up 
data. After exclusions, the analytical cohort of the PLCO included 101,449 participants 
(49,347 men and 52,102 women) and the NIH-AARP had a final sample size of 533, 256  
(314,139 men and 219,117 women). Therefore, the pooled analytical cohort of PLCO and 
NIH-AARP has a total of 634,705 participants (363,486 men and 271,219 women).  
In the analytical cohort of 101,449 PLCO participants, we further excluded 
participants who did not have valid supplemental questionnaire, which contained follow-
up data on diabetes and was introduced at a median of nine years after randomization into 
the trial (n=22,046), and those who had baseline diabetes (n=4,577), leaving a total of 
74,826 participants involved in the PLCO mediation analysis cohort. Similarly, after 
excluding 321,377 participants who did not have follow-up questionnaire or the 
questionnaire was filled out by proxy, and 17,064 people who had baseline diabetes, 
194,815 subjects remained in the mediation analysis cohort of NIH-AARP. In the pooled 
mediation cohort of PLCO and NIH-AARP, there were a total of 269,641 participants 
(144,999 men and 124,642 women).  
The PLCO was approved by the institutional review boards of the National 
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Cancer Institute and each of the centers that participated, and the NIH-AARP was 
approved by the National Cancer Institute Special Studies Institutional Review Board. All 
participants from the two studies gave informed consent.  
6.3.2 Dietary assessment and E-DII score calculation 
Both PLCO and NIH-AARP used self-administered NCI-developed DHQ to 
assess participants’ usual frequency of intakes and portion sizes on 124 food items over 
the previous year, using multiple frequency categories ranging from “never” to “>=6 
times/d” for beverages and from “never” to “>=2 times/d” for solid foods, and each item 
has 3 options of portion size.48,363 Supplement intake questions also were included in 
FFQs from both studies.396,361,363 In the PLCO, the DHQ was introduced to trial 
participants within a median of three years after randomization,396 while the DHQ was 
completed at baseline in the NIH-AARP. Responses from the DHQ were linked to the 
USDA’s CSFII survey databases in both studies, in order to estimate individuals’ 
nutrients, foods, and food group intakes.364 Results from comparisons with multiple 24 
hour recalls in both cohorts suggested moderate energy-adjusted correlation coefficients 
for important dietary factors such as fat, total energy, fiber and micronutrients, which 
generally exceeded 0.4.361,363 
  The DII, a literature-derived index designed to assess the overall inflammatory 
potential of an individual’s diet, was used in each study to calculate the overall E-DII 
score for each participant. The details of the development of the DII have been published 
previously.22 Briefly, 1,943 eligible peer-reviewed primary research articles published 
through 2010 on the effect of dietary factors on six inflammatory markers (IL-1β, IL-4, 
IL-6, IL-10, TNF-α, and CRP) were identified and scored to derive the component-
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specific inflammatory effect scores for 45 dietary factors (i.e. components of DII), which 
comprised macronutrients, micronutrients and some bioactive components such as spices 
and tea.22 Thirty-five FFQ-derived dietary factors in the PLCO were used to calculate the 
E-DII, and 34 components were used for E-DII score calculation in the NIH-AARP (refer 
to table 6.1 footnote for details of the dietary components in each cohort for E-DII 
calculation).  
To calculate individual’s E-DII score in each study, the FFQ-derived food and 
nutrient intake values were first adjusted for total energy intake and expressed per 1000 
calories. The energy-adjusted dietary intake was subsequently standardized to a global 
composite dietary database representing average energy-adjusted dietary intake from 11 
populations living in different countries across the world, to avoid the arbitrariness of 
simply using raw intake amounts.22,201 The energy-adjusted standardized dietary intake 
was then multiplied by the literature-derived inflammatory effect score for each DII 
component, and summed across all components to obtain the overall E-DII score. Higher 
E-DII scores represent more pro-inflammatory diets and lower (i.e., more negative) E-DII 
scores indicate more anti-inflammatory diets. The DII score has been construct validated 
and found to be positively associated with several inflammatory biomarkers such as IL-
6,24 TNF-α receptor 2,24 high-sensitivity CRP23,27 and homocysteine.25 
In both the PLCO and NIH-AARP, a majority of the partipants consumed 
supplements. Given that most dietary supplements contain anti-inflammatory 
components, we calcuated the E-DII from food plus supplement as the exposure in all 
analyses to quantify the association between the inflammatory potential of overall dietary 
exposures and pancreatic cancer risk with type-2 diabetes as the mediator.   
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6.3.3 Mediator assessment  
Information on incident diabetes occurrence during follow up was obtained 
through the follow-up questionnaires of both studies. In the PLCO, participants were 
asked on supplemental questionnaire whether or not they were ever diagnosed with 
diabetes (yes, no, or missing), and at what age they were first diagnosed with diabetes. 
Participants could choose their age of first-diagnosed diabetes at "< 50", "50-59", "60-
69", "older than 70" or can leave it blank. Participants in the NIH-AARP reported 
whether they were ever diagnosed with diabetes (yes, no, unknown) and year of first 
diagnosis of diabetes (no, before 1985, 1985-1994, 1995-1999, 2000 to present, 
unknown) on follow up questionnaire. Because we excluded participants with baseline 
diabetes in the mediation analysis, the study-specific responses to the two above-
mentioned diabetes questions on the follow-up questionnaires can be used to identify 
incident diabetes that occurred during follow-up. The mediator was coded as a 
categorical variable with three levels: “yes”, “no” and “missing” using the following 
method: 1) if subjects answered they were never diagnosed with diabetes on the study-
specific follow-up questionnaire, these subjects were assigned “no”; 2) if subjects 
reported they were ever diagnosed with diabetes, we further compared their ages at first 
diagnosis of diabetes using the median value of each category of the variable indicating 
diabetes occurrence time on the study-specific follow-up questionnaires, with their ages 
at primary pancreatic cancer diagnosis, and coded mediator as “yes” if diabetes occurred 
before primary pancreatic cancer or no primary pancreatic cancer occurred, “no” if 
diabetes occurred after primary pancreatic cancer (because mediator as defined should 
occur before the occurrence of outcome of interest), or “missing ” if no information on 
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age at first diagnosis of diabetes; and 3) if subjects did not report whether they were 
diagnosed with diabetes, these subjects were assigned “missing” as their mediator level. 
Figure 6.1 illustrates this method used to code the mediator. We assume the incident 
diabetes in our study is type-2 diabetes as type-2 diabetes accounts for 90%-95% of those 
with diabetes, while the majority of type-1 diabetes which results from a cellular-
mediated autoimmune destruction of the β-cells of the pancreas, is typically a juvenile-
onset disease.425                                                                                                                                                                                               
6.3.4 Covariates assessment  
Data on covariates were retrieved from study-specific self-reported baseline 
questionnaires, which included demographic information, personal medical history, 
family history, and health behaviors such as smoking and alcohol drinking. BMI was 
calculated as weight (kg)/height(m)2 and categorized based on the World Health 
Organization criteria.368 In PLCO, information on physical activity over the past year was 
not assessed at baseline, but was assessed on supplemental questionnaire, while physical 
activity was assessed in the baseline questionnaire in the NIH-AARP. We did not use 
follow-up data of covariates in analyses because of the large missing proportion and 
inconsistent assessment time.  
6.3.5 Harmonization of potential confounders across two studies 
In the aggregated analysis where data from two cohorts were combined into one 
dataset, we created harmonized categories for the shared potential confounding variables 
of the E-DII and pancreatic cancer association across two studies. Because the physical 
activity variable was measured from essentially different questions and using different 
units in the two studies (physical activity in NIH-AARP was measured as frequency but 
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in PLCO it was measured using Met-hours), we excluded this variable as a potential 
confounder in the aggregated analysis. Family history of pancreatic cancer also was 
excluded because this variable was not available in the NIH-AARP. The other potential 
confounders shared between the two studies were created with harmonized categories for 
categorical variables, including age at baseline (continuous), sex (male or female), total 
energy intake (kcal/day), race (White non-Hispanic; Black non-Hispanic; Hispanic; 
Asian, Pacific Islander or American Indian/Alaskan Native; or unknown), BMI 
(underweight, normal, overweight, obese, or missing), alcohol intake (g/day), diabetes 
history at baseline (yes, no, or missing), combination of smoking status and years since 
quitting smoking (never smoked, stopped 10 or more years ago, stopped 5-9 years ago, 
stopped 1-4 years ago, stopped within last year, currently smoking, or missing), and 
education levels (<=11 years, high school completion, post high school training other 
than college, some college, college and postgraduate, or missing).  
6.3.6 Pancreatic cancer case ascertainment   
Incident pancreatic cancer cases in the PLCO were identified through an annual 
study update questionnaire in which participants reported if they had been diagnosed with 
any cancer, the type of cancer, and date of diagnosis. State registries, death certificates, 
and physician reports were used as additional sources for identification of pancreatic 
cancer cases. In the NIH-AARP, incident cases of pancreatic cancer were identified 
through linkage between the NIH-AARP cohort membership and eight state cancer 
registry databases. Uncertain matches underwent a final manual review. The follow-up 
questionnaire used to record participants’ cancer status and other non-cancer endpoints in 
the NIH-AARP was used as an additional resource. In the present analysis, pancreatic 
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cancer case was defined as primary incident adenocarcinoma of the exocrine pancreas 
(International Classification of Diseases for Oncology, Third Edition, codes C25.0-C25.3, 
C25.7- C25.9). Our case definition excluded pancreatic endocrine tumors and other rare 
histology types of pancreatic cancer in each study, as etiology may differ,248,370 and we 
censored these types of pancreatic cancer at the date of diagnosis.  
6.4 Statistical analysis  
The baseline characteristics of the study population in the pooled mediation 
analysis cohort combining PLCO and NIH-AARP (n=269,641) were presented by 
quintiles of E-DII with cut-off points determined from the distribution of the entire 
pooled cohort.  Means and SE for continuous variables and frequencies and percentages 
for categorical variables were calculated. ANOVA was used to test the difference across 
E-DII quintiles for continuous variables, and Chi-square test was performed to test the 
difference for categorical variables. Because we excluded a substantial amount of 
individuals in the pooled mediation cohort, we assessed the difference of important 
baseline characteristics between study population in the pooled mediation cohort and 
those in the combined PLCO and NIH-AARP cohorts.  
We first assessed the study-specific total, direct, and indirect effects of E-DII on 
pancreatic cancer risk with type-2 diabetes as a mediator by using the causal mediation 
approach in a counterfactual framework.378,423,426 In this approach, total effect can be 
decomposed into direct effect (not mediated by type-2 diabetes) and indirect effect 
(mediated by type-2 diabetes). A SAS macro developed by Valeri and Vanderweele379 
was used to calculate the study-specific mediation parameters: natural direct effect 
(NDE), natural indirect effect (NIE), and marginal total effect (MTE) of E-DII on 
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pancreatic cancer risk with type-2 diabetes as a mediator. Briefly, mediation parameter 
estimates were obtained using the causal mediation approach in three steps: 1) type-2 
diabetes was regressed on E-DII using the logistic regression with inclusion of the set of 
confounding variables which were the same as those we reported in the association 
between E-DII and pancreatic cancer in each cohort except that diabetes history at 
baseline was removed (Zheng et al. unpublished data in chapter 4 and 5); 2) pancreatic 
cancer was regressed on type-2 diabetes and E-DII with inclusion of the E-DII and type-2 
diabetes interaction and the same set of confounders as in 1) using a logistic regression 
model; since the interaction was not statistically significant, we removed it from the 
model; 3) based on the specified comparison levels of exposure, parameters derived from 
these two logistic models gave way to essential mediator parameters through a series of 
mathematical calculations.379 In the study-specific mediation analysis, we calculated and 
reported the NDE, NIE, and MTE of E-DII on pancreatic cancer risk for subjects in each 
higher E-DII quintile (i.e., quintile 2, quintile 3, quintile 4, quintile 5) compared to those 
in the lowest quintile with type-2 diabetes as mediator, by using ordinal E-DII variable in 
the model (compare 2,3,4,5 with 1, respectively). We also centered each E-DII value to 
the mean to report the effect of a one-unit increase in centered E-DII on pancreatic cancer 
with type-2 diabetes as mediator (1 and 0 were specified as two exposure levels of 
comparison). The Z-score of E-DII was calculated by dividing the centered value by the 
standard deviation, and used in the mediation model to demonstrate the mediation effect 
of type-2 diabetes on the association of increment of one standardized unit of E-DII with 
pancreatic cancer risk (1 to 0 were specified as two exposure levels of comparison). For 
all these mediation analysis, we also calculated the mediation proportion by type-2 
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diabetes using the equation as follows:  Proportion of mediation by type-2 diabetes= 
[NDE x (NIE – 1)]/ (NDE x NIE – 1) 
The following four assumptions suffice to identify valid NDE and NIE from the 
data: 1) there is no unmeasured exposure-outcome confounding given measured 
covariates, 2) there is no unmeasured mediator-outcome confounding given measured 
covariates and exposure, 3) there is no unmeasured exposure-mediator confounding given 
measured covariates, and 4) there is no effect of the exposure that confounds the 
mediator-outcome relationship.378 Under such assumptions, the NDE and NIE can be 
conceptually evaluated as follows: NDE is the contrast between the counterfactual 
outcome if all subjects were exposed at a higher E-DII quintile and the counterfactual 
outcome if the same subjects were exposed at the lowest E-DII quintile, with probability 
of having type-2 diabetes assuming the value at when E-DII quintile was at the lowest 
level. The NIE is the contrast, having set the E-DII at each higher quintile, between the 
counterfactual outcome if probability of developing type-2 diabetes assumed whatever 
value it would have taken at a value of the higher E-DII quintile and the counterfactual 
outcome if probability of developing type-2 diabetes assumed whatever value it would 
have taken at the lowest E-DII quintile. The MTE was the average of the NDE and NIE 
estimated at the population level. 426,427  
Each study-specific mediation effect (i.e., NDE, NIE, MTE) for pancreatic cancer 
comparing each higher E-DII quintile to the lowest quintile, weighted by the inverse of 
the sum of their variance and the estimated between-studies variance component, was 
pooled using a random effects model.428 The study-specific NDE, NIE and MTE for 
pancreatic cancer associated with each one unit increment of centered E-DII value and z-
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score of E-DII with type-2 diabetes as the mediation factor, also were pooled using the 
same method. 428 Between-studies heterogeneity was evaluated using the Q statistics380,381 
and I2 statistics.382  
  There was no significant between-study heterogeneity on the mediation parameter 
estimates as assessed using the random effects models, and diet and other covariates were 
measured using comparable ways across two studies. Thus, we further combined primary 
data from two cohorts to take advantage of differences in the distributions of the exposure 
variable across studies and to increase number of pancreatic cancer cases to increase 
power.429 In addition, we can directly calculate the mediation parameter estimates in the 
pooled cohort instead of combining the results from separate studies with larger statistical 
errors. In this aggregated dataset, we considered all variables listed in the section of 
“Harmonization of potential confounders across two studies” as potential confounders 
during model building and selected and added those as confounders in the model if they 
were associated with both pancreatic risk and E-DII (in either continuous or categorical 
format), or changed the crude risk estimate by more than 10%. We finally adjusted for 
age at baseline, sex, total energy intake, BMI, education levels, alcohol intake, and the 
combined variable of smoking status and years since quitting smoking in the mediation 
analysis with aggregated data from PLCO and NIH-AARP mediation cohorts. The same 
mediation analyses as performed in each study as stated above were conducted in this 
pooled cohort.   
 We also conducted analysis of association between E-DII and pancreatic cancer 
among the participants in the pooled mediation cohort since this subset of people may be 
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different from the full cohort because they were survivors and chose to complete the 
follow-up questionnaire of both studies. 
All statistical analyses were conducted using SAS® (version 9.4, Cary, NC) 
except that the assessment of between-studies heterogeneity was conducted in STATA 
(release 14, College Station, TX). All tests were two-sided with p values <0.05 
considered to be statistically significant if not otherwise noted. 
6.5 Results  
As shown in Table 6.1, the range of the E-DII in the pooled mediation cohort of 
269,641 participants from the PLCO and NIH-AARP was from -8.43 to 6.66. Compared 
to participants who had the most anti-inflammatory E-DII scores (i.e., E-DII quintile 1), 
participants consuming a more pro-inflammatory diet (i.e., higher E-DII scores) were 
younger at baseline but consumed more alcohol and energy, were more likely to develop 
incident type-2 diabetes during follow-up, and more likely to be males, Black non-
Hispanic or Hispanic race/ethnicities, overweight or obese, current smokers or former 
smoker who stopped smoking within last 9 years, and have below-college education 
level, but there was no difference in developing pancreatic cancer comparing high to low 
dietary inflammatory potential.  
Table 6.2 presents the study-specific NDE, NIE and MTE of E-DII on pancreatic 
cancer risk comparing subjects in each higher E-DII quintile to those in the lowest 
quintile with type-2 diabetes as the mediator, using the ordinal E-DII variable. In each 
study, when comparing risk of pancreatic cancer for subjects in each higher E-DII 
quintile to the lowest group, we observed a similar NDE, NIE, MTE and mediation 
proportion with type-2 diabetes as a mediator, and identified a similar P value of each 
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effect across different comparisons. The mediated effect of type-2 diabetes was 
significant in both studies although the effect was small (slightly over 1). The overall 
mediation proportion by type-2 diabetes was larger in the NIH-AARP than in the PLCO. 
The total effect of E-DII on pancreatic cancer averaged over NDE and NIE was not 
significant for each higher level of E-DII quintile compared to the lowest quintile. In both 
studies, the association between E-DII and pancreatic cancer was fully mediated by 
incident type-2 diabetes. The NDE, which was the E-DII and pancreatic cancer 
association that was not mediated through type-2 diabetes, was not significant. When 
pooling the mediation effect estimates from two studies using random effects model, 
significant between-study heterogeneity for NDE, NIE and MTE was not observed in any 
comparison group (Pheterogeneity >0.5). The pooled results generally provide the same 
information as suggested by the study-specific results. There was a significant although 
small mediated effect of type-2 diabetes and the E-DII and pancreatic cancer association 
was fully mediated through type-2 diabetes. No significant overall effect of E-DII on 
pancreatic cancer was identified (Table 6.3).   
Study-specific NDE, NIE, and MTE of one-unit increase in centered E-DII and E-
DII z-score on pancreatic cancer risk with type-2 diabetes as mediator are presented in 
Table 6.4 along with the pooled results from two studies using the random effects model. 
Similar to the categorical E-DII results, in both studies and pooled results, NDE, NIE and 
MTE effects of continuous E-DII on pancreatic cancer still presented the significant 
mediated effect of type-2 diabetes which was in a small magnitude. The continuous 
association between E-DII and pancreatic cancer also was fully mediated through type-2 
diabetes. But overall there was no significant total effect of centered E-DII value or a 
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standard unit of E-DII (z score) averaged over NDE and NIE on pancreatic cancer risk. 
Between-study heterogeneity on three mediation effects of these two continuous E-DII 
variables was not observed. The mediation proportion by type-2 diabetes was larger when 
using the continuous E-DII format than the categorical comparisons in the PLCO.  
When we combined the primary data into a single dataset, we still identified the 
significant though small mediated effect of type-2 diabetes (i.e., NIE was significant), 
whether it was in the association for categorical E-DII or in the continuous association by 
using the centered E-DII value or z-score of E-DII (Tables 6.5 and 6.6). However, 
compared to the study-specific results and pooled analysis results using random effects 
model, the aggregated analysis presented the attenuated MTE averaged over NDE and 
NIE of E-DII on pancreatic cancer with point estimates less than 1 in both categorical and 
continuous associations, but the association was not significant. In the aggregated 
analysis, the NDE attenuated too with point estimate below 1, thus it was in an opposite 
direction with NIE in both the categorical and continuous associations between E-DII and 
pancreatic cancer, which impeded us from obtaining an interpretable mediation 
proportion.  
Compared to subjects included in the pooled mediation analyses, excluded 
subjects tended to be younger at baseline and had baseline characteristics that were more 
likely to be associated with higher risk of health outcome, including male, Black or 
Hispanic, recent smoking, a more pro-inflammatory diet, more calories intake, more 
alcohol consumption, lower education attainment. Excluded participants also had higher 
pancreatic cancer incidence (Table 6.7).  
In the pooled mediation cohort, we did not find an association between E-DII 
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from food plus supplement and pancreatic cancer risk after adjusting for confounders 
(OR Q5vsQ1=1.04, 95% CI=0.82-1.33; P-trend=0.86), which was consistent with the null 
association we identified in the separate cohort of PLCO and NIH-AARP (Table 6.8).  
6.6 Discussion  
The present study is the first to use the causal mediation approach to evaluate the 
mediation role of type-2 diabetes incidence in the relation between dietary inflammatory 
potential and pancreatic cancer risk in two large well-established nationally 
representative cohorts in the U.S. In the pooled mediation cohort of the PLCO and NIH-
AARP, incident type-2 diabetes significantly mediated both categorical and continuous 
associations between E-DII and pancreatic cancer, although the mediated effect was 
small. The E-DII and pancreatic cancer association was fully mediated by type-2 diabetes 
with the aggregated data from two cohorts. We did not observe a statistically significant 
association of E-DII on pancreatic cancer, averaged over direct and indirect effect with 
type-2 diabetes as a mediator. In both studies and pooled analyses, we identified a null 
MTE of E-DII on pancreatic cancer, which was consistent with the findings of the E-DII 
and pancreatic cancer association we observed in each study (Zheng et al. unpublished 
data in Chapters 4 and 5) and with similar point estimate of effect.  
In our analyses, we found the E-DII and pancreatic cancer association was fully 
mediated through incident type-2 diabetes. There was strong biologic and 
epidemiological evidence of the positive link between inflammation and diabetes. The 
leading hypothesized mechanisms to explain insulin resistance in type-2 diabetics 
suggests oxidative stress, endoplasmic reticulum stress, amyloid deposition in the 
pancreas, ectopic lipid deposition in the muscle, liver and pancreas, and lipotoxicity and 
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glucotoxicity are each thought to either induce inflammation or to be exacerbated by or 
associated with inflammation.42,430,431 Prospective studies have also found that elevated 
levels of IL-1β, IL-6, IL-1 receptor antagonist (IL-1Ra) and CRP are associated with 
type-2 diabetes. 226,432,433 Although only one study to date has reported an association 
between the DII and fasting glucose, postload glucose or insulin resistance,434 there is a 
substantial amount of research reporting a positive association between DII scores and 
insulin-resistance-related conditions such as metabolic syndrome and various types of 
cancers, 189,435,26,203 supporting our observed link between type 2 diabetes and the DII. 
The strong and positive association of type 2 diabetes with pancreatic cancer risk has 
been verified in a large number of studies. Recent data from five pooled analyses40,41,306-
308 have concordant findings, showing that diabetics have 40% to 90% increased 
pancreatic cancer risk compared to non-diabetics, and the relative risk decreases with 
duration of diabetes, though a significant excess risk was still evident 10 years 
after diabetes diagnosis. Even in the absence of diabetes mellitus, higher fasting blood 
sugar and blood glucose or impaired glucose tolerance are associated with higher 
pancreatic cancer risk.285,309,310  However, it is still controversial whether type-2 diabetes 
is a consequence or a cause of the pancreatic cancer.305,436,437  
The significant mediated effect of type-2 diabetes in the E-DII and pancreatic 
cancer association is well-supported by the biologic mechanism stated as consecutive 
steps as follows: 1) Pro-inflammatory diets can increase insulin resistance through 
multiple mechanisms including regulation of pro-inflammatory cytokines, NF-κB 
pathway activation, changes in DNA methylation, increase in oxidative stress, and 
influences on antioxidant defense;79,73 2) Defective response of body tissues to insulin, 
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i.e., reduced insulin sensitivity, increases demand on pancreatic islets to secrete higher 
quantities of insulin, leading to hyperinsulinemia and subsequent type-2 diabetes 
development;438,439 and 3) Locally elevated insulin supply coming from the endocrine 
islets of pancreas, which acts as a potential growth factor in the promotion of cell 
proliferation and angiogenesis,440 lead to increased loss of tumor suppressor function, and 
stimulated oncogene expression which altogether form a malignant transformation of 
pancreatic cells, predominantly the ductal epithelial cells of the exocrine pancreas, and 
ultimately cause malignancy.58,419  
Our study has some major strengths. First, the PLCO and NIH-AARP were very 
similar in the measurement of diet and important covariates and in the characteristics of 
their study populations related to many key risk factors for pancreatic cancer such as age, 
BMI, education level, smoking behavior. Additionally, the two studies were initiated at 
similar times and follow-up diabetes was measured at a similar length of follow-up 
(about 9 years into each study) These similarities enabled us to combine primary data 
from the two cohorts to increase the number of pancreatic cancer cases and incident type-
2 diabetes cases, as well as take advantage of differences in the distributions of the 
exposure variable across studies. Second, there are several advantages of using PLCO 
and NIH-AARP: the prospective cohort design of both studies minimizes the possibility 
of recall bias and selection bias; the long follow-up in both cohorts among a large study 
population accumulated a large number of pancreatic cancer cases, especially in the NIH-
AARP; and detailed information on a comprehensive list of covariates which were 
assessed in a similar way in two cohorts allowed for harmonization with less 
misclassification bias in the pooling analysis and also allowed for careful adjustment in 
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the analyses. Third, the E-DII was a strength, as it was designed specifically related to the 
biologic mechanism of inflammation which links the DII-diabetes-pancreatic cancer 
pathway and it provided a comprehensive assessment of dietary inflammatory potential. 
Fourth, the null MTE of E-DII on pancreatic cancer in each study and in the pooled 
cohort further confirmed the lack of association in each study separately as reported 
previously (Zheng et al. unpublished data). Finally, in all the mediation analyses of this 
paper (no matter in study-specific mediation analysis or in pooled cohort, and whether we 
conducted categorical or continuous mediation analyses), we consistently observed the 
significant mediated effect of type-2 diabetes, which suggested type-2 diabetes played a 
role as a mediator in the DII and pancreatic cancer association.    
Despite these advantages, limitations of this study are also noted. When we 
created the mediator variable, we compared the age at first diagnosis of diabetes and age 
at incident primary pancreatic cancer if the subject had both diseases occur in the follow-
up, using the median value of each category of the follow-up diabetes occurrence time 
variable. As we cannot obtain the precise age at diabetes occurrence, it may cause non-
differential misclassification of mediator variable, but the measurement error as a result 
of using mean value of range was estimated to be small, because in PLCO only 21 
subjects and in NIH-AARP only 86 subjects undergone the comparison of diagnosis 
times at two diseases. Although the two studies we combined were very similar in many 
aspects and there was no significant between-study heterogeneity, there was still the 
possibility that the assumption of pooling the primary data may not be fully met in that 
differences in the measurement and distribution of covariates (i.e., different questions to 
obtain data, different categories of a covariate, different units) and in the number of 
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available DII components used to calculate the E-DII score were present; however, there 
was no method to test the assumptions.429 The follow-up data on many covariates were 
available in each study but the large missing percentage impeded our ability to use these 
data. Diet was only assessed at baseline, therefore, any changes in diet over follow up 
were not captured, which could result in non-differential misclassification of exposure. 
However, we previously found DII scores were relatively stable over a long timeframe in 
postmenopausal women where the study participants were of comparable age as our 
study.405 Although important potential confounders were adjusted for in our analyses, 
residual or unmeasured confounding may still be a possibility. In addition, we can only 
calculate the mediation proportion when the NDE and NIE were in the same direction, so 
in some situations in this paper we cannot derive an interpretable mediation proportion.  
6.7 Conclusion 
In conclusion, in the pooled cohort of PLCO and NIH-AARP, we identified a 
significant though small mediated effect of incident type-2 diabetes in the association 
between dietary inflammatory potential and pancreatic cancer with the use of causal 
mediation approach. The association of inflammatory potential of diet with pancreatic 
cancer was fully mediated through incident diabetes. No significant overall effect of E-
DII on pancreatic cancer, averaged over direct and indirect effect with type-2 diabetes as 
a mediator, was observed. Future large cohort studies are warranted to test other possible 
mediators in the pathway from dietary inflammatory potential to pancreatic cancer risk.  
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Table 6.1 Baseline characteristics of 269,641 subjects by quintiles of E-DII in the 
pooled mediation cohort of PLCO Cancer Screening Trial and NIH-AARP Diet and 
Health Study  
 
 Most anti-
inflammato
ry diet  
   Most pro-
inflammat
ory diet  
 
 
 
 
     P-
valuea 
 E-DII 
Q1 
(-8.43, -
5.57) 
E-DII Q2 
(-5.56, -
4.47) 
E-DII Q3 
(-4.46, -
3.24) 
E-DII 
Q4 
(-3.23, - 
1.46) 
E-DII Q5 
(-
1.45,6.66) 
N 53929 53927 53928 53929 53928  
 
Mean (SE) Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
 
Age at baseline 
(y) 
62.7 (0.02) 62.8 (0.02) 62.6 (0.02) 62.5 (0.02) 62.2 (0.02) <.0001 
Total energy 
intake (kcal/d) 
1553.7 (2.4) 1675.1 
(2.8) 
1756.9 
(3.0) 
1874.1 
(3.3) 
2107.1 
(4.0) 
<.0001 
Alcohol 
consumption 
(g/d) 
9.3 (0.06) 9.0 (0.08) 9.7 (0.09) 11.7 (0.1) 19.9 (0.2) <.0001 
 n (%)b n (%)b n (%)b n (%)b n (%)b  
Incident 
diabetes  
     <.0001 
Yes 3198 (5.9) 3835 (7.1) 4205 (7.8) 4696 (8.7) 5456 
(10.1) 
 
No 45950 
(85.2) 
45368 
(84.1) 
45087 
(83.6) 
44489 
(82.5) 
43839 
(81.3) 
 
Missing 4781 (8.9) 4724 (8.8) 4636 (8.6) 4744 (8.8) 4633 (8.6)  
Primary 
pancreatic 
cancer  
     0.95 
Yes 153 (0.3) 146 (0.3) 159 (0.3) 148 (0.3) 149 (0.3)  
No  53776 
(99.7) 
53781 
(99.7) 
53769 
(99.7) 
53781 
(99.7) 
53779 
(99.7) 
 
Sex       <.0001 
Male  21886 
(40.6) 
25020 
(46.4) 
28048 
(52.0) 
32290 
(59.9) 
37755 
(70.0) 
 
Female  32043 
(59.4) 
28907 
(53.6) 
25880 
(48.0) 
21639 
(40.1) 
16173 
(30.0) 
 
Race/ Ethnicity      <.0001 
White non-
Hispanic 
50323 
(93.3) 
50406 
(93.5) 
50402 
(93.5) 
50391 
(93.4) 
50334 
(93.3) 
 
Black non-
Hispanic  
1173 (2.2) 1274 (2.4) 1388 (2.6) 1454 (2.7) 1636 (3.0)  
Hispanic 645 (1.2) 722 (1.3) 765 (1.4) 813 (1.5) 783 (1.5)  
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Asian, Pacific 
Islander or 
American 
Indian/Alaskan 
Native 
1434 (2.7) 1189 (2.2) 1023 (1.9) 927 (1.7) 803 (1.5)  
Unknown  354 (0.7) 336 (0.6) 350 (0.7) 344 (0.6) 372 (0.7)  
BMI      <.0001 
Underweight  453 (0.8) 392 (0.7) 402 (0.8) 370 (0.7) 347 (0.6)  
Normal  24510 
(45.5) 
21778 
(40.4) 
20006 
(37.1) 
18086 
(33.5) 
15700 
(29.1) 
 
Overweight  20701 
(38.4) 
21840 
(40.5) 
22711 
(42.1) 
23495 
(43.6) 
24196 
(44.9) 
 
Obese  7441 (13.8) 9135 
(16.9) 
10028 
(18.6) 
11167 
(20.7) 
12781 
(23.7) 
 
Missing 824 (1.5) 782 (1.5) 781 (1.5) 811 (1.5) 904 (1.7)  
Education level       <.0001 
less than or equal 
to 11 years  
1197 (2.2) 1644 (3.1) 1869 (3.5) 2435 (4.5) 3382 (6.3)  
High school 
completion  
7668 (14.2) 8990 
(16.7) 
9586 
(17.8) 
10608 
(20.0) 
12611 
(23.4) 
 
Post high school 
training other 
than college  
4801 (8.9) 5348 (9.9) 5585 
(10.4) 
5659 
(10.5) 
6459 
(12.0) 
 
Some college 12108 
(22.5) 
12166 
(22.6) 
11980 
(22.2) 
11943 
(22.2) 
11973 
(22.2) 
 
College and 
postgraduate  
27311 
(50.6) 
24929 
(46.2) 
24101 
(44.7) 
22499 
(41.7) 
18717 
(34.7) 
 
Missing 844 (1.6) 850 (1.6) 807 (1.5) 785 (1.5) 786 (1.5)  
Smoking status 
and years of 
quit combined 
       <.0001 
Never smoked 23526 
(43.6) 
23834 
(44.2) 
23425 
(43.4) 
22293 
(41.3) 
19297 
(35.8) 
 
Stopped 10 or 
more years ago 
21166 
(39.3) 
19919 
(36.9) 
19546 
(36.2) 
19154 
(35.5) 
18299 
(33.9) 
 
Stopped 5-9 
years ago  
3125 (5.8) 3050 (5.7) 3018 (5.6) 3162 (5.9) 3320 (6.2)  
Stopped 1-4 
years ago 
1529 (2.8) 1623 (3.0) 1619 (3.0) 1779 (3.3) 2072 (3.8)  
Stopped within 
last year 
723 (1.3) 825 (1.5) 882 (1.6) 960 (1.8) 1202 (2.2)  
Currently 
smoking  
2571 (4.8) 3527 (6.5) 4277 (7.9) 5453 
(10.1) 
8533 
(15.8) 
 
Missing 1289 (2.4) 1149 (2.1) 1161 (2.2) 1128 (2.1) 1205 (2.2)  
Abbreviations: SE, standard error  
a  Statistical analyses were performed by ANOVA test for continuous variables and by Chi-Square test for 
categorical variables. 
b Sum of percentages may not add up to 100% because of rounding or missing.   
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Table 6.2 Study-specific natural direct effect, natural indirect effect and marginal 
total effecta of E-DIIb on pancreatic cancer risk with incident type-2 diabetes as 
mediator 
 
 Natural direct 
effect 
Natural indirect effect Marginal total effect Mediation 
Proportionc 
 Estimate 
with 
95% (CI) 
P 
value 
Estimate 
with 95% 
(CI) 
P value Estimate 
with 95% 
(CI) 
P 
value 
PLCO Cancer Screening Trial 
Q5 vs Q1 1.14 
(0.59-
2.17) 
0.70 1.02 (1.002-
1.03) 
0.03 1.16 (0.61-
2.21) 
0.66 13.0% 
Q4 vs Q1 1.10 
(0.68-
1.79) 
0.70 1.01 (1.00-
1.03) 
0.03 1.11 (0.69-
1.81) 
0.66 12.6% 
Q3 vs Q1 1.07 
(0.77-
1.47) 
0.70 1.01 (1.00-
1.02) 
0.03 1.07 (0.78-
1.49) 
0.66 12.3% 
Q2 vs Q1 1.03 
(0.88-
1.21) 
0.70 1.004 (1.00-
1.01) 
0.03 1.04 (0.88-
1.22) 
0.66 11.9% 
NIH-AARP Diet and Health Study 
Q5 vs Q1 1.01 
(0.79-
1.30) 
0.93 1.009 
(1.004-
1.015) 
0.001 1.02 (0.79-
1.31) 
0.88 46.2% 
Q4 vs Q1 1.01 
(0.84-
1.22) 
0.93 1.007 
(1.003-1.01) 
0.001 1.02 (0.84-
1.23) 
0.88 45.6% 
Q3 vs Q1 1.01 
(0.89-
1.14) 
0.93 1.004 
(1.002-
1.007) 
0.001 1.01 (0.89-
1.14) 
0.88 45.1% 
Q2 vs Q1 1.00 
(0.94-
1.07) 
0.93 1.002 (1.00-
1.003) 
0.001 1.00 (0.94-
1.07) 
0.88 44.5% 
a. Logistic models involved in the causal mediation approach to derive the mediation parameter estimates 
were adjusted for study-specific confounders. 
b. Ordinal E-DII format was used in the model to compare risk of pancreatic cancer for subjects in each 
higher E-DII quintile to subjects in the lowest quintile with type-2 diabetes as mediator. E-DII score 
was derived in the PLCO based on 35 dietary components: alcohol, vitamin B12, vitamin B6, beta-
carotene, caffeine , carbohydrate , cholesterol, food energy, total fat, total dietary fiber, folate , iron, 
magnesium, monounsaturated fatty acids,  poly-unsaturated fatty acids, niacin, onions, protein, 
riboflavin, saturated fatty acids, selenium, thiamin, total trans-fatty acids, Vitamin A, Vitamin C, 
Vitamin E , Vitamin D,  zinc, tea, Flavan-3-ols, flavones, flavonones, anthocyanidin, isoflavone, and 
peppers. E-DII score was derived in the NIH-AARP based on 34 dietary components: data on onions 
were not included and the others are same as those in PLCO.  
c. Mediation proportion of type-2 diabetes was calculated using the equation NDE x (NIE – 1)/ (NDE x 
NIE – 1) 
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Table 6.3 Pooled PLCO and NIH-AARP natural direct effect, natural indirect effect 
and marginal total effecta of categorized E-DIIb on pancreatic cancer risk with 
incident type-2 diabetes as mediator, using random effect model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Pooled mediation estimates from PLCO and NIH-AARP mediation analyses were obtained using the 
random effects model.  
b. DII was treated as an ordinal variable in the study-specific mediation model to compare risk of 
pancreatic cancer for subjects in each higher E-DII quintile to subjects in the lowest quintile with type-
2 diabetes as mediator.  
c. I2 statistic describes the percentage of total variation that is due to heterogeneity rather than chance; 
0% represents no heterogeneity.  
d. Pheterogeneity was calculated from test for between-studies heterogeneity using the random effect model. 
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Table 6.4 Study-specific and random-effect model pooled natural direct effect, 
natural indirect effect and marginal total effecta of one-unit increase in centered E-
DII and E-DII z-score on pancreatic cancer risk with type-2 diabetes as mediator 
 
 Natural direct effect Natural indirect effect  Marginal total effect Mediati
on 
proporti
ond  
 Estim
ate 
with 
95% 
(CI) 
P 
val
ue 
I2
b 
Phe
te
c 
Estim
ate 
with 
95% 
(CI) 
P 
valu
e  
I2
b 
Phe
te
c 
Estim
ate 
with 
95% 
(CI) 
P 
val
ue  
I2
b 
Phe
te
c 
 
PLCO Cancer Screening Trial  
one 
unit 
incre
ase in 
cente
red 
E-DII 
value 
1.00 
(0.91-
1.10) 
0.9
6 
N
A 
N
A 
1.002 
(1.00-
1.004) 
0.04 N
A 
N
A 
1.01 
(0.91-
1.10) 
0.9
2 
N
A 
N
A 
50% 
one 
unit 
incre
ase in 
E-DII 
z-
score 
1.01 
(0.8-
1.26) 
0.9
6 
N
A 
N
A 
1.006 
(1.00-
1.01) 
0.04 N
A 
N
A 
1.01 
(0.81-
1.27) 
0.9
2 
N
A 
N
A 
50% 
NIH-AARP Diet and Health Study 
one 
unit 
incre
ase in 
cente
red 
E-DII 
value 
1.00 
(0.96-
1.04) 
0.9
7 
N
A 
N
A 
1.002 
(1.00-
1.003) 
0.00
1 
N
A 
N
A 
1.001 
(0.96-
1.04) 
0.9
7 
N
A 
N
A 
Not 
interpret
ablee 
one 
unit 
incre
ase in 
E-DII 
z-
score 
1.00 
(0.91-
1.09) 
0.9
7 
N
A 
N
A 
1.004 
(1.001
-
1.005) 
0.00
1 
N
A 
N
A 
1.00 
(0.92-
1.10) 
0.9
7 
N
A 
N
A 
Not 
interpret
ablee 
Pooled estimates from PLCO and NIH-AARP using random effect model 
one 
unit 
incre
ase in 
cente
red 
1.00 
(0.96-
1.04) 
0.9
9 
0
% 
1.0 1.002 
(1.001
-     
1.003 
0.00
1 
0
% 
1.0 1.00 
(0.97-     
1.04)   
0.9
0 
0
% 
0.8
7 
NA 
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E-DII 
value 
one 
unit 
incre
ase in 
E-DII 
z-
score 
1.00 
(0.92-    
1.09) 
0.9
8 
0
% 
0.9
4 
1.004 
(1.002
-     
1.006) 
<0.0
01 
0
% 
0.4
7 
1.00 
(0.92-
1.09) 
0.9
7 
0
% 
0.9
4 
NA 
Abbreviation: NA, not available 
a. Logistic models involved in the causal mediation approach to derive the mediation parameter 
estimates were adjusted for study-specific confounders.  
b. I2 statistic describes the percentage of total variation that is due to heterogeneity rather than chance; 
0% represents no heterogeneity.  
c. Pheterogeneity was calculated from test for between-studies heterogeneity using the random effect model. 
d. Mediation proportion of type-2 diabetes was calculated using the equation [NDE x (NIE – 1)]/ (NDE 
x NIE – 1) 
e. Because the direction of NDE and NIE is different, the mediation proportion is not interpretable  
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Table 6.5 Natural direct effect, natural indirect effect and the marginal total effecta 
of the categorized E-DIIb on pancreatic cancer mediated by type-2 diabetes using 
primary data of 269,641 subjects from the PLCO and NIH-AARP  
 
 Natural direct effect  Natural indirect effect  Marginal total effect  
 Estimate with 
95% (CI) 
P value  Estimate with 
95% (CI) 
P 
value  
Estimate with 
95% (CI) 
P value  
Q5 vs Q1 0.91 (0.72-1.15) 0.45 1.009 (1.004-
1.013) 
0.0002 0.92 (0.73-1.16) 0.49 
Q4 vs Q1 0.93 (0.78-1.11) 0.45 1.006 (1.003-
1.01) 
0.0002 0.94 (0.79-1.12) 0.49 
Q3 vs Q1 0.96 (0.85-1.07) 0.45 1.004 (1.002-
1.006) 
0.0001 0.96 (0.85-1.08) 0.49 
Q2 vs Q1 0.98 (0.92-1.04) 0.45 1.002 (1.001-
1.003) 
0.0001 0.98 (0.92-1.04) 0.49 
a. Logistic models involved in causal mediation approach to derive the mediation parameter estimates 
were adjusted for age at baseline (continuous), sex (male and female), total energy intake (kcal/day), 
BMI (underweight, normal, overweight, obese, missing), alcohol intake (g/day), combination of 
smoking status and years since quitting smoking (never smoked, stopped 10 or more years ago, 
stopped 5-9 years ago, stopped 1-4 years ago, stopped within last year, currently smoking, missing), 
education levels (<=11 years, high school completion, post high school training other than college, 
some college, college and postgraduate, missing). 
b. Ordinal E-DII format was used in the model to compare risk of pancreatic cancer for subjects in each 
higher E-DII quintile to subjects in the lowest quintile with type-2 diabetes as mediator.  
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Table 6.6 Natural direct effect, natural indirect effect and marginal total effecta of 
one-unit increase in centered E-DII and E-DII z-score on pancreatic cancer risk 
with type-2 diabetes as mediator using primary data of 269,641 subjects from the 
PLCO and NIH-AARP 
 
 Natural direct effect  Natural indirect effect  Marginal total effect  
 Estimate 
with 95% 
(CI) 
P 
value  
Estimate with 
95% (CI) 
P 
value  
Estimate 
with 95% 
(CI) 
P value  
One unit 
increment of 
centered E-DII 
value  
0.98 (0.95-
1.02) 
0.28 1.001 (1.00-
1.002) 
0.0001 0.98 (0.95-
1.02) 
0.31 
 One unit 
increase of z-
score of E-DII   
0.95 (0.88-
1.04) 
0.28 1.003 (1.002-
1.005) 
0.0001 0.96 (0.88-
1.04) 
0.31 
a. Logistic models involved in causal mediation approach to derive the mediation parameter estimates 
were adjusted for age at baseline (continuous), sex (male and female), total energy intake (kcal/day), 
BMI (underweight, normal, overweight, obese, missing), alcohol intake (g/day), combination of 
smoking status and years since quitting smoking (never smoked, stopped 10 or more years ago, 
stopped 5-9 years ago, stopped 1-4 years ago, stopped within last year, currently smoking, missing), 
education levels (<=11 years, high school completion, post high school training other than college, 
some college, college and postgraduate, missing). 
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Table 6.7 Comparison of important demographic and lifestyle characteristics 
between study sample and excluded sample in the pooled PLCO Cancer Screening 
Trial and NIH-AARP  
 
 Study population 
(n=269,641) 
Excluded subjects  
(n=365,064) 
P-valuea 
 Mean (SE) Mean (SE)  
Age at DHQ (years) 62.6 (0.01) 62.1 (0.01) <.0001 
Total energy intake 
(kcal/d) 
1793.4 (1.5) 1852.9 (1.4) <.0001 
Alcohol consumption 
(g/d) 
11.9 (0.06) 12.4 (0.06) <.0001 
E-DII from food and 
supplement  
-3.6 (0.004) -3.3 (0.003) <.0001 
 N (%)b N (%)b  
Primary pancreatic 
cancer  
  <.0001 
Yes 755 (0.3) 2397 (0.7)  
No  268886 (99.7) 362667 (99.3)  
Sex   <.0001 
Male  144999 (53.8) 218487 (59.9)  
Female  124642 (46.2) 146577 (40.1)  
Race/ Ethnicity   <.0001 
White non-Hispanic 251856 (93.4) 327882 (89.8)  
Black non-Hispanic  6925 (2.6) 16789 (4.6)  
Hispanic 3728 (1.4) 7662 (2.1)  
Asian, Pacific Islander or 
American Indian/Alaskan 
Native 
5376 (2.0) 7508 (2.1)  
Unknown  1756 (0.7) 5223 (1.4)  
BMI   <.0001 
Underweight  1964 (0.7) 2836 (0.8)  
Normal  100080 (37.1) 113802 (31.2)  
Overweight  112943 (41.9) 152290 (41.7)  
Obese  50552 (18.8) 86200 (23.6)  
Missing 4102 (1.5) 9936 (2.7)  
Education level    <.0001 
less than or equal to 11 
years  
10527 (3.9) 27456 (7.5)  
High school completion  49463 (18.3) 78227 (21.4)  
Post high school training 
other than college  
27852 (10.3) 37619 (10.3)  
Some college 60170 (22.3) 85316 (23.4)  
College and postgraduate  117557 (43.6) 124730 (34.2)  
Missing 4072 (1.5) 11716 (3.2)  
Smoking status and years 
of quit combined 
  <.0001 
Never smoked 112375 (41.7) 122133 (33.5)  
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Stopped 10 or more years 
ago 
98084 (36.4) 130113 (35.6)  
Stopped 5-9 years ago  15675 (5.8) 26715 (7.3)  
Stopped 1-4 years ago 8622 (3.2) 15881 (4.4)  
Stopped within last year 4592 (1.7) 7523 (2.1)  
Currently smoking  24361 (9.0) 48641 (13.3)  
Missing 5932 (2.2) 14058 (3.9)  
a P value was calculated from independent t-test for continuous variables and from Chi-Square test for 
categorical variables. 
b The sum of percentages for some categorical variables may not add up to 100% because of rounding.  
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Table 6.8 Hazard ratios of pancreatic cancer by quintiles of E-DII score from food 
and supplement in the pooled mediation cohort of 269,641 subjects  
 
 Most anti-
inflammato
ry diet 
   Most pro-
inflammat
ory diet 
 
 
 
P-
trenda 
 
 
 
Continuous 
HR (95% 
CI)b 
 E-DII 
Q1 
 
E-DII 
Q2 
 
E-DII 
Q3 
E-DII 
Q4 
 
E-DII Q5 
 
Cases (n) 153 146 159 148 149   
Sample size 53929 53927 53928 53929 53928   
Age and 
energy- 
adjusted HR 
(95% CI) 
1.00 1.02 
(0.81-
1.28) 
1.14 
(0.91-
1.42) 
1.08 
(0.86-
1.35) 
1.14 
(0.91-
1.44) 
0.28 1.04 (0.97-
1.12) 
Multivariable
-adjusted HR 
(95% CI)c 
1.00 1.00 
(0.80-
1.26) 
1.11 
(0.89-
1.39) 
1.03 
(0.82-
1.30) 
1.04 
(0.82-
1.33) 
0.86 1.01 (0.93-
1.09） 
a Continuous DII score was used to determine P for trend 
b The continuous HR and associated 95% CI for one standard deviation increase of E-DII score 
c Adjusted for age at baseline (continuous), sex (male and female), body mass index at baseline 
(underweight, normal, overweight, obesity and missing), years of quit and smoking status combined (never 
smoked, stopped 10 or more years ago, stopped 5-9 years ago, stopped 1-4 years ago, stopped within last 
year, currently smoking, unknown), total energy intake (kcal/d), education level (<=11 years, 12 years or 
completed high school, post-high school, some college, college and post graduate, unknown), alcohol 
intake (g/day) 
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Figure 6.1 Coding of mediator of type-2 diabetes on the association between E-DII 
and pancreatic cancer risk in the pooled analysis of the PLCO and NIH-AARP. 
Abbreviations: PanC, primary pancreatic cancer; D, mediator variable indicating 
incident type-2 diabetes occurrence during follow-up; P, primary pancreatic cancer.  
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CHAPTER 7 
7  
DIETARY INFLAMMATORY POTENTIAL AND PANCREATIC 
CANCER RISK: DISCUSSION OF STUDY RESULTS OF 
INTERACTION AND MEDIATION ANALYSES IN TWO 
PROSPECTIVE COHORTS 
7.1 Summary of results  
This dissertation aimed to investigate the association between inflammatory 
potential of diet and pancreatic cancer in the PLCO Cancer Screening Trial and the NIH-
AARP Diet and Health Study, and examine important inflammation-related lifestyle 
effect modifiers in the association. In the pooled analysis with combined data from the 
PLCO and NIH-AARP, we aimed to examine whether incident type-2 diabetes mediated 
the association between inflammatory potential of diet and pancreatic cancer using the 
causal mediation approach. Generally, we did not observe a significant association 
between E-DII and pancreatic cancer after adjusting for confounders in both PLCO and 
NIH-AARP cohorts. However, in the PLCO specifically, time (<4 and >=4 years) was 
found to be the only significant effect modifier (P-interaction=0.02). Among subjects 
with follow up <4 years, there was an inverse association between E-DII and pancreatic 
cancer (HRQ5vsQ1=0.55; 95% CI=0.32-0.95; P-trend=0.15), while there was a positive 
trend among those with ≥4 years of follow-up (HRQ5vsQ1 =1.36; 95% CI=0.85-2.17; P-
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trend=0.03). Similar results were observed for E-DII from food only. In the NIH-AARP, 
inflammation-related lifestyle factors including BMI, smoking status, alcohol drinking, 
NSAIDs use, and history of diabetes did not modify the E-DII and pancreatic cancer 
association. Dietary inflammatory potential was not associated with pancreatic cancer 
risk by cancer stage or grade. Both study-specific and pooled mediation analysis using 
combined data from both the PLCO and NIH-AARP confirmed the significant though 
small mediated effect of incident type-2 diabetes on the association between E-DII and 
pancreatic cancer. However, the overall effect of E-DII on pancreatic cancer averaged 
over direct and indirect effects with type-2 diabetes as a mediator was not significant.  
7.2 Comparisons of dissertation findings with findings from two case-control 
studies  
Findings from our dissertation did not confirm the significant positive 
associations of the E-DII and pancreatic cancer reported in the two previously published 
case-control studies.38,39 In both case-control studies, an approximate 2.5-fold increased 
risk of pancreatic cancer in the highest compared to the lowest quintile of the E-DII 
group was observed (U.S.: ORQ5vsQ1 =2.54, 95% CI=1.87-3.46, P-trend<0.0001;39 Italy: 
ORQ5vsQ1=2.48, 95% CI=1.50-4.10, P-trend=0.00238). In addition to the primary 
association results, both studies also identified evidence of effect modification by a few 
inflammation-related factors including smoking, BMI, and diabetes history. The Italy 
case-control study documented evidence of effect modification by smoking status and 
BMI where a significant positive association was observed among never and past 
smokers but not among current smokers, and among normal and overweight rather than 
obese subjects, respectively.38 In the  U.S. case-control study, using a joint effect 
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approach, Antwi et al. demonstrated that dietary inflammatory potential may act 
synergistically with cigarette smoking and diabetes to increase the risk of pancreatic 
cancer beyond the risk of any of these factors alone.39 However, this dissertation using 
data from two large well-established prospective cohorts in the US consistently 
demonstrated the null overall E-DII and pancreatic cancer association and no significant 
effect modification by inflammation-related factors, although a significant positive trend 
was detected in the PLCO among participants with follow up>=4 years. The major 
reasons for the inconsistent results may be owing to the strengths and limitations of the 
different study designs utilized. Differential misclassification of exposure is minimized in 
a cohort design but is inextricable in a case-control design as a result of recall bias and 
selection bias. In addition, due to the high fatality of pancreatic cancer, case-control study 
of pancreatic cancer is susceptible to measurement error induced by using proxy’s 
responses, which also could distort the association. However, as observed in Aim 1 
analyses, although prospective studies measured exposure before outcome occurrence 
which may minimize reverse causality bias, such bias can occur in prospective studies 
given the unknown latency of pancreatic cancer. In addition, its precursor conditions have 
profound effects on digestion, implying that dietary changes may be made at the early 
stage of cancer development.  
7.3 Potential mechanisms of action  
Chronic inflammation has been identified as an underlying pathophysiological 
foundation for many chronic diseases, including cancers.407,408 Uncontrolled pro-
inflammatory responses could create a chronic inflammatory state, promoting a tumor-
favorable microenvironment that supports the development of genomic mutations and 
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potentially triggers immune overactivation and initiation of pancreatic cancer.58,441 The 
process for pro-inflammatory cytokines (e.g., tumor necrosis factor, IL-6, IL-11 or IL-22) 
to trigger signaling cascades that activate key transcription factors directly or indirectly 
which control cell-cycle, cell death, dedifferentiation, stemness, motility, and migration 
have gone astray in chronic inflammation.442 In addition, inflammatory states are 
etiologically linked to well-recognized risk factors for pancreatic cancer, including 
chronic pancreatitis, cigarette smoking, obesity, and diabetes.58,384   
Dietary factors could affect cancer risk through modulation of inflammation,385,386 
mainly realized through their impact on visceral obesity,387 oxidative damage,78 and 
insulin resistance.387 Multiple mechanisms are involved in this process, including 
regulation of the pro-inflammatory cytokines, NF-κB pathway activation, changes in 
DNA methylation and influence on the antioxidant defense.79,73 Dietary patterns, which 
take into account the complex interaction between foods or nutrients, such as Western 
type diet and the Mediterranean diet, have been found to affect inflammatory 
biomarkers.6,443-445  
 Pro-inflammatory diets can increase insulin resistance, increase  reactive oxygen 
species, and influence mediators in the inflammatory pathway (e.g., NF-kB and COX-2), 
leading to increased cell cycling, loss of tumor suppressor function, stimulated oncogene 
expression, genetic alterations, and modifications of key cancer-related proteins, 
ultimately causing malignancy.57,58,418,419 Diets high in red and processed meat may 
contain high amount of nitrosamine and nitrate which may cause DNA damage.243 A 
recent investigation also found a chemical contributed primarily from red meat 
consumption (dietary Nϵ-(carboxymethyl) lysine (CML) glycation end products) had a 
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pancreatic cancer promoting effect.249An anti-inflammatory diet has strong antioxidant 
and carcinogenesis inhibition properties, which could help to reduce insulin resistance, 
oxidative stress and damage, and inhibit pancreatic tumor development.182,420   
There are other lifestyle factors known to be associated with inflammation besides 
diet and that may have an effect on pancreatic cancer development. Obesity and diabetes 
are inflammatory conditions, and recent data have demonstrated that the plasma 
concentration of inflammatory mediators, such as TNF-α and IL-6, are increased in the 
insulin-resistant states of obesity and type-2 diabetes.217,385,446 Cigarette smoking has 
been shown to augment the production of pro-inflammatory cytokines and decrease the 
levels of anti-inflammatory biomarkers.447,448 Chronic alcohol exposure promotes pro-
inflammatory immune responses, and also impairs anti-inflammatory cytokines.449,450 The 
pro-inflammatory effects of high-level alcohol drinking also play a major role in the 
pathogenesis of pancreatitis.449 Non-steroidal anti-inflammatory drugs (NSAIDs), which 
include aspirin, piroxicam, ibuprofen and other COX-2 inhibitors, have shown the ability 
to alter systemic inflammation, reduce tumor recurrence and improve moderate cancer 
cachexia.235  
7.4 Strengths and limitations  
This dissertation has several major strengths. The use of two large, well-
characterized prospective cohorts with long follow-up and adequate numbers of 
pancreatic cancer cases and incident type-2 diabetes cases provided us with ample power 
to test our hypotheses in three aims. In the pooled analyses (Aim 3), the similarities 
between the PLCO and NIH-AARP cohorts provided us a strong justification to combine 
primary data from these two cohorts to increase outcome and mediator numbers as well 
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as take advantage of differences in the distributions of the exposure variable across 
studies, in order to better test the mediated effect of incident type-2 diabetes. With diet 
and lifestyle factors assessed before cancer diagnosis, recall bias and selection bias that 
are inevitable in a typical case-control study were minimized in our research. To the best 
of our knowledge, we are among the first to test the dietary inflammatory potential and 
pancreatic cancer association in a prospective manner and examine whether inflammatory 
potential of diet acted synergistically with other inflammation-related lifestyle factors to 
influence pancreatic cancer risk. Using the NIH-AARP, this also is the first prospective 
investigation to examine the association between a dietary index and pancreatic cancer 
severity. The other strengths included detailed information on a comprehensive list of 
covariates which allowed for careful adjustment in the analyses, the use of a construct-
validated dietary index which was designed specifically on the inflammation mechanism 
and provided a comprehensive assessment of inflammatory potential of an individual’s 
entire diet, and the application of majority of DII components to calculate the E-DII 
scores which created a large contrast of exposure. We obtained consistent results from 
three aims to support the lack of overall association of E-DII and pancreatic cancer. In all 
the mediation analyses of Aim 3, we consistently observed the significant mediated effect 
of type-2 diabetes, which suggested type-2 diabetes may play a role as a mediator in the 
DII and pancreatic cancer association.    
Several limitations should be considered in the interpretation of the results. In 
each study, we excluded a substantial number of participants based on exclusion criteria, 
but differences of some pancreatic cancer risk factors may exist between excluded and 
included participants which may have introduced selection bias and resulted in 
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underestimation of the association. The FFQ and other questionnaires used in each study 
were prone to measurement error as another unavoidable limitation, which may have 
resulted in some misclassification of the E-DII score and covariates. Although follow-up 
data were available on most covariates, the large amount of missing information impeded 
our ability to use these data.  Evaluation of the E-DII at a single time point could result in 
non-differential misclassification of exposure given diet may change over time. However, 
we previously found DII scores were relatively stable over time in postmenopausal 
women who were of comparable ages as our study populations.405 Another limitation of 
the study was that not all of the 45 DII components were available in both the PLCO and 
NIH-AARP to calculate the E-DII scores. However, the range of DII scores may rely 
more on the amount of foods actually consumed rather than the number of available DII 
components,406 and a previous study found a significant association between the DII and 
colorectal cancer using data from the NIH-AARP,34 suggesting that the smaller number 
of DII components would not limit the ability to detect an effect. While we adjusted for 
important potential confounders, residual or unmeasured confounding cannot be ruled 
out. In the mediation analysis specifically (Aim 3), we cannot rule out the possibility that 
the assumption of pooling the primary data may not be fully met in that differences in the 
measurement and distribution of covariates (i.e., different questions to obtain data, 
different categories of a covariate, different units) and in the number of available DII 
components used to calculate the E-DII score were present; however, there was no 
method to test the assumptions.429  We also were unable to report some of the mediation 
proportion as the NDE and NIE were not in the same direction.  
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7.5 Public health implications 
Pancreatic cancer has a high case-fatality rate, and due to lack of reliable 
screening method for early detection, it is usually diagnosed at an advanced stage with a 
very low survival rate. Therefore, identifying modifiable factors, including diet, can help 
reduce the burden of this malignancy. Findings from this dissertation had scientific, 
clinical, and public health significance.  
The null association identified from the PLCO and NIH-AARP between the DII 
and pancreatic cancer suggested that the total dietary inflammatory potential may not be a 
major contributor to pancreatic cancer risk, which implies that maybe other mechanisms, 
other dietary factors, or only a portion of the DII components are associated with 
pancreatic cancer. These possible explanations warrant future studies to test and confirm. 
Since our studies obtained a null association conclusion with several limitations, future 
studies that can overcome these limitations are needed to confirm our results. 
Nevertheless, striving toward a more anti-inflammatory diet may have other potential 
health benefits beyond pancreatic cancer prevention.  
Providing evidence of inflammation-related effect modifiers on the dietary 
inflammatory potential and pancreatic cancer relationship is informative to evaluate total 
risk of pancreatic cancer while taking into account other common lifestyle factors, 
especially for people who have a pro-inflammatory diet such as Western type diet. 
However, we did not observe any significant effect modification in the association, which 
could be due to the small numbers in some strata or because we only conducted 
multiplicative interaction test in the COX model but did not use the joint effect approach 
to test the multiplicative and additive interactions. Therefore, our results laid the 
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groundwork for future studies without these limitations to confirm our findings. Even if 
there is a lack of significant results from statistical tests, that does not actually mean no 
biologic interactive effects.  
The finding of the significant mediated effect of type-2 diabetes in the association 
between dietary inflammatory potential and pancreatic cancer not only elucidated a 
mechanism through which dietary inflammatory potential could lead to development of 
pancreatic cancer, it also provides clinical evidence and guidance to identify possible 
intermediate biomarkers related to type-2 diabetes mechanism such as insulin resistance 
in order to indirectly identify high risk population for developing pancreatic cancer, 
especially for those who consume a more pro-inflammatory diet. In addition, our findings 
could help with the design and guidance of an effective dietary intervention to reduce risk 
of pancreatic cancer through intervening on type-2 diabetes.  
7.6 Implications for future research  
Given the conclusion from the PLCO that time was a significant effect modifier 
of the E-DII and pancreatic cancer association, future prospective cohort studies 
assessing dietary factors and pancreatic cancer risk should consider differences in 
associations by follow-up time. It is possible for future studies to investigate how diet has 
been changed in the early period of pancreatic cancer diagnosis. Future large cohort 
studies with repeated diet measurements are warranted to confirm our findings in this 
dissertation. Studies that have follow-up data missing at a small percentage are also 
needed to test our hypotheses and confirm the results. Large cohort studies are needed to 
test the effect modification of E-DII and pancreatic cancer by important inflammation-
related lifestyle factors and the association between E-DII and severity of pancreatic 
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cancer to confirm our findings in the NIH-AARP. Since age at diagnosis of diabetes 
during the follow-up was not measured in a precise way in both the PLCO and NIH-
AARP, future prospective cohort studies with follow-up type-2 diabetes measured in 
more details are needed to test and confirm our mediation analysis findings. Other 
possible mediators in the pathway from dietary inflammatory potential to pancreatic 
cancer risk may exist. Therefore, future studies could test other possible mediators in the 
association and further investigate the relationship between multiple mediators in the DII 
and pancreatic cancer association. Given the significant mediator role of type-2 diabetes 
in the association between DII and pancreatic cancer, the inclusion of diabetes as a 
covariate in future analysis of DII and pancreatic cancer is not recommended.  
7.7 Conclusion 
Both the PLCO and NIH-AARP did not support a significant association between 
inflammatory potential of diet and pancreatic cancer risk. However, in the PLCO cohort, 
time significantly modified the E-DII and pancreatic cancer association. An inverse 
association between E-DII and pancreatic cancer in the first four years of follow up was 
observed, suggesting dietary changes due to undiagnosed disease might have affected 
appetite or food choices to lower the E-DII scores in the early stages. A positive 
association, as hypothesized, was suggested by a significant trend after excluding 
subjects with follow-up time <4years. In the NIH-AARP, inflammation-related lifestyle 
factors including BMI, smoking status, alcohol drinking, NSAIDs use, and history of 
diabetes did not modify the association. Dietary inflammatory potential was not 
associated with pancreatic cancer risk by cancer stage or grade.  
In the pooled analysis of the PLCO and NIH-AARP, we identified a significant 
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though small mediated effect of incident type-2 diabetes in the associations between both 
categorical and continuous DII and pancreatic cancer. The association of inflammatory 
potential of diet with pancreatic cancer was fully mediated through incident type-2 
diabetes. However, the overall effect of E-DII on pancreatic cancer, averaged over direct 
and indirect effect with type-2 diabetes as a mediator, was not significant. 
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